

Interested in joining or collaborating with New Frontier Health?  
You are welcome to reach us by

**SCANNING THE QR CODE BELOW**

and talk with our dedicated New Frontier Representative.



Anchored in Hong Kong,  
Connecting the Greater Bay Area

「立足香港 聯動灣區」

Global Health Summit

全球醫療峰會



# Content

---

01

## Joint letter | 聯合致辭

Breaking Boundaries, Innovating Change and Leading the New Frontier of Chinese Healthcare Services

突破界限，創新變革，引領中國醫療服務展新風

---

08

## Vision from the Frontier | 前瞻視野

Building a Healthcare and Life Sciences Ecosystem Driven by Technology and Empowered by Artificial Intelligence

建設以科技為驅動、以人工智慧賦能的醫療及生命科學生態系統

---

36

## New Frontier Group's Platform | 新風天域產業平台

- Primary to Tertiary Clinical Network  
臨牀醫療網絡
  - Insurance Solutions  
新風保險服務
  - Rehabilitation Health  
康復醫療服務
  - International Medical Services  
跨境醫療服務
  - Home Health  
家庭醫療照護
- 

49

## From GBA to Global Health Summit Agenda 大灣區 - 全球醫療峰會議程

- Advancing Innovation in Clinical Research and Treatments Solutions  
臨床研究與治療方案創新
  - AI and Implications on Healthcare  
人工智慧與醫療變革
  - New Trends in Cross-Border Healthcare and Clinical Care  
跨境醫療與護理新趨勢
- 

55

## Guests | 高峰會嘉賓

---

109

## Editorial | 醫研評論

- Building an intelligent Healthcare Informatics System that is responsive, adaptive and salable
  - 減輕國民醫療負擔：康復醫療的獨特價值
  - Tales of Two Systems:  
Maximizing Medical Strengths in the Greater Bay Area
  - A Global Race: The Shifting Landscape of International Medical Care
-



Co-Founder and Group Chairman of  
New Frontier Group

新風天域集團聯合創始人兼集團董事長

## Mr. Antony Leung 梁錦松先生

Mr. Leung has extensive experience in the fields of government, public service, commercial and financial services. He has served as the Financial Secretary of The Government of the Hong Kong Special Administrative Region, unofficial member of the Executive Council, the Chairman of the Education Commission and Chairman of the University Grants Committee.

Prior to founding the New Frontier Group, Mr. Leung had a long career in international financial services, he was Senior Managing Director, Chairman of Greater China and a member of the Executive Committee of Blackstone, the Chairman of Asia for JP Morgan Chase; Country Corporate Officer of Citi for China and Hong Kong, Head of Investment Banking for North and South West Asia and Head of Private Banking for Asia.

Mr. Leung is currently also the Chairman of Nan Fung Group, Co-founder and Chairman of Solomon Education Group. Nan Fung Group's business includes property, financial investment and life sciences. Solomon Group is a Hong Kong-based social enterprise that promotes education of money and morals, as well as generative AI. Mr. Leung is an Independent Non-Executive Director of China Construction Bank and chairman of two charity organizations - Heifer Hong Kong and Food Angel.

梁先生在政府、公共服務、商業、金融以及社會公益等領域擁有豐富的經驗，曾歷任香港特別行政區政府財政司司長、非官守行政會議成員、教育統籌委員會主席、大學教育資助委員會主席等政府要職。

創辦新風天域集團前，梁先生長期在國際金融機構任職，他擔任黑石集團執行委員會成員、高級董事總經理和大中華區主席、摩根大通亞洲業務主席、花旗集團中國和香港地區業務主管、投資銀行、商業銀行和私人銀行亞洲區主管。

梁先生現時也是香港南豐集團董事長、所羅門教育集團聯合創始人及董事長。南豐集團業務包括房地產、金融投資及生命科技。所羅門教育是一家成立於香港的社會企業，旨在推廣金錢和品格、以及生成式人工智慧教育。梁先生現時亦擔任中國建設銀行獨立非執行董事，兩家慈善機構「香港小母牛」及「惜食堂」的主席。



Co-Founder and CEO of New Frontier Group and  
CEO of United Family Healthcare

新風天域集團聯合創始人兼首席執行官  
和睦家醫療首席執行官

## Mr. Carl Wu 吳啟楠先生

Under Carl and Antony's leadership, New Frontier has developed into an integrated healthcare system and life science company in China, with operations ranging from general and specialty hospitals, primary and urgent care services, rehabilitation hospitals, home health care, health insurance solutions, and clinical trial services. Through an integrated system of 33 hospitals and more than 200 outpatient and home health centers, New Frontier services approximately 15 million patients annually across 78 cities in China.

Carl is currently the Group CEO as well as CEO of United Family Healthcare. He also co-founded and serves as Executive Chairman of NF subsidiaries including YD Care, HEAL Medical, HEAL Oncology, HEAL Fertility, Hong Kong Intergrated Oncology Centre, NF Greater Bay Health Holding, Better Health and Prosper Health, NF Nova and serves as the Chairman of Care Alliance.

Prior to founding New Frontier, Carl was a Managing Director at Blackstone. Carl was acknowledged by Fortune as one of the "40 under 40" global business and political leaders.

吳啟楠是新風天域聯合創始人兼首席執行官。在梁錦松和吳啟楠的帶領下，新風天域發展成爲一個覆蓋綜合和專科醫院、初級診療和急診、康復、居家醫療、健康保險服務、醫療科技的多元化健康產業集團，提供全生命週期、多場景的高質量醫療服務。通過由 33 家醫院和 200 多家門診與家庭健康護理中心組成的綜合體系，集團業務在中國已覆蓋 78 個城市，每年爲近 1500 萬名患者提供服務。

吳啟楠現任新風天域旗下和睦家醫療的首席執行官，也是集團成員企業易得康醫療、希愈醫療中心、希愈腫瘤中心，希愈生殖醫學中心及香港綜合腫瘤中心，新風大灣區醫療集團 / 深圳三九醫院、柏泰健康保險的聯合創始人和執行董事長，以及顧連醫療的董事長。

吳啟楠畢業於倫敦政治經濟學院，獲得經濟學一級榮譽學士。在成立新風天域之前，他曾任黑石集團的董事總經理，負責黑石大中華區私募投資業務。先後在倫敦、香港、上海和北京辦公。吳先生是黑石中國主要管理成員，聯合創立黑石亞洲和大中華區業務。加入黑石之前，吳先生就職於瑞銀集團 (UBS) 倫敦總部。

吳啟楠於 2021 年獲《財富》雜誌選爲全球「40 位 40 歲以下的政商精英」。吳啟楠先生任上海市第十四屆政協委員。



Member of the Executive Council of  
The Government of The Hong Kong Special Administrative Region  
香港特別行政區行政會議成員

## Dr. the Honourable Ko Wing-man, GBS, JP

### 高永文 醫生

Dr. Ko is a member of the Standing Committee of the National Committee of the Chinese People's Political Consultative Conference and the Standing Committee of the Chao Zhou City Committee of the Chinese People's Political Consultative Conference. He is also Council Member of the Hong Kong Committee for UNICEF, Vice Chairman of the Federation of Hong Kong Chiu Chow Community Organisations and Vice President of the Hong Kong China Chamber of Commerce. Dr. Ko was Secretary for Food and Health from July 2012 to June 2017 and previously Chairman of the Hong Kong Anti-Cancer Society and Director of the Hong Kong Red Cross. He was awarded the Gold Bauhinia Star in 2017.

高醫生是現任全國政協常務委員及政協潮州市委員會常委。他擔任聯合國兒童基金會香港委員會委員、香港潮屬社團總會常務副主席以及香港中國商會常務副會長。高醫生於2012年7月至2017年6月期間任食物及衛生局局長，亦曾任香港防癌會主席及香港紅十字會總監。2017年獲香港特區政府頒授金紫荊星章。



Director of New Frontier Corporation,  
Honorary President of Shenzhen New Frontier United Family Hospital

新風醫療董事會成員  
深圳新風和睦家醫院榮譽院長

## Dr. CH Leong, GBM, GBS, JP

### 梁智鴻 醫生

Dr. Leong is a medical doctor in private practice specializing in Urology. After graduating from the University of Hong Kong in 1962, Dr. Leong worked in the Department of Surgery in Hong Kong University. In 1975, he was awarded a Hunterian Professorship of the Royal College of Surgeons of England.

Dr. Leong was a member of the Legislative Council of Hong Kong and was appointed as the chairman of the Hong Kong Hospital Authority. Dr. Leong served as a non-official member of the Executive Council HKSAR. He was awarded the Gold Bauhinia Star in 2001 and the Grand Bauhinia Medal in 2010, and was appointed as Chairman of the Hong Kong University Council in 2009.

Dr. Leong was also the President of the Hong Kong Academy of Medicine and Founding President of the Hong Kong College of Surgeon. He established the HKU-SZ Hospital and was the founding Honourary Chairman.

梁醫生是泌尿科私人執業醫生。1962年從香港大學畢業後，梁醫生在香港大學外科工作。1975年，梁醫生被英國皇家外科醫學院任命為 Hunterian Professor。

梁醫生曾是香港立法會議員，曾被任命為香港醫管局主席及香港特別行政區行政會議的非官守成員。他於2001年獲頒授金紫荊星章及2010年大紫荊勳章，2009年獲委任為香港大學校董會主席。

梁醫生亦曾任香港醫學專科學院院長及香港外科專科學院創校院長，並參與創辦香港大學深圳醫院及擔任其創院榮譽主席。

## Breaking Boundaries, Innovating Change, and Leading the New Frontier of Chinese Healthcare Services

### 突破界限，創新變革， 引領中國醫療 服務展新風

Co-Founders of New Frontier Group  
新風天域集團聯合創始人

Antony Leung | 梁錦松  
Carl Wu | 吳啟楠

Feb.12 2025  
2025年2月12日



Driven by technological innovation, the global healthcare industry is entering a new era brimming with opportunities and has become an integral part of a nation's new-quality productive forces.

The Guangdong-Hong Kong-Macao Greater Bay Area is emerging as a global medical hub, boasting unique strengths in research, clinical practice, services, facilities, and outstanding talent. Across the region, cities are setting new benchmarks in these areas, making cutting-edge, high-quality healthcare services accessible to the general public.

Today marks a significant milestone for New Frontier Group. The group is honored to sign a strategic cooperation agreement with Hong Kong Investment Corporation Limited (HKIC). We extend our special thanks to Mr. Paul Chan, Financial Secretary of the Hong Kong Special Administrative Region, for witnessing the signing and delivering the keynote speech. The Hong Kong SAR Government's high regard for the collaboration between HKIC and New Frontier reflects its anticipation of innovative and breakthrough developments in artificial intelligence (AI), innovative medical technologies, and interdisciplinary treatment solutions.

New Frontier is also launching a medical summit themed "**Anchored in Hong Kong, Connecting the Greater Bay Area**" From GBA to Global Health Summit. At this summit, we are honored to gather numerous leaders and authorities from around the world in the fields of clinical medicine, public health, healthcare investment, and artificial intelligence. They will share their insights on international healthcare, innovative drugs, therapeutic research, artificial intelligence (AI), and the latest industry trends, offering a unique perspective on the future of healthcare.




在科技創新引領推動下，全球醫療保健產業正進入一個充滿機遇的新時代，並且成為國家發展新質生產力重要的一部分。

粵港澳大灣區作為新興的全球醫學中心，在研究、臨床、服務、設施以及優秀的人才方面，擁有獨特優勢。大灣區各線城市，不斷在這些領域開創嶄新的標準，使普羅大眾能夠獲得尖端而高品質醫療服務。

今天，是新風天域一個重要的里程碑日子，集團非常榮幸與香港投資管理有限公司 (HKIC) 簽定戰略合作協定，在此特別感謝香港特別行政區政府財政司司長陳茂波先生見證簽約和發表主旨演講。香港特區政府此次高度重視港投與新風的合作，期待在人工智慧 (AI)、創新醫療技術和跨專業治療解決方案上，有創新和突破性的發展。

新風天域同時發起這場以「**立足香港 聯動灣區**」為主題的醫療高峰會。此次峰會，我們有幸邀請來自世界各地的臨床醫療、公共衛生、健康投資以及人工智慧領域的多位領袖和權威，從國際醫療、創新藥物、治療研究、人工智 (AI) 等各個層面以及最新行業發展趨勢，發表真知灼見，預示未來，為醫療發展開創獨特新視角。







China is rapidly entering an aging society, which brings challenges of increasing demand for medical care. As part of developing new-quality productive forces, the country is actively encouraging private enterprises to participate in the healthcare industry to enhance the quality of medical services. Against this backdrop of challenges and opportunities, New Frontier has been born, grown, and strengthened into an international medical and life sciences group headquartered in Hong Kong.

Since its founding in 2016, New Frontier Group has been dedicated to developing and providing the most innovative and cutting-edge healthcare services, creating an integrated, patient-centered medical service system across the entire life cycle.

To date, New Frontier has established seven major business segments across China, including:

- **United Family Healthcare:** Providing high-quality acute care services through general and specialty hospitals;
- **The Greater Bay Area Medical Platform**, which uses Shenzhen and Hong Kong as fulcrums to explore medical integration in the region (including United Family Healthcare, Hong Kong Heal Medical, and Hong Kong Integrated Oncology Centre);
- **Care Alliance**, a leading domestic chain of rehabilitation hospitals for non-acute medical care;
- **YD Care**, which promotes home-based medical care and builds an efficient home-based elderly care service system;
- **Better and Prosper**, which offer diversified insurance products to support the construction of a multi-tiered medical security system;
- **New Frontier Nova:** which builds clinical research capabilities and drives innovation and translation of pharmaceuticals and medical devices;
- **New Frontier Digital Hub**, which empowers medical services with technology to promote intelligent and personalized services.

中國正迅速步入老齡化社會，帶來醫護需求緊缺的問題。作為發展新質生產力的一部分，國家積極鼓勵民營企業參與發展醫療健康產業，提升醫療服務質，新風天域就在這樣充滿挑戰和機遇大背景下，誕生、成長、壯大成為一家總部位於中國香港的國際醫療和生命科學集團。

自 2016 年成立以來，集團一直致力於發展和提供醫療保健方面最創新、最前沿的服務，在全身命週期，打造一體化，以患者為中心的醫療服務。

至今，新風天域已在全中國建立了七個大板塊，其中包括：

- 綜合和專科醫院網路、提供卓越醫療服務的**和睦家醫療**；
- 以深港為支點，探索大灣區醫療融合的**大灣區醫療平台**（包括**和睦家、香港希愈醫療和香港綜合腫瘤中心**）；
- 發展非急性期醫療，國內領先的康復醫院連鎖品牌**顧連醫療**；
- 推動居家醫療，構建高效居家養老服務體系的**易得康醫療**；
- 多元化保險產品，助力多層次醫療保障體系建設的**柏盛健康與柏泰保險**；
- 構建臨床研究能力，推動藥械創新與轉化的**新風新研**
- 以及科技賦能醫療，推動智慧化與個性化服務的**新風數位化基地**。





For a long time, the nation has encouraged Hong Kong to leverage the advantages of "one country, two systems," to be rooted in Hong Kong, connect with the world, and contribute to the nation and the Greater Bay Area with higher quality. Throughout its development, New Frontier has placed great emphasis on building a global network of medical resources. Currently, the Group has established partnerships with world-renowned medical centers such as the Hospital for Special Surgery in New York, The Hospital for Sick Children in Toronto, Canada, Hong Kong Sanatorium & Hospital, and Chinese University of Hong Kong Hospital. Additionally, the Group has forged strategic partnerships with Peking Union Medical College Hospital, Tsinghua University School of Medicine, and Capital Medical University and The Chinese University of Hong Kong - Shenzhen School of Medicine to jointly advance international medical research and educational development.

United Family Healthcare has established two hospitals in Shenzhen and Guangzhou, providing affordable, high-quality medical services to residents of mainland China and Hong Kong citizens traveling north. Recently, with the support of the Special Administrative Region government, Shenzhen New Frontier United Family Hospital has been approved to accept the Hong Kong Elderly Health Care Voucher, bringing benefits to more elderly people from Hong Kong.

Founded in 2016, New Frontier will celebrate its first decade next year. Looking back and forward, today New Frontier Group has established its presence in 92 cities across mainland China and Hong Kong, operating 11 JCI-accredited international general and specialty hospitals, 22 rehabilitation hospitals, 5 oncology treatment centers, more than 20 clinics and over 300 home healthcare stations. With over 12,000 full-time employees, the Group serves approximately 12 million patients annually.

Moving forward, we will focus on four strategic growth themes:

- **Technology-Driven and AI-Enabled Innovation**
- **Seamless Care Continuum**
- **Life Sciences Integration**
- **Greater Bay Area (GBA) Expansion**

These themes will synergize and integrate our ecosystem, solidifying New Frontier's leading position in the healthcare industry and driving innovation and transformation in Chinese healthcare services.

Breaking boundaries and innovating for the future! New Frontier will work with all of you, make a difference in this world by doing good by doing well, with love.

長期以來，國家一直寄語香港借助一國兩制的優勢，立足香港，聯通世界，更高品質地為祖國和大灣區貢獻建設。新風天域在發展過程中，非常重視搭建國內外醫療資源網路。目前，新風天域已和紐約特種外科醫院、加拿大多倫多大學兒童醫院、養和醫院、中文大學醫院等全球知名的醫學中心建立合作。集團並與協和醫院、清華大學醫學院、首都醫科大學及中文大學深圳醫學院等大學建立戰略夥伴關係，共同推動國際化的醫學研究及教育建設工作。

和睦家在深圳和廣州設立兩家醫院，為內地的居民和北上的香港市民，提供可負擔的高品質醫療服務。近期，在特區政府的支持下，深圳新風和睦家醫院獲批使用香港長者醫療券，造福更多香港長者。

新風天域成立於 2016 年，明年將迎來我們的第一個 10 年，回首與展望，今天，集團在中國內地及香港地區佈局 92 個城市，旗下有 11 家綜合及專科 JCI 認證國際醫院、22 家康復醫院、5 家綜合腫瘤中心、20 餘家診所和超過 300 個居家醫療護理站，每年服務約 1,200 萬名患者。

未來，我們將聚焦於四大戰略增長主題：

- **科技驅動與人工智慧賦能創新、**
- **無縫銜接的全程醫療體系、**
- **生命科學深度融合、**
- **大灣區 (GBA) 戰略拓展、**

這些主題將協同與整合我們的生態系統，並鞏固新風在醫療行業中的領先地位，為中國醫療服務創新變革。

突破界限，創新發展！新風天域集團將和大家，以愛之心，做好事情，以改變這個世界。





# Vision

## From the Frontier

---

Co-Founder and CEO, New Frontier Group  
新風天域集團 聯合創始人兼首席執行官

CEO, United Family Healthcare  
和睦家醫療 首席執行官

Carl Wu | 吳啟楠



---

Building a Healthcare and Life Sciences  
Ecosystem Driven by Technology and  
Empowered by Artificial Intelligence

建設以科技為驅動、以人工智慧賦能的  
醫療及生命科學生態系統



## Building a Healthcare and Life Sciences Ecosystem Driven by Technology and Empowered by Artificial Intelligence

Co-Founder and CEO,  
New Frontier Group

CEO, United Family Healthcare

**Carl Wu**

### The Changing Landscape of China's Healthcare Industry

China's demographics are facing rapid and unprecedented changes. According to data from the National Bureau of Statistics, by 2024, the population aged 60 and above has surpassed 300 million, accounting for 22%<sup>1</sup> of the total population. It is projected that the elderly population will surpass 400 million by 2035, making up more than 30% of the total population<sup>2</sup>.

This is the largest and fastest population aging in human history. China's economic development, social security, and healthcare systems will face immense pressure. This puts higher demands on all healthcare professionals and will also bring significant opportunities of paradigm and technology innovations in our industry.

### The overall demand for healthcare services is surging, and innovation of healthcare delivery model is imperative:

As our society accelerates into an aging demographic, the demand for healthcare services is showing a significant upward trend. According to statistics, more than 78% of elderly people suffer from one or more chronic diseases<sup>3</sup>, and their medical expenses are significantly higher than ones in younger age cohorts. This phenomenon not only highlights the challenge of meeting surging healthcare service demand but also brings unprecedented development opportunities to industry. How to promote the comprehensive upgrading of healthcare service models through building a multi-tiered healthcare system, how to apply technological innovations into real-world healthcare service delivery, how to further optimize the patient experience, and how to use medical resources more efficiently - these questions bring along vast market opportunities.



1. National Bureau of Statistics. "2024 Economic Operation Steady with Progress, Major Development Goals Successfully Achieved" [EB/OL]. (2025-01-17). [https://www.stats.gov.cn/sj/zxfb/202501/t20250117\\_1958332.html](https://www.stats.gov.cn/sj/zxfb/202501/t20250117_1958332.html).
2. National Health Commission. "Script of Press Conference of National Health Commission on 20 Sep 2022" [EB/OL]. (2022-09-20). <http://www.nhc.gov.cn/xcs/s3574/202209/ee4dc20368b440a49d270a228f5b0ac1.shtml>.
3. State Council. "Notice on Issuing the 14th Five-Year Plan for National Aging Development". (2022-02-21). [http://www.gov.cn/gongbao/content/2022/content\\_5692863.htm](http://www.gov.cn/gongbao/content/2022/content_5692863.htm).

## 建設以科技為驅動、 以人工智慧賦能 的醫療及生命科學 生態系統

新風天域集團  
聯合創始人兼首席執行官  
和陸家醫療首席執行官

吳啟楠

### 中國醫療產業面臨的變局

中國的人口結構正面臨前所未有的快速變化。國家統計局數據顯示，2024 年全國 60 歲及以上人口已經突破 3 億人，佔全國人口的 22%<sup>1</sup>；預計 2035 年左右，60 歲及以上老年人口將突破 4 億，在總人口中的佔比將超過 30%<sup>2</sup>。

這是人類歷史上規模最大和速度最快的人口老齡化。因此，國家的經濟發展、社會保障、醫療體系、科研創新將面臨巨大調整和機遇，給全體醫療行業從業者提出了更高的要求，也會為我們的行業帶來巨大的模式創新和技術創新的機會。

### 整體醫療服務需求激增，醫療服務交付模式創新勢在必行：

隨著老齡化社會的加速到來，整體醫療服務需求呈現顯著增長趨勢。據統計，78% 以上的老年人至少患有一種以上慢性病<sup>3</sup>，且老年人群的醫療費用支出顯著高於其他年齡段。這一現象不僅凸顯了醫療服務需求的緊迫性，也為行業帶來了前所未有的發展機遇。如何通過多層次診療系統的構建、技術創新的應用、患者體驗的優化以及醫療資源的高效利用，推動醫療服務模式的全面升級，這些問題中蘊藏著巨大的市場機遇。



1. 國家統計局，2024 年經濟運行穩中有進主要發展目標順利實現 [EB/OL]. (2025-01-17). [https://www.stats.gov.cn/sj/zxfb/202501/t20250117\\_1958332.html](https://www.stats.gov.cn/sj/zxfb/202501/t20250117_1958332.html).

2. 國家衛生健康委員會，國家衛生健康委員會 2022 年 9 月 20 日新聞發佈會文字實錄 [EB/OL]. (2022-09-20). <http://www.nhc.gov.cn/xcs/s3574/202209/ee4dc20368b440a49d270a228f5b0ac1.shtml>.

3. 國務院，衛生健康委 教育部 科技部 工業和資訊化部 財政部 人力資源社會保障部 住房城鄉建設部 退役軍人部 市場監管總局 廣電總局 體育總局 醫保局 銀保監會 中醫藥局 中國殘聯關於印“十四五”健康老齡化規劃的通知 [EB/OL]. (2022-02-21). [http://www.gov.cn/gongbao/content/2022/content\\_5692863.htm](http://www.gov.cn/gongbao/content/2022/content_5692863.htm).





### **Non-acute healthcare demand is rising, creating significant market opportunities:**


Another distinctive feature of an aging society is the sharp rise in demand for non-acute medical care, driven by the high prevalence of chronic diseases among the elderly, which often require long-term care and ongoing healthcare management. The traditional healthcare model focuses on acute care, but non-acute care—such as rehabilitation, nursing, and other services—plays an irreplaceable role in enhancing treatment outcomes, optimizing healthcare resource allocation, and reducing costs. At present, China faces a significant shortage of professional rehabilitation institutions, nursing resources, and related talent reserves, leading to restricted service capacity. The development of non-acute rehabilitation and long-term care systems is still at its early stage, with substantial space for future growth. Increasing investment in this area will not only meet the growing demand but also yield significant social and economic benefits.

### **Pressure on healthcare financing highlights broad scope for innovation in diversified payment systems:**

China's health insurance fund is the main source of payment for basic coverage, but the aging of the population continues to drive diversified and layered demand for medical services and medicines. This provides an important opportunity for innovation in the healthcare payment system, and there is an urgent need to meet these new needs through the construction of a diversified payment system. The health insurance industry is actively exploring and innovating a range of insurance products, such as the "Huiminbao" promoted by local governments in cooperation with insurance companies, narrow-network managed care products, direct-payment products for private healthcare organizations, and cross-border healthcare products, but the road to innovation and development has only just begun. The innovation of a diversified payment system will not only help ease the pressure on healthcare financing but will also provide patients with more flexible and diverse payment options.

### 非急性期醫療需求攀升，創造巨大市場機會：

老齡化社會的另一顯著特徵是非急性期醫療需求的急劇上升，原因在於老年人群體中慢性病高發，這些疾病往往需要長期護理和持續管理。傳統的醫療模式以急性期治療為核心，但非急性期醫療——包括康復、護理等服務——在提升治療效果、優化醫療資源配置以及降低醫療成本方面發揮著不可替代的作用。目前我國在專業康復機構、護理資源以及相關人才儲備方面仍存在明顯不足，服務供給能力有限，非急性期康復及長期護理體系的建設尚處於發展中階段，未來增長空間廣闊。加大在這一領域的投入，不僅能夠滿足日益增長的需求，還將帶來顯著的社會和經濟效益。



### 醫療資金壓力凸顯，多元化支付體系創新空間廣闊：

我國醫保基金是基礎保障的主要支付來源，但人口老齡化持續推動對醫療服務和藥品的多元化、分層次需求。這為醫療支付體系的創新提供了重要契機，亟需通過多元化支付體系的構建來滿足這些新的需求。健康保險行業正在積極探索和創新多種保險險種，例如地方政府與保險公司合作推廣的“惠民保”、窄網路管理式醫療產品、私立醫療機構直付產品、跨境醫療產品等，但是創新和發展的道路才剛剛開始。多元化支付體系的創新不僅有助於緩解醫療資金壓力，還將為患者提供更加靈活和多樣化的支付選擇。

**Technology and artificial intelligence are changing healthcare's landscape, while life sciences are deeply integrating with healthcare service industry:**

With the rapid advancements in artificial intelligence technology, the growing demand for healthcare services presents vast opportunities for artificial intelligence applications in healthcare sector. Through disruptive innovations, artificial intelligence can optimize the allocation of healthcare resources, enhance the efficiency of healthcare systems, and deliver more personalized and precise care to patients. This not only upgrades existing healthcare models but also redefines the future of healthcare services. At the same time, improving the quality of healthcare also depends on ongoing research and development of novel drugs and advanced medical devices. The real-world data generated from healthcare service delivery continually provides inspiration and momentum for clinical trials, as well as the development of novel drugs and devices. Breakthroughs in life sciences have introduced cutting-edge therapies and medical technologies that not only enhance patient care but also broaden the range of treatment options available. At the frontier of healthcare industry, achieving the deep integration of life sciences and healthcare services represents both a challenge to the innovation capabilities and an opportunity of all the industry players to drive the healthcare industry moving forward.

New Frontier Group was set up to meet those challenges and capture those opportunities.

New Frontier Group is a healthcare and life sciences group headquartered in Hong Kong. Since its establishment in 2016, it has rapidly grown into one of the leading integrated private healthcare groups in mainland China and Hong Kong. Adhering to the "patient-centered" philosophy, the Group strives to creating an integrated ecosystem that transforms the way people access healthcare services, supports breakthrough medical innovations, and creates lasting value for patients, healthcare providers, and communities.

New Frontier Group's businesses include United Family Healthcare, a comprehensive primary to tertiary healthcare service provider; Care Alliance, a rehabilitation healthcare service provider; YD Care, a home healthcare service provider; Prosper, a health insurance services provider; Better Insurance Brokerage, a health insurance brokerage; New Frontier Nova, a clinical research centre; New Frontier Digital Home; and United Family Healthcare International Medical Services.

New Frontier Group has established its presence in 92 cities across mainland China and Hong Kong, operating 11 JCI-accredited international general and specialty hospitals, 22 rehabilitation hospitals, 5 oncology treatment centers, more than 20 clinics and over 300 home healthcare stations. With over 12,000 full-time employees, the Group serves approximately 12 million patients annually.





**科技驅動與人工智慧賦能，醫療與生命科學深度融合：**

在人工智慧技術迅猛發展的背景下，醫療服務需求的增長為人工智慧在醫療領域的應用提供了廣闊前景。通過顛覆性的技術革新，人工智慧能夠優化醫療資源配置，提升醫療系統的工作效率，併為患者提供更加個人化和精準的醫療服務。這不僅是對現有醫療模式的升級，更是對未來醫療服務的重新定義。與此同時，醫療服務品質的提升還依賴於創新藥物和先進醫療設備的持續研發。醫療服務中產生的真實世界數據為臨床實驗研究和創新藥械研發提供了源源不斷的靈感和動力。生命科學的發展帶來了尖端療法和醫療技術，不僅提升了患者的治療品質，還擴大了治療選擇的多樣性。在產業層面，實現生命科學與醫療服務的深度融合，既是對企業創新能力的挑戰，也是推動醫療行業整體進步的機遇。

在這樣的大背景下，新風天域集團應時而生。

新風天域集團是一家總部位於中國香港的醫療和生命科學集團，自 2016 年創立以來，已迅速成長為中國內地和香港地區領先的一體化私立醫療集團之一。集團秉承「患者為中心」的理念，致力於打造一個整合型生態系統，變革人們獲取醫療服務的方式，支持開創性的醫療創新，併為患者、醫護人員以及社區創造持久價值。旗下業務涵蓋綜合國際醫療集團和睦家醫療、康復醫療集團顧連醫療、居家醫療集團易得康醫療、健康保險服務提供者柏盛健康、健康保險經紀公司柏泰保險經紀、臨床研究中心新風新研、新風數位化居家服務及和睦家跨境醫療服務等。

集團在中國內地及香港地區佈局 92 個城市，旗下有 11 家綜合及專科 JCI 認證國際醫院、22 家康復醫院、5 家綜合腫瘤中心、20 餘家診所和超過 300 個居家醫療護理站，每年服務約 1,200 萬名患者。



## Where We Are Today

### **United Family Healthcare: Providing high-quality acute care services through general and specialty hospitals**

Founded in 1997, United Family Healthcare is a long-established and nationally recognized healthcare brand. United Family Healthcare boasts an international team of experts and a diverse patient base, with over 800 full-time physicians and healthcare professionals from more than 30 countries, serving international patients from 180 countries. It has become a symbol of China's healthcare service internationally. To date, United Family Healthcare is the only international medical brand with full coverage in all first-tier cities, including Beijing, Shanghai, Guangzhou, Shenzhen, and Hong Kong. The Group operates 11 hospitals, 5 cancer centres and a national clinics network. The group owns HEAL Medical, HEAL Oncology, HEAL Fertility and Hong Kong Integrated Oncology Centre. It provides international healthcare services to patients from more than 200 countries and regions every year. It has established a tiered healthcare service system of "general hospitals + specialty hospitals + clinics".

United Family Healthcare adopts an area-specific, multi-tiered approach tailored to the unique needs of each region: In the Beijing-Tianjin Area, leveraging the existing five international hospitals and the soon-to-be-launched Beijing United Family International Hospital (BJU 2.0), the group adopts a stratified service model to expand its patient base.

In the Shanghai Area, the focus is on enhancing medical and operational capabilities to ensure sustainable development and differentiated competition. Advanced technologies, such as the Da Vinci surgical robot systems are adopted, and oncology is positioned as a leading specialty to lay the foundation for the development of other high acuity specialties. In the Greater Bay Area, the strategic emphasis is to leverage the group's GBA Healthcare Platform to promote cross-border integration between Hong Kong, Shenzhen and Guangzhou.

In 2024, United Family Healthcare (including Heal and HKIOC in Hong Kong) served over 1 million patients, with approximately 20,000 inpatient volume and nearly 10,000 surgeries, nearly half of which were classified as Level 3 or above. The total number of surgeries has increased by 49%, and the number of Level 3 and 4 surgeries has grown by 55%. Throughout the year, we provided medical coverage for nearly 30 major national events, state-level conferences and exhibitions. In 2024, two newest model da Vinci surgical systems were installed at UFH and the volume of da Vinci robotic surgeries exceeded 1,000, leading among private hospitals in China.



## 新風天域現階段 業務發展情況

**和睦家醫療：**  
通過綜合醫院和專科醫院網路，  
提供卓越品質的醫療服務

新風天域旗下的和睦家醫療成立於 1997 年，是歷史悠久且全國知名的高端醫療服務品牌。和睦家醫療擁有國際化的專家團隊及患者構成，全職醫生超過 800 位，醫護團隊來自超過 30 個國家，在中國服務來自 180 個國家的國際患者，成為了中國醫療服務對外交流的一張名片。時至今日，和睦家醫療集團作為唯一一家北上廣深港一線城市全覆蓋的國際醫療品牌，全國佈局共 11 家醫院、5 家腫瘤治療中心以及覆蓋全國的診所網路；集團在香港運營希愈醫療中心、希愈腫瘤中心、希愈生殖醫學中心及香港綜合腫瘤中心的業務；每年為來自 200 多個國家和地區的病人提供超國際化醫療服務，形成了“綜合醫院 + 專科醫院 + 診所”的分級醫療服務系統。

和睦家醫療根據各個大區市場因地制宜，精準契合各市場的獨特需求進行多層次佈局：在和睦家京津區，依託現有 5 家國際醫院和即將面世的北京和睦家國際醫院 (BJU2.0)，採用分層服務模式，擴大患者群體；在上海區，提升醫療和運營能力，確保可持續發展和差異化競爭，藉助達芬奇手術機器人平臺等先進技術，將腫瘤科作為先進專科發展，為其他專科的拓展奠定基礎；在大灣區，依託集團大灣區醫療平臺，促進香港、深圳和廣州的跨境融合。在 2024 年，和睦家醫療（包含香港希愈與香港綜合腫瘤中心）共服務患者超過 100 萬人次，住院量約 2 萬，全年手術近 10,000 台，近一半為 3 級以上手術，（總手術量增長 49%，三四級手術量增長 55%）。全年為近 30 場全國重大賽事、國家級會議和展會提供醫療保障。2024 年，兩台最新型號的達芬奇手術機器人系統落地和睦家，達芬奇機器人手術量也突破了 1,000 台，位居全國私立醫院前列。



**GBA Healthcare Platform:  
Anchored in Shenzhen, Guangzhou and Hong  
Kong, Exploring healthcare integration in the  
Greater Bay Area**

New Frontier Group is the only healthcare group that has completed an integrated private healthcare layout in Hong Kong and Mainland China, facilitating healthcare integration across the Greater Bay Area. With Shenzhen, Guangzhou and Hong Kong as its strategic anchors, the Greater Bay Area healthcare platform has established a close connection within one of the most dynamic markets in China.

Since its inception, the development of the platform has made significant progress. In 2024, the newly opened New Frontier Shenzhen United Family Hospital provided over 50,000 outpatient visits (63% growth from 2023), including more than 8,500 visits for over 4,000 patients from Hong Kong, with surgical services increasing sixfold and inpatient services nearly tripled compared to 2023.

Guangzhou and Shenzhen United Family Hospitals have also established cross-border referral services with Heal and HKIOC, strengthening bidirectional medical collaboration between Shenzhen, Guangzhou and Hong Kong. Through the Hong Kong-Macau drug and medical device policy, we have introduced over 16 innovative drugs and medical devices to mainland China, benefiting more than 1,600 patients. New Frontier Shenzhen United Family Hospital has also been enrolled in the Hong Kong SAR government's "Elderly Health Care Voucher Greater Bay Area Pilot Scheme".



**大灣區醫療平臺：  
以深圳、廣州、香港為支點，探索大灣區醫療融合**

新風天域集團是唯一在香港與內地完成整合性私立醫療佈局的醫療集團，為整個大灣區的醫療融合架起橋樑。以深圳和香港為戰略支點，大灣區醫療平臺使我們與國內最具活力的市場之一實現了緊密連接。

自成立以來，大灣區醫療平臺的發展突飛猛進。2024年，新開業的深圳和睦家醫院提供超過 50,000 次門診（較 23 年增長 63%），其中為超過 4,000 位香港患者提供超過 8,500 次門診；手術服務量較 2023 年增長超過 6 倍，住院服務量增長近 3 倍。

廣州、深圳和睦家醫院，也實現與希愈醫療中心，希愈腫瘤中心和香港綜合腫瘤中心的跨境轉診服務，加強深圳、廣州、香港間醫療聯動，服務灣區居民。利用港澳藥械通政策，我們將創新藥械引入大陸，共落地超過 16 種創新藥品，惠及超 1,600 名患者。深圳和睦家還憑藉著優質的醫療和服務品質，成為特區政府「長者醫療券大灣區試點計劃」的落地機構。





### **Care Alliance: Developing Non-Acute Healthcare and Building a Leading Rehabilitation Healthcare Brand in China**

Currently, there are over 190 million elderly individuals<sup>4</sup> with chronic diseases and more than 85 million people with disabilities<sup>5</sup> in China, with the demand for rehabilitation healthcare services for these groups continuously increasing. However, China's healthcare expenditures are primarily focused on acute care treatment, while rehabilitation healthcare, a critical part of non-acute healthcare, has yet to receive adequate attention. According to the China Health Statistics Yearbook, in 2021, the number of rehabilitation beds in China was only 327,000<sup>6</sup>, far from meeting the national demand for rehabilitation healthcare services.

Care Alliance, a subsidiary of New Frontier Group, is a leading player in rehabilitation healthcare sector in China. It currently operates 27 rehabilitation facilities nationwide, covering over 10 subspecialties such as neurology rehabilitation and orthopedics rehabilitation, with nearly 8,000 beds in operation or under construction. Its scalable hospital expansion model has been market-tested and lays a solid foundation for expanding its business nationwide. According to the July 2024 rankings of private rehabilitation hospitals in China by Ailibi, 9 of New Frontier's rehabilitation hospitals were enlisted the top 50 private rehabilitation hospitals, further consolidating our leadership position in the industry.

**Innovative Regional Expansion:** Continuously building rehabilitation medical centers in Southwest, East, and Central China to bring new development momentum to regional rehabilitation services.

**Innovative Rehabilitation Concepts:** Promoting comprehensive coverage of ten subspecialties and interdisciplinary clinical team building; enhancing talent development through platforms such as Care Alliance Academy; building Care Alliance Research Institute to focus on key specialty development and hospital classification assessments, producing numerous academic achievements; establishing the Care Alliance Quality and Safety Committee to minimize medical incidents; and setting pilot hospitals for payment-by-value healthcare reimbursement under medical insurance reform.

**Innovative Medical Services:** Care Alliance focuses on a patient-centered and function-oriented approach to medical service departments, successfully advancing the development of specialties such as Hyperbaric Oxygen Rehabilitation Unit (HORU), Integration of Clinical Care and Rehabilitation, and Alzheimer's Disease Treatment Center. It also promotes the integration of medical education and research, bringing in high-quality medical resources.

4. National Health Commission. "Report of the State Council on Strengthening and Advancing the Progress of Aging-Related Work" [EB/OL]. (2022-09-03). <http://www.nhc.gov.cn/wjw/mtbd/202209/2ca97b572ee34a38819ccea5207dd1a.shtml>.

5. State Council. "Notice of the State Council on Issuing the 14th Five-Year Plan for the Protection and Development of Persons with Disabilities" [EB/OL]. (2021-07-21). [https://www.mee.gov.cn/zcwj/gwywj/202107/t20210721\\_849487.shtml](https://www.mee.gov.cn/zcwj/gwywj/202107/t20210721_849487.shtml).

6. National Health Commission Statistical Information Center. "2022 China Health and Wellness Statistical Yearbook" [EB/OL]. (2023-05-17). <http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb/files/b05b3d958fc546d98261d165cea4adba.pdf>.

**顧連醫療：**  
**發展非急性期醫療，**  
**打造國內領先的康復醫院連鎖品牌**

目前，我國患有慢性病老年人超過 1.9 億<sup>4</sup>，有 8,500 多萬殘疾人<sup>5</sup>，面向老年人和殘疾人群體的康復醫療需求不斷增加。中國的醫療支出主要集中在急性期治療上，而康復醫療作為非急性期的重要環節，尚未引起足夠重視。據衛生統計年鑒數據，2021 年我國康復醫學科床位數僅為 32.7 萬張<sup>6</sup>，遠遠不能滿足全社會對康復服務的需求。

新風天域集團旗下顧連醫療是中國康復醫療領域的領軍企業，現已在全國設立 27 家康復機構，覆蓋神經康復、骨科康復等 10 多個亞專科，運營及在建中床位近 8,000 張，可複製醫院擴張模式通過市場檢驗，為全國範圍拓展業務打下了堅實基礎。根據 2024 年 7 月發佈的艾力比中國私立康復醫院排名，新風天域集團有 9 家醫院成功躋身中國前 50 家私立康復醫院，進一步鞏固了其行業領導地位。

**地域佈局創新：**持續建設西南、華東、華中三大區域康復醫療中心，為區域康復醫療服務帶來新的發展動力。

**康復理念創新：**推進十大亞專科全面覆蓋和跨學科臨床團隊建設；通過顧連學院等平臺促進人才梯隊建設；辦好顧連研究院，著力建設旗下醫院的重點專科以及醫院等級評審，產出多項學術成果；設立顧連醫療品質與安全委員會，減少安全事件；順應醫保改革趨勢，按價值付費醫保支付方式改革示範醫療機構。

**醫療服務創新：**顧連堅持以患者為中心，以功能為導向建設醫療服務科室，成功推進了包括高壓氧康復科室、臨床康復一體化、阿爾茨海默症診療中心等多項學科建設專案，推動醫教研建設，引進優質醫療資源。



4. 國家衛生健康委員會。國務院關於加強和推進老齡工作進展情況的報告 [EB/OL]. (2022-09-03). <http://www.nhc.gov.cn/wjw/mtbd/202209/2ca97b572ee34a38819cceaaf5207dd1a.shtml>.

5. 國務院。國務院關於印發“十四五”殘疾人保障和發展規劃的通知 [EB/OL]. (2021-07-21). [https://www.mee.gov.cn/zcwj/gwywj/202107/t20210721\\_849487.shtml](https://www.mee.gov.cn/zcwj/gwywj/202107/t20210721_849487.shtml).

6. 國家衛生健康委員會統計資訊中心。2022 年中國衛生健康統計年鑒 [EB/OL]. (2023-05-17). <http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb.shtml>.

### **YD Care: Promoting Home Healthcare and Building an Efficient Home Elderly Care Service System**

In recent years, the number of people in China with full or partial loss of functional ability has reached 46.54 million<sup>7</sup>, creating an urgent demand for high quality long-term care services. The Long-Term Care Insurance (LTCI) policy is an important social insurance scheme in China to improve the welfare of the aging population, and since inception of the program, it has made remarkable progress. During the eight years of the pilot program, 180 million people have been covered under this program, and over 2.6 million disabled population received benefits<sup>8</sup>. Studies show that for every RMB 1 yuan invested in home health or home care services, about RMB 8.6 yuan of medical insurance funds is saved, which helped realize optimal allocation of medical insurance resources<sup>9</sup>. Further, discharged hospital patients receiving home health services saw approximately 60% reduction in hospital readmissions<sup>10</sup>.

YD Care, a subsidiary of New Frontier Group, is a leading player in the home healthcare sector in China, operating across 33 cities and serving 70,000 people nationwide.

**Long Term Care Insurance Services:** Expanding the service scope and entering new markets, with plans for nationwide coverage by 2029.

**New Business Model Development:** Providing "Cradle-to-rocking-chair" services, including maternity and elderly care, and establishing caregiver training schools to cultivate high-quality home healthcare talents.

**Innovative Payment Service:** Collaborating with insurance companies to offer diversified payment options, including private payments and commercial insurance, further expanding service coverage and providing customers with more flexible payment choices.

**Home Medical Services:** In line with the international trend of Hospital-at-Home, the hospital continues to expand its home-based medical and nursing services. It is developing multi-tiered, refined, and personalized care plans to provide post-surgery rehabilitation, wound care, and other services for long-term care insurance users and discharged hospital patients.

7. Wuhan University. "Tracking Elderly Health Trends: Launch of the 'China Elderly Health Report'" [EB/OL]. (2024-08-19). <http://www.whudfr.com/newsinfo.aspx?NewsId=1497&CatId=9>.

8. National Medical Insurance Administration. "National Healthcare Security Administration Holds Press Conference on 'Safeguard-ing People's Health and Empowering Economic Development'" [EB/OL]. (2025-01-17). [https://www.nhsa.gov.cn/art/2025/1/17/art\\_14\\_15491.html](https://www.nhsa.gov.cn/art/2025/1/17/art_14_15491.html)

9. Wang Zhen, Feng Jin. "The Substitution Effect of Long-Term Care Insurance on Medical Expenses and Comparison of Different Compensation Models" [EB/OL]. Fudan University School of Economics, 2021-03. <https://nsd.pku.edu.cn/docs/20210503141558821227.pdf>.

10. Amedisys. Reducing Hospital Readmissions with Home Health Care [EB/OL]. <https://resources.amedisys.com/reducing-hospital-readmissions-with-home-health-care>



**易得康醫療：  
推動居家醫療，  
構建高效居家養老服務體系**

近年來，我國失能和部分失能人口達到 4,654 萬人<sup>7</sup>，所帶來的失能護理需求亟待滿足。長期護理保險（長護險）政策是我國應對人口老齡化、提升老年人群體護理水準的重要社會保障舉措。自 2016 年以來，我國在多個城市進行長期護理保險制度試點，取得顯著成效，試點 8 年來覆蓋 1.8 億人，累計 260 餘萬失能參保人享受待遇<sup>8</sup>。研究表明，居家醫療每投入 1 元錢，將節約醫保基金約 8.6 元，促進了醫保基金的優化配置<sup>9</sup>。另外，研究顯示，出院后接受居家護理服務的患者，再入院的風險降低了約 60%<sup>10</sup>。


新風天域集團旗下的易得康醫療是中國居家醫療領域的領軍企業，業務佈局全國 33 個城市，服務中人數達到 7 萬人。

**長護險居家照護業務：**不斷擴大服務範圍，進入各地市場，計劃到 2029 年實現全國範圍內的全面覆蓋。

**拓展新業務模式：**提供「從搖籃到搖椅」的母嬰護理和養老護理服務；開設護工培訓學校，培養高素質的護理人才。

**創新支付業務：**通過與保險公司合作，推出多樣化支付方式，包括私人支付、商業保險等，進一步拓寬了服務覆蓋面，助力客戶獲得更靈活的支付選擇。

**居家醫療服務：**順應國際 Hospital-at-Home 的發展趨勢，持續豐富以居家為場景的醫療與護理業務，發展多層次、精細化、個人化的照護方案，為長護險使用者及醫院出院客戶提供居家術后康復、傷口護理等服務。



7. 武漢大學. 追蹤老年健康趨勢：“中國老年健康報告”發佈會舉行 [EB/OL]. (2024-08-19). <http://www.whudfr.com/newsinfo.aspx?NewsId=1497&CatId=9>.

8. 國家醫療保障局. 國家醫保局召開“保障人民健康 賦能經濟發展”新聞發佈會 [EB/OL]. (2025-01-17). [https://www.nhsa.gov.cn/art/2025/1/17/art\\_14\\_15491.html](https://www.nhsa.gov.cn/art/2025/1/17/art_14_15491.html)

9. 王貞, 封進. 長期護理保險對醫療費用的替代效應及不同補償模式的比較 [J]. 經濟學 (季刊), 2021, 20 (2) : 557-576.

10. Amedisys. Reducing Hospital Readmissions with Home Health Care [EB/OL]. <https://resources.amedisys.com/reducing-hospital-readmissions-with-home-health-care>

### **Health Insurance: Diversified Insurance Products to Support the Construction of a Multi-Tiered Healthcare System**

In the context of the national initiative focused on the development of a multi-tiered healthcare system, commercial health insurance, with its diverse product offerings, is set to become a crucial complement to healthcare service payor system.

New Frontier Group's subsidiaries, Prosper and Better Insurance Brokerage are leading innovations in the healthcare insurance sector. Collaborating closely with China's leading insurance companies, public and private healthcare institutions, and pharmaceutical partners provides customized health management services and insurance solutions to top-tier insurance companies, large state-owned enterprises, leading foreign enterprises, and local governments. Since its inception, New Frontier's health insurance network has expanded to cover 296 cities and over 2,800 institutions. It has also established direct case-referral and appointment systems with key hospitals, significantly enhancing service convenience.

New Frontier Health Insurance has creatively launched the artificial intelligence "Care Copilot" to reconstruct the PCM service process, empowering customers with the whole process of consultation through the private health management team throughout pre-, mid-, and post-diagnosis, and utilizing advanced artificial intelligence and data mining technology to establish health profiles for customers. It also utilizes advanced artificial intelligence and data mining technologies to provide 24/7 family doctor services and establish inter-hospital medical records files for customers and significantly improves service efficiency by more than two times through functions such as pre-diagnosis advice, quick benefit check and flash claim.





**健康保險：  
多元化保險產品，  
助力多層次醫療保障體系建設**

在國家推動多層次醫療保障體系建設的大背景下，商業健康保險憑藉其多元化的產品供給將成為醫療服務支付工具的有力補充。

新風天域集團旗下的柏盛健康與柏泰保險經紀正引領醫療支付領域的創新。我們與中國領先的保險公司、公私立醫療機構和藥企夥伴緊密合作，為頭部保險公司、大型國央企、領先外企民企以及地方政府提供定製化的健康管理服務及保險解決方案。成立以來，新風健康險服務國內醫療網路已經覆蓋了 296 個城市以及超過 2,800 家機構，並與核心醫院打通病例、預約直連系統，大幅提升服務便捷度。

在產品方面，新風健康險服務創造性地推出了人工智慧「Care Copilot」重構 PCM 服務流程，通過私人健康管理團隊貫穿就診前、中、后三個階段賦能客戶就診全流程，並利用先進的人工智慧和數據挖掘技術，為客戶提供 24x7 家庭醫生服務和建立跨院區病例檔案，通過預診建議、福利快查與閃賠等技術顯著提升 2 倍以上服務效率。



### **New Frontier Nova: Building Clinical Research Capabilities to Promote Drug and Medical Device Innovation and Transformation**

Progress in drug and medical device innovation relies on robust clinical research. Efficient teams, advanced facilities, and quality data accelerate R&D, yet fragmented data, standardization gaps, and limited collaboration hinder outcomes.

New Frontier Group launched its Clinical Research Organization (CRO), New Frontier Nova, leveraging its network and global partnerships to integrate data, accelerate trials, and boost recruitment. Adopting decentralized trials (DCT), Nova reduces participation barriers, enhances data diversity, and employs AI analytics to streamline processes. It strengthens research capabilities through GCP certification, training, and trial centres, driving faster innovation in therapies and devices.

Under its 2023 AI strategy, New Frontier achieved key 2024 milestones: its Chinese-English model tripled accuracy, handling 1.3 million calls; the Intelligent Doctor Workstation boosted record retrieval by 400%; and the Patient Mini Program delivered 500,000 appointments. A new SCRM cut wait times by 70%, while innovations like Flash Claims, Care Copilot, and AI recovery plans debuted. Enhanced AI infrastructure, including model evaluation and multi-agent systems, enables scalable applications.

By merging clinical excellence with AI agility, New Frontier Nova redefines medical innovation and care.



**新風新研：  
構建臨床研究能力，  
推動藥械創新與轉化**

藥物和醫療器械的創新進展需要依賴強大的臨床研究能力。高效的研發團隊、完善的設施及高質量的數據資源是加速研發和創新落地的關鍵。然而，數據碎片化和標準化不足限制了分析和轉化能力，且國內與國際機構間的協作不足，進一步阻礙了創新的快速推進。

新風天域集團近期開設了旗下的臨床研究組織業務新風新研。新風新研依託集團廣泛的醫療網路和全球合作資源，整合豐富的患者數據，加速患者招募和試驗進展。通過引入去中心化臨床試驗 (DCT)，新風新研降低患者參與試驗的門檻，提升患者招募效率和數據多樣性，同時利用實時數據和人工智慧技術優化試驗流程。新風新研還通過 GCP 認證、人員培訓和試驗中心建設，全面提升新風天域旗下機構的臨床研究能力，助力新藥和醫療器械的快速研發和轉化。

2023 年，新風天域提出積極擁抱人工智慧的發展策略。2024 年，這一戰略取得了顯著成果：在模型研發上，我們自主研發的中英翻譯大模型將準確率提升三倍，累計調用達 130 萬次。醫生智慧工作台讓病歷檢索效率提升了 400%。我們不斷優化和睦家患者小程序的用戶體驗，累計為客戶提供了 50 萬次預約服務；通過新的 SCRM 系統，使回復時長縮短了 70%。集團了發佈第一代多智慧體框架，並再次之上推出閃賠、Care Copilot、人工智慧自動生成康復計劃書等創新功能。同時我們加大人工智慧應用開發基礎設施投入，包括模型評估機制、預訓練平臺、多智慧體系統、知識檢索增強技術和提示詞範本庫，為多場景應用奠定基礎。





## Our Path Forward

Looking ahead, New Frontier's vision is to become a "technology-driven, artificial intelligence-empowered healthcare and life sciences company." This vision underscores our strong belief in the transformative power of technology and our unwavering commitment to advancing healthcare and fostering innovation across the ecosystem.

To realize this vision, we have identified four cross-cutting growth themes that will drive success across all business units. These themes will synergize, integrate our ecosystem, and reinforce our leadership position in the private healthcare services industry.

### Seamless Care Continuum

**1+X Regional Strategy:** Utilizing the "1+X" model, we are methodically enhancing our medical footprint in key cities to forge a comprehensive, integrated medical service network. Our focus extends beyond the functional upgrade of core hospitals to the integration of regional resources, aiming to construct an efficient and collaborative medical ecosystem that addresses the full spectrum of patients' needs. Within our 1+X three-dimensional medical system structure, we have established a comprehensive medical service network that includes tertiary general hospitals, specialized hospitals (such as oncology hospitals, women and children's hospitals, rehabilitation hospitals, and cardiovascular centers), primary care and clinic networks, home medical services, 24/7 online remote services, and health insurance services, providing a full range of seamless medical services.

**Fully Integrated Patient Service Pathway:** We will integrate insurance, acute care, rehabilitation, home healthcare, and health insurance services to create a seamless patient journey. The transitions between various medical stages are not only more efficient but also achieve better clinical outcomes and service experiences, providing patients with truly coherent, high-quality medical services.

**Optimizing Personal Case Management Service System:** Care transition management is not only the continuation of nursing services but also ensures a smooth connection for patients between different business units, such as hospitalization, rehabilitation, and home care. By expanding the Personal Case Management (PCM) service, we offer patients comprehensive guidance, reduce readmission rates, and ensure full health management from the acute phase to the rehabilitation phase.

## 未來發展路徑

展望未來，新風天域的願景是成為一家「以科技為驅動、以人工智慧賦能的醫療及生命科學公司」。這一願景彰顯了我們對科技變革力量的堅定信念，以及我們致力於推動整個生態系統中醫療和創新發展的不懈決心。

為了實現這一願景，我們確定了四大跨領域增長主題，推動所有營業單位邁向成功。這些主題將協同與整合我們的生態系統，並鞏固我們在私立醫療服務行業中的領先地位。

### 無縫銜接的全程醫療體系

**1+X 樞紐城市深化佈局：**通過“1+X”模式，紮實推進重點城市的醫療佈局，打造全鏈條、一體化醫療服務網路。我們不僅關注核心醫院的功能升級，更專注於整合區域資源，構建高效協同的醫療生態系統，以滿足患者的全方位需求。在我們的1+X的立體型醫療系統構造內建立三級綜合醫院、專科醫院（包括腫瘤醫院、婦兒醫院、康復醫院、心血管中心）、初級診療和診所網路、居家醫療、線上24x7遠端服務、健康保險服務的全方位、無縫銜接的醫療服務。

**全程一體化患者服務路徑：**我們將整合保險、急性期醫療、康復及居家醫療和健康險服務，構建無縫連接的患者旅程。患者在各個醫療環節之間的轉移不僅更高效，而且可以實現更優的臨床效果與服務體驗，為患者提供真正連貫的高品質醫療服務。

**優化個人病例管理服務體系：**護理過渡管理不僅是護理服務的延續，更是患者在不同業務單元（如住院、康復、居家護理）之間的順暢銜接。我們將擴大私人健康管理（PCM）服務，為患者提供全面指導，降低再入院率，確保患者從急性期到康復期的全程健康管理。





### **Technology-Driven and AI-Empowered Innovation**

**Constructing Digital Hospitals:** Within clinical and institutional settings, we empower doctors, nurses, and administrators with artificial intelligence and advanced technologies to construct a more intelligent hospital ecosystem. Artificial intelligence technology will be more widely applied in areas such as disease prediction and diagnosis, personalized treatment plan design, pathology writing, and quality supervision, significantly enhancing our clinical efficiency and management level. At the same time, by optimizing the patient journey through intelligent navigation systems, we reduce waiting times and improve the medical service experience. The digital hospital also empowers clinical collaboration across multiple hospitals and departments. Functions such as global literature and data retrieval will play an important role, helping medical staff quickly obtain the latest research results and apply them to clinical practice, ensuring that medical plans and technologies always remain at the forefront internationally. As the core hub of medical services, the digital hospital effectively promotes seamless integration of in-hospital and out-of-hospital services, providing patients with comprehensive and high-quality medical experience.

**Expanding Digital Home Healthcare Services:** Digital Home is a business model that integrates AI with offline service capabilities, based on smart software and hardware, to offer patients personalized health management. This service not only enables real-time health monitoring, remote diagnosis, and virtual nursing but also leverages data-driven approaches to improve patients' health conditions and alleviate the resource pressure on medical institutions.



### 科技驅動與人工智慧賦能創新

**打造數位化醫院 (Digital Hospital):** 在臨床和機構內，通過人工智慧和先進科技賦能醫生、護士和管理人員，構建更加智慧化的醫院生態。人工智慧技術將被更廣泛應用於疾病預測診斷、個人化治療方案設計、病歷書寫和品質監管等領域，顯著提升我們的臨床效率與管理水準。與此同時，通過患者智慧導航系統優化患者就醫流程，減少等待時間，提升醫療服務體驗。數字化醫院還賦能多院區，多科室的臨床協作。全球文獻和數據檢索等功能也將發揮重要作用，說明醫護人員快速獲取最新科研成果並應用於臨床實踐，確保醫療方案 and 技術始終保持在國際前沿。作為醫療服務的核心樞紐，數位化醫院有效推動了院內外服務的無縫銜接，為患者提供全方位高品質的醫療體驗。

**拓展數位化居家醫療服務 (Digital Home):** 數位化居家醫療將是集團未來投入的智慧院外醫療的業務模式，通過整合人工智慧與線下服務能力，為患者提供個人化居家護理，健康管理和慢性病管理。這一服務不僅能實現即時健康監測、遠端診療和護理管理，還能通過數據驅動的方式監控患者健康情況。通過整合醫院與居家醫療的數據資源，實現服務的最優配置，為患者提供更高效率的醫療服務，同時緩解醫療機構的資源壓力。







### Life Sciences Integration

#### **Strengthening Clinical Trial Participation and Organizational Capabilities:**

Not only does New Frontier Nova CRO focus on clinical trials, but we also actively collaborate with global biotech and pharmaceutical companies to establish United Family Healthcare and Care Alliance hospitals as platforms for the development of innovative therapies and new technologies. Through these collaborations, our research capabilities are further expanded to include more complex trial design and execution.

#### **Accelerating Real-World Data-Driven Healthcare Innovation:**

Not only does United Family Healthcare have an abundance of real-world data, but so do Care Alliance and YD Care, which possess powerful data resources. By integrating this data, we can accelerate the introduction of innovative therapies, optimize treatment options, and expand the healthcare choices available to patients, setting new benchmarks for the industry.

### Greater Bay Area (GBA) Strategic Expansion

**Comprehensive Healthcare Network:** Develop a comprehensive healthcare ecosystem in the GBA, one of the most economic developed and technologically vibrant regions in the world with the special "one country two system" structure that links a large integrated domestic market and global connectivity. We hope to bring our acute care, insurance, clinical trials and digital health services to meet the region's growing demand for high-quality healthcare services.

**Capture Regional Growth Opportunities:** We will seize the opportunity of the rapid development of the Greater Bay Area to coordinately expand our operations in Shenzhen, Guangzhou and Hong Kong. We will leverage Hong Kong's resources in novel drugs and innovative devices, world-standard diagnostic and treatment services, and international clinical and scientific research talent pool, and at the same time, Mainland China's large-scale, cost-efficient innovation pool, to provide world-class healthcare services to patients from GBA, China, Asia and beyond, and facilitate the prosperous development of healthcare market in Hong Kong and the Greater Bay Area.



### 前沿生命科學深度融合

**強化臨床試驗參與與組織能力：**新風新研 CRO 不僅專注於臨床試驗，還積極與全球生物技術與製藥公司合作，將和睦家及顧連旗下的醫院打造成創新療法和新技術開發的平臺。通過合作，我們的研究能力將進一步擴展到更複雜的試驗設計和實施中。

**加速真實世界數據驅動的醫療創新：**不僅和睦家擁有豐富的真實世界數據，顧連醫療和易得康同樣具備強大的數據資源。通過整合這些數據，我們能夠加速創新療法的引入，優化治療方案，擴大患者可及的醫療選擇，為行業發展樹立新標杆。

### 大灣區 (GBA) 戰略拓展

**綜合醫療網路擴展：**我們將利用一國兩制的優勢，在全球經濟及技術發展最為活躍的粵港澳大灣區發展全方位醫療健康服務生態系統，鏈接國內和國際市場，使我們的服務覆蓋到急性期醫療、保險、臨床試驗和數位健康服務等領域，促進大灣區醫療融合，滿足該地區對高品質醫療服務日益增長的需求。

**把握區域增長機遇：**我們將抓住大灣區迅猛發展的機遇，在香港、深圳和廣州協同運營，利用香港創新原研藥械、國際化診療服務、國際化臨床和科研人才儲備優勢和中國大陸龐大的創新、成本和經驗優勢，為大灣區乃至中國和亞洲的患者提供國際一流的醫療服務，促進香港和大灣區醫療創新和市場繁榮發展。



The future of healthcare in China is about to be revolutionized. In the coming years, a lung cancer patient will be able to undergo world-class robotic surgery with AI assistance, be discharged from the hospital quickly after the procedure, and continue receiving rehabilitation care at home while all the medical data can be seamlessly monitored by the personal care team. Primary care services will be fully integrated into mobile devices, with AI assistants who are fully aware of the patient's medical history, available 24/7 to answer health-related inquiries. Drug development will heavily rely on real-world data to reach a larger patient population, supported by real-time data collection from home environments. All health records will be centralized on a single platform, including data from wearable devices, home sensors, and hospitals and clinics within the healthcare system, all of which will be shared with the patient's healthcare team to enable personalized care while safeguarding privacy. This is a future envisioned by New Frontier. This future healthcare model will truly realize the intelligence of healthcare services, ensuring seamless integration between different phases of care systems, and will be genuinely "patient centered".

Realizing this vision for the future will require the concerted efforts of the entire industry. We look forward to working together to set a new benchmark for the healthcare industry and revolutionize the industry of healthcare services and innovation in China.

Lastly, we are excited by this meaningful journey and will continue to do what we have done over the last 8 years:

**Do good and do well, with love.** Thank you all!

未來的中國醫療行業將迎來徹底的變革。在未來，一位肺癌患者可以接受世界一流的結合人工智慧輔助的機器人手術，完成手術後能夠迅速出院。接受術後居家康復護理的同時，患者居家醫療信息即時對接到臨床醫護團隊。在未來，初級醫療服務也將全面融入移動終端，全面瞭解患者的病歷信息的人工智慧助手 24 小時待命，隨時回答患者的健康諮詢。在未來，藥物研發將大量利用真實世界數據，覆蓋更大範圍的患者群體，並即時收集來自家庭環境的數據支援。在未來，所有健康記錄將集中在一個平臺上，從穿戴設備、家庭感測器，到醫療體系中醫院和診所產出的數據，都會在保障隱私的前提下與患者的醫療團隊共用。這就是新風天域醫療生態在努力實現的目標。這樣的未來醫療模式將真正實現醫療服務的智慧化、各醫療體系之間的無縫連接，真正做到“以患者為中心”。

要實現這些未來的願景，需要全行業的共同努力。讓我們攜手，為醫療行業樹立新的標杆，為中國醫療服務和創新帶來革命性的變革。

最後，我們會持續堅持新風天域成立 8 年以來堅守的使命：

**Do good and do well, with love.** 感謝大家！











---

New Frontier Group's  
**Platforms**



---

Primary to Tertiary Clinical Network

臨牀醫療網絡

Rehabilitation Health

康復醫療服務

Home Health

家庭醫療照護

Insurance Solutions

新風保險服務

International Medical Services

跨境醫療服務



## Primary to Tertiary Clinical Network

### 臨牀醫療網絡

Amid evolving challenges and opportunities, New Frontier Health has continued to forge ahead in 2024, achieving milestones through perseverance, innovation, and strategic collaboration. Year 2024 marked a significant chapter in our growth as New Frontier Group acquired the Hong Kong Integrated Oncology Centre (HKIOC) and unified its subsidiaries—HEAL Medical, HEAL Oncology, and HEAL Fertility—under the New Frontier Health (Hong Kong) network. Partnering with United Family Healthcare (UFH), we further solidified our presence in the Greater Bay Area (GBA). Together, we have established a pioneering, nationwide multidisciplinary clinical network that delivers advanced cross-specialty and oncology diagnostics and treatments, driving forward cancer care innovation in the GBA.

In 2024, New Frontier Health served over 1 million patients across the GBA, representing an 11% increase from 2023, including approximately 200,000 international patients—a testament to our contribution to improving the region's healthcare ecosystem and business environment. Our inpatient admissions reached 20,000, reflecting a 30% year-on-year growth, while 11,000 surgeries were performed, nearly half of which were Grade III/IV complex procedures. Total surgical volume surged by 49%, with high-acuity surgeries growing by 55%. We provided medical support for nearly 30 major national events, including high-profile conferences and sporting competitions.

Clinically, we achieved breakthroughs in overcoming technical challenges and performing highly complex surgeries. The deployment of two additional da Vinci Surgical Systems elevated our robotic-assisted surgery volume to over 1,000 procedures, ranking among the highest in China's private healthcare sector.

As the only integrated healthcare provider with established hospitals in both Hong Kong and mainland China, New Frontier Health serves as a vital bridge for medical integration in the GBA. Shenzhen United Family Hospital, recognized for its exceptional service quality, was designated as the implementation site for the Hong Kong government's "Elderly Healthcare Voucher GBA Pilot Scheme." In 2024, the hospital provided over 8,500 outpatient consultations and recorded a 6-times increase in surgeries and triple growth in-patient services for Hong Kong patients. Our oncology network in Guangzhou and Shenzhen UFH hospitals further strengthened cross-border referral channels with Heal Medical, Heal Oncology Centre and HKIOC.

The four centres in Hong Kong, equipped with cutting-edge facilities and expert teams, offer integrated cancer care spanning prevention, screening, imaging, diagnostics, and advanced treatments such as novel drug therapies and precision radiotherapy. These efforts underscore our commitment to seamless "one-stop" services and reinforce medical collaboration between Shenzhen and Hong Kong.

Pioneering partnerships with Prudential Hong Kong, we became the first in the UFH system to establish direct billing agreements with a Hong Kong insurer, simplifying access of care for patients. Leveraging the GBA's simplified drug and medical device access policy, we introduced 16 innovative therapies to the mainland, benefiting more than 1,600 patients.

New Frontier Health remains steadfast in advancing clinical excellence, fostering regional healthcare synergy, and redefining standards for patient-centered, cross-border medical innovation in the Greater Bay Area and beyond.

新風醫療：歲序更新，往事難忘。2024年，我們在挑戰中砥礪前行，在奮鬥中取得收穫，在發展中不斷創新。這一年，新風天域集團收購香港綜合腫瘤中心，並聯合新風天域子公司——香港希愈醫療中心、香港希愈腫瘤中心、香港希愈生殖醫學中心構建了新風醫療（香港），與和睦家醫療進一步強化新風醫療在大灣區的佈局，共同優化跨境醫療服務，與兩地內外科、腫瘤科及輔助醫療團隊等攜手合作，形成一個新的、全國性的多學科的治療網路，為大灣區患者提供前沿的跨專科與癌症診斷及治療服務，共同推動大灣區癌症治療發展。

2024年裡，大灣區新風醫療共服務患者超過100萬人次，較之2023年增長約11%，其中外籍患者約20萬，為當地改善營商環境做出積極貢獻；住院量近2萬，較之2023年增長近30%；全年手術近11000台，約一半為3級以上手術，總手術量增長49%，三四級手術量增長55%。全年為近30場全國重大賽事、國家級會議和展會提供醫療保障。我們不斷夯實臨床醫療水準，解決技術瓶頸，完成多例高難度手術；兩台新的達芬奇手術機器人落地，達芬奇機器人手術量也突破了1000台，位居全國私立醫院前列。

過去一年，大灣區的發展突飛猛進。新風醫療是唯一在香港與內地完成綜合醫院佈局的醫療機構，為整個大灣區的醫療融合架起橋樑。深圳和睦家憑藉優質的服務和醫療品質，成為特區政府「長者醫療券大灣區試點計劃」的落地機構，2024年，深圳和睦家醫院服務了為超過4000位香港患者提供超過8500次門診，手術服務量較之前年增長6倍，住院服務量增長近3倍。

在癌症治療的領域上，廣州、深圳和睦家醫院，也實現與香港希愈醫療中心、香港希愈腫瘤中心和香港綜合腫瘤中心跨境轉診服務。香港4所中心配備了先進的醫療設施與專業的醫護團隊，服務涵蓋癌症預防、篩查、影像診斷、臨床化驗服務，以及綜合治療方案（如新藥治療、體外和體內放射治療），充分體現了一站式服務的優勢，更加強深港醫療雙向聯動。兩家大灣區醫院與香港保誠成功達成直付協定，這是和睦家體系內首家香港保險公司的直付合作關係。利用港澳藥械通政策，我們將創新藥械引入大陸，共落地超過16種創新藥品，惠及超1600名患者。

## Rehabilitation Health

### 康復醫療服務

Rehabilitation medicine plays a crucial role in the modern healthcare system, significantly enhancing patients' quality of life and alleviating the burden on medical resources. With the aging population, the demand for rehabilitation services is set to grow substantially.

New Frontier Health's rehabilitation business is advancing steadily, innovating continuously, and reaping rewards through its services. We have deepened our focus in the rehabilitation field, with 28 institutions spread across 14 cities nationwide. We have over 8,000 beds under construction or in operation, providing professional rehabilitation services to patients. Over 40,000 patients are discharged annually, with a net promoter score for patient satisfaction as high as 95%, establishing a strong reputation locally. We are constantly improving our medical techniques and optimizing our service processes, committed to offering every patient a higher quality and more comprehensive rehabilitation experience.

In terms of strategic layout, New Frontier Health is continuously expanding and deepening its footprint. In 2024, the company has been actively promoting new rehabilitation projects in multiple locations across the country. In Ningbo, the East China Regional Rehabilitation Center project is in full preparation and is expected to start operations in March 2025.

In Chengdu, the Mango High-Tech Second Store and the Chenghua Education and Rehabilitation Center have successively opened, safeguarding the comprehensive development and healthy growth of more children. Meanwhile, the group has integrated Qingdao United Family Healthcare into the Care Alliance system, exploring the potential for integrated clinical and rehabilitation services in the high-end medical field.

Looking ahead, the group has reserved several promising expansion projects in multiple locations, including Shanghai, Nanjing, Wuhan, Changsha, and the Greater Bay Area, laying a solid foundation for further entering strategic cities and deepening regional and intra-city layouts. As these projects gradually take shape, New Frontier Health will further perfect its national rehabilitation medical service network, providing more patients with high-quality and professional rehabilitation medical services, and continuing to lead the development of China's rehabilitation medical industry.



康復醫療在現代醫療體系中扮演著至關重要的角色，對於提高患者生活品質和減輕醫療負擔都具有重要意義。隨著人口老齡化，康復醫療的需求將越來越大。新風天域旗下的康復醫療業務在穩健中發展，在創新中突破，在服務中收穫。

我們深耕康復領域，旗下 28 家機構遍布全國 14 個城市，在建和展開床位超 8000 張，為患者提供專業的康復服務。全年出院患者超 40000 人，患者滿意度淨推薦值高達 95%，在當地樹立了良好的口碑。我們不斷提升醫療技術，優化服務流程，致力於為每一位患者提供更優質、更全面的康復體驗。

在戰略佈局方面，新風天域持續發力，不斷深化拓展版圖。2024 年，新風天域在全國多地積極推進康復醫療新項目建設。在寧波，華東區域康復醫療中心專案正緊鑼密鼓籌備中，預計於 2025 年 3 月投入運營；在成都，芒果高新二店、成華教康中心相繼開業，為更多兒童的全面發展和健康成長保駕護航；同時，集團將青島和睦家併入顧連體系，探索臨床康復一體化在高端醫療領域的發展可能。

展望未來，集團在上海、南京、武漢、長沙、大灣區等多地儲備了多個極具潛力的拓展專案，為繼續進軍戰略城市、深化區域及同城佈局奠定了堅實基礎。隨著這些專案的逐步落地，新風天域將進一步完善全國性的康復醫療服務網路，為更多患者提供優質、專業的康復醫療服務，持續引領中國康復醫療行業的發展。

## Home Health

### 家庭醫療照護

With an aging population, advancements in healthcare, and evolving patient needs, home medical services are becoming an essential part of modern healthcare, covering everything from basic care to in-home medical visits.

International experience highlights the benefits of home medical services in easing healthcare system pressure, reducing costs, and improving recovery outcomes. A U.S. study of 19,000 discharged patients found that those receiving home medical care had a 60% lower readmission risk within 30 days. Medicare data revealed that home medical services cut healthcare costs by over 87% compared to nursing facilities, saving an average of \$14,000 per patient. Similarly, Fudan University estimates that every yuan invested in home care saves 8.6 yuan in medical insurance funds.

YD Care's home health services primarily serve two groups. The first includes long-term care patients, many of whom require wound care for conditions like pressure ulcers and diabetic foot. The second consists of clients from United Family Healthcare and public hospitals, mainly patients recovering from surgery who need post-operative rehabilitation or at-home stoma dressing changes.

YD Care's services focus on three key areas. First is comprehensive assessment and personalized care planning. A senior medical team evaluates the wound condition based on doctor recommendations, considering size, depth, and healing progress.

A tailored care plan is then developed, outlining treatment duration, frequency, and necessary medical supplies. Additionally, a professional nutrition plan supports healing, while home environment assessments help optimize recovery conditions. Second is home-based wound care management. Experienced nurses with BLS international first aid certification provide wound care at home, bringing necessary consumables so patients don't need to purchase them separately. This service ensures sterility, safety, and proper hygiene while offering patients the convenience of receiving professional care at home. Lastly, wound recovery tracking and ongoing support are provided. Nurses document wound progress during each visit, adjusting care plans as needed to ensure optimal healing. Throughout the treatment cycle, patients and their families receive expert guidance, addressing concerns and providing continuous support.

YD Care's impact is evident in real cases. A 90-year-old woman who had suffered from chronic pressure sores for five years fully recovered after just eight treatments over three weeks and later switched to using YD Care's medical supplies. Her family found the service highly convenient, saving time and effort compared to hospital visits.

Currently, each YD Care nurse completes over 40 home visits per month on average. As services continue to expand, YD Care aims to grow its patient base, deepen collaborations with medical institutions, and further enhance service quality and accessibility, bringing professional and convenient medical care to more patients in need.

隨著我國人口老齡化加劇、醫療體制發展及需求多樣化，居家醫療服務應該成為現代醫療體系不可或缺的重要組成部分，涵蓋從基礎護理到醫護人員上門診療等多層次服務。

國際經驗表明，居家醫療服務在減輕醫療系統壓力、降低成本、提升康復效果等方面作用顯著。例如，美國一項對 1.9 萬名出院患者的追蹤研究顯示，接受居家醫療服務的患者出院 30 天內再入院風險降低超 60%；Medicare 醫保數據顯示，出院 30 天內，居家醫療服務醫保支出較護理機構減少 87% 以上，平均每位患者可節約 1.4 萬美元左右。據復旦大學測算，每投入 1 元居家護理費用，可節約醫保基金 8.6 元。

易得康居家醫療服務主要面向兩類人群。一類是現有長護險客戶，他們在日常生活中需要長期的護理照料，其中不少人面臨壓瘡、糖尿病足等傷口護理難題。另一類是和睦家及其他公立醫療機構的客戶，包括在醫院接受手術治療出院後尚處急性恢復期，需要居家進行術後康復、造口換藥的患者。

易得康居家醫療服務主要包含三個方面，首先是精準評估與個人化護理計劃制定。由資深醫療團隊結合醫囑，對傷口狀態進行全面評估，從傷口大小、深度、癒合情況等多維度考量。依據評估結果，定製包含護理週期、頻率以及所需耗材的個人化護理方案。同時，提供專業營養計劃助力傷口癒合，評估並優化居家環境，為傷口恢復創造最佳條件。其次是上門換藥服務，服務團隊由具備五年以上臨床經驗且持有 BLS 國際急救證的護師組成。

護士上門提供敷料更換服務，還會提供配套耗材，患者無需額外採購。這種上門服務讓患者在家就能享受專業護理，既便捷又能確保換藥過程的無菌安全和手衛生。最後是傷口恢復追蹤與答疑，護士上門服務時會詳細記錄傷口恢復情況，追蹤恢復進度。根據恢復狀況動態調整護理計劃，確保達到最佳恢復效果。在換藥週期內，還為患者及家屬提供專業答疑服務，消除他們在護理過程中的疑慮，給予全程專業指導與支援。

通過實際案例可以看到，易得康居家醫療服務取得了顯著成效。例如，第一位 90 歲患有 5 年難治壓瘡的老年女性患者，經過 3 周 8 次治療後即完成康復，後續還轉為採購易得康的敷料。家屬認為該服務節省了去醫院換藥的時間和精力，便民又值得。

目前，易得康醫療服務團隊單名護士平均每月可開展 40 餘次上門服務。隨著服務的持續推進，未來將不斷拓展客戶群體，深化與醫療機構的合作，以進一步提升服務品質和覆蓋範圍，為更多有需求的患者帶來便利和專業的醫療護理服務。



## Insurance Solution

### 新風保險服務

Against the backdrop of China's healthcare payment reforms (DRG/DIP), the country's medical payment system is undergoing a structural shift, with increasing cost-control pressures and a more refined approach to resource allocation. As people seek better doctors, better treatments, and better services, high-net-worth individuals are driving a surge in demand for commercial health insurance that runs parallel to social security. Consumers' expectations for health protection are evolving—from traditional indemnity-based insurance to a more holistic model that spans disease prevention, precision medicine, and rehabilitation management. With breakthroughs in artificial intelligence, digital healthcare, and managed care models, the commercial health insurance industry is at a turning point, presenting unprecedented opportunities: deeper integration between insurance and healthcare, a shift from reactive claims processing to proactive health management, and a user experience that is more efficient, accessible, and personalized—all laying the groundwork for long-term industry growth.

Prosper is a medical insurance service provider. We work hand in hand with China's leading insurers and local healthcare providers to offer highly personalized health management services and insurance solutions for both corporate and individual clients. Our approach seamlessly integrates healthcare into every aspect of the insurance journey. At the heart of our offering is the "Personal Care Manager", a trusted, personalized managed care service that supports members across prevention, treatment, and rehabilitation. Backed by the New Frontier Group ecosystem, we are committed to making high-quality healthcare accessible to more people. By 2024, Prosper had established a nationwide network spanning 296 cities and 2,800

top-tier providers. Our direct integration with leading hospitals has streamlined access to medical records and appointment scheduling, significantly enhancing service convenience. Through AI-powered "Care Copilot", we have redefined the PCM service experience—leveraging past medical records to build digital health profiles, offering pre-diagnosis recommendations, instant benefit checks, and lightning-fast claims processing—more than doubling service efficiency. By year-end, our growth in new group insurance premiums ranked among the top two in the industry, while visit volume to leading public hospitals such as Peking Union Medical College Hospital and China-Japan Friendship Hospital saw the highest increase nationwide.

As a key pillar of the New Frontier Group ecosystem, Better Insurance Brokerage is built on a team of seasoned professionals dedicated to supporting clients in both health management and wealth preservation. Our mission is to set the gold standard in high-end health insurance. Since our inception, we have leveraged outstanding risk management expertise and deep industry integration to serve over 6,000 families. Through strategic partnerships with more than 10 health insurers, we have accumulated a total insured risk value exceeding 50 billion RMB, underscoring our leadership in driving industry innovation and elevating the value of health insurance. Looking ahead, Better will continue to join forces with industry partners, empowering the sector and contributing to the creation of a more comprehensive and sustainable health protection system.

在醫保支付方式改革 (DRG/DIP) 的大背景下，中國醫療支付體系正在經歷結構性調整，控費壓力加劇，醫療資源配置趨於精細化。廣大群眾對「好醫」、「好藥」、「好服務」的嚮往催生了中高淨值人群對社保平行類商業健康險的強烈需求。消費者對健康保障的需求正從單一的賠付型保險，向涵蓋疾病預防、精準醫療、康復管理等全生命周期的綜合健康服務轉變。隨著人工智慧、數位化醫療及管理式醫療模式的創新突破，商業健康險行業迎來了前所未有的戰略機遇：保險與醫療服務深度融合，從被動理賠向主動健康管理升級，以更高效、更便捷、更人性化的方式提升用戶體驗，為行業可持續增長奠定基礎。

柏盛健康是以會員為中心的健康險服務供應商。攜手中國領先保司，深度協作本土醫療服務提供者，為企業、個人客戶提供個人化的健康管理服務與保險解決方案。我們將醫療融入健康險服務全流程。“私人健康管家”個性化、可信賴的管理式醫療服務，貫穿預防、治療、康復等環節。擁有新風天域集團生態支持，我們致力於將高品質醫療服務帶給更多人。2024 年，柏盛健康完成覆蓋全國 296 個城市、2800 家優質醫療機構的網路佈局，並與核心醫院打通病例、預約直連系統，大幅提升服務便捷度。通過 AI “Care Copilot” 重構 PCM 服務流程，基於歷史就診記錄為客戶建立健康檔案，且預診建議、福利快查與閃賠等技術顯著提升 2 倍以上服務效率。年內團險新單保費增量行業前二，協和、中日等頭部公立醫院就診增量排名第一。

作為新風天域生態佈局中的重要力量，柏泰保險經紀以專業化團隊為核心，以服務客戶健康管理和財富傳承為使命，致力於打造高端健康險領域的標杆企業。自成立以來，柏泰以卓越的風險管理能力及深度行業整合優勢，成功服務超過 6000 個家庭，與 10 餘家頭部健康險公司形成戰略合作，累計風險保額突破 500 億元，彰顯了在推動健康險行業創新與價值升級中的領導力。展望未來，柏泰將繼續攜手廣大夥伴，積極賦能行業發展，為構建更加完善的健康保障體系貢獻力量。

## International Medical Service

### 跨境醫療服務

We understand the anxiety and confusion that arise when someone you love is faced with a complex medical situation. Navigating the healthcare system can be overwhelming, especially when specialized care is needed far from home. At United Family Healthcare International Medical Service, we are here to alleviate that burden. With our patient-centered approach, we provide seamless, world-class care, helping patients and their families access the best possible treatment, no matter where they are in the world.

As part of China's leading premium private healthcare network, we offer comprehensive services that span the full spectrum of international medical care—from pre-trip evaluations to post-treatment rehabilitation. Our goal is to ensure that patients receive the highest standard of care, and we achieve this by connecting them with top medical institutions and experts across the globe.

One of the hallmarks of our service is our supplier-agnostic approach. We do not represent any single hospital or healthcare provider, which allows us to offer unbiased, patient-focused medical guidance. Our recommendations are based solely on the individual's needs, ensuring that every decision made is in the patient's best interest. We never tie ourselves to the cost of a medical treatment, allowing us to provide transparent and ethical care that is fully aligned with the patient's health priorities.

Our patients' experience is our top priority. We understand that each patient's journey is unique, which is why we provide personalized care every step of the way. Each patient is assigned a dedicated medical case manager who serves as their main point of contact throughout the entire process. From arranging consultations with top-tier specialists to coordinating travel logistics and ensuring smooth post-treatment rehabilitation, our case managers provide continuous support to ease the patient's experience.

In addition to the case manager, we also have an in-country concierge team that offers logistical support on the ground. Whether it's arranging transportation, accommodations, or assisting with any other local needs, our concierge team ensures that patients and their families can focus on what matters most—their health—while we take care of the rest.



We recognize the urgency that often comes with complex medical conditions. That's why we offer expedited services to ensure swift access to the best care available. We can arrange teleconsultations within just three days and facilitate treatment abroad within seven days. Our global clinical trial and drug search AI system also enables us to identify cutting-edge treatment options and clinical trials that may not be available in the patient's home country. By providing access to the latest medical advancements, we ensure that our patients receive the most effective treatments available.

Our extensive network of partnerships with world-renowned medical institutions ensures that our patients have access to the best medical care available. We work with leading hospitals such as Mayo Clinic, MD Anderson Cancer Center, Mass General Brigham, Memorial Sloan Kettering Cancer Center, Dana Farber Cancer Institute, City of Hope, the University of Tokyo, and top hospitals in China, including Peking Union Medical College Hospital (PUMCH), Chinese PLA General Hospital (301 Hospital), Shanghai Ruijin Hospital, Fudan University Zhongshan Hospital, and The First Affiliated Hospital of Zhejiang University. These partnerships ensure that our patients have access to the most advanced and appropriate care for their specific conditions, whether they need treatment in oncology (including hematology), neurology, cardiology, pediatrics, or fertility.

United Family Healthcare International Medical Service serves a broad range of patients, including individuals, companies, and states with complex medical needs. Our services are designed for affluent individuals who require specialized care for themselves or their loved ones, as well as organizations seeking comprehensive medical solutions. We understand that when it comes to health, there is no room for compromise, and we are trusted by our patients to provide the highest quality of care.

At the heart of United Family Healthcare International Medical Service is our mission to provide unbiased, technology-driven global medical navigation that empowers patients to make informed decisions about their healthcare. Our commitment to transparency, personalized support, and ethical care ensures that every patient receives exceptional treatment, no matter where their journey takes them.

By choosing United Family Healthcare International Medical Service, patients gain access to a global network of top medical experts, advanced treatment options, and the compassionate support they need to face complex medical challenges.

當您所愛的人面臨複雜的醫療狀況時，我們深知您可能會感到焦慮和困惑，尤其是在需要前往遠離家鄉的地方尋求專業醫療服務時，這一過程可能更加令人不知所措。為了減輕您的負擔，和睦家跨境醫療服務致力於提供無縫銜接的世界級醫療服務，確保患者及其家人無論身處何地都能獲得最佳的治療方案。

作為中國領先的高端私立醫療網絡的一部分，我們提供涵蓋國際醫療服務全流程的全面支持——從行前評估到治療後的康復護理。我們的目標是通過連接全球頂尖醫療機構和專家，確保患者獲得最高標準的醫療服務。我們的核心原則是保持中立，提供客觀且以患者為中心的醫療指導，這意味著我們不代表任何特定的醫院或醫療機構。我們的推薦完全基於每位患者的實際需求，所有決策都以患者的利益為出發點。我們與醫療費用無關聯，因此能夠提供透明且符合道德標準的服務，始終將患者的健康放在首位。

患者的體驗是我們的首要任務。我們明白每位患者的醫療旅程都是獨一無二的，我們在每個環節都提供個性化服務。每位患者都會被分配一位專屬的醫療案例經理，作為整個過程中的主要聯絡人。從安排與頂級專家的會診，到協調旅行事務，再到治療後的康復護理，我們的案例經理全程陪伴，提供支持，以簡化患者的就醫體驗。此外，我們還設有本地禮賓團隊，為患者及其家屬提供周到的地面後勤支持。無論是安排交通、住宿，還是協助其他本地需求，禮賓團隊都確保患者及家屬能夠專注於最重要的事情——健康，而其他事務交由我們來處理。

我們深知複雜醫療狀況往往伴隨著緊迫性，因此我們提供加速服務，確保患者能夠迅速獲得最佳醫療資源。我們可以在三天內安排遠程會診，並在七天內協調海外治療。同時，我們的全球臨床試驗與藥物搜尋 AI 系統能夠幫助患者找到可能在本國無法獲得的前沿治療方案和臨床試驗。透過提供最新的醫學進展，確保患者獲得最有效的治療選擇。

我們與全球知名醫療機構建立了廣泛的合作網絡，包括妙佑醫療國際、MD 安德森癌症中心、麻省總醫院、紀念斯隆 - 凱特琳癌症中心、達納法伯癌症研究所、希望之城、東京大學，以及中國頂級醫院如北京協和醫院、中國人民解放軍總醫院（301 醫院）、上海瑞金醫院、復旦大學中山醫院和浙江大學附屬第一醫院。這些合作夥伴涵蓋腫瘤科（包括血液腫瘤科）、腦神經科、心臟科、兒科與生殖醫學等多個頂尖專科。

和睦家跨境醫療服務面向多個群體，包括個人、企業和政府機構。我們的服務專為需要為自己或親人尋求專業醫療服務的個人，以及尋求全面醫療解決方案的機構而設計。我們深知在健康問題上沒有妥協的餘地，因此患者信任我們為其提供最高品質的醫療服務。

和睦家跨境醫療服務的核心使命是提供中立、技術驅動的全球醫療導航服務，賦能患者做出明智的醫療決策。我們對透明性、個性化支持和道德醫療的承諾，確保每位患者都能獲得卓越的治療。

選擇和睦家跨境醫療服務，患者將獲得全球頂尖醫療專家網絡、先進的治療選項，以及應對複雜醫療挑戰所需的關懷與支持。



# Your Partner for Global Medical Navigation

For the Rarest and Most Complex Cases

As Fast as

**3** Days

to Tele-Consultation

As Fast as

**7** Days

to Treatment Abroad

Access to

**1,200+**

Global Clinical Trials

Partnering with over 20 Global Medical Institutions

U.S.

- MD Anderson Cancer Center
- Mayo Clinic
- Dana-Farber Cancer Institute
- City of Hope Comprehensive Cancer Center
- Massachusetts General Hospital
- University of Chicago Medical Center
- New York-Presbyterian Hospital - Columbia and Cornell
- Cedars-Sinai Medical Center
- Children's Hospital Los Angeles
- Boston Children's Hospital

Japan

- Cancer Institute Hospital of JFCR
- National Cancer Center Hospital
- The University of Tokyo Hospital

Hong Kong

- HEAL Medical Group
- Hong Kong Integrated Oncology Center
- CUHK Medical Centre
- Hong Kong Sanatorium and Hospital
- Gleneagles Hospital Hong Kong
- Adventist Hospital



Scan to Begin  
Your Journey to Healing



International  
Medical  
Services



	<p>01 Section   主題</p> <h2>Advancing Innovation in Clinical Research and Treatments Solutions 臨床研究與治療方案創新</h2>	
<p>English   英語 11:10 - 11:25</p>	<p>Keynote Speech   主題演講</p> <h3>Redefining Cancer Care: Smarter Therapies, Global Impact</h3> <p>重新定義癌症護理：更智慧的療法與全球影響</p>	<p>Keynote Speaker   主題演講者</p> <p><b>Prof. Tony Mok   莫樹錦 教授</b> Chairman, Department of Clinical Oncology, The Chinese University of Hong Kong 香港中文大學臨床腫瘤學系系主任</p>
<p>Mandarin   普通話 11:25 - 11:40</p>	<p>Keynote Speech   主題演講</p> <h3>Precision Redefined: The Future of Non-Invasive Surgery, Cancer Operations, and Lung Transplant Technology</h3> <p>精準再定義：無管手術、癌症手術與肺移植技術的未來</p>	<p>Keynote Speaker   主題演講者</p> <p><b>Prof. He Jianxing   何建行 教授</b> Director of National Respiratory Medical Center; President of Guangzhou Respiratory Health Research Institute 國家呼吸醫學中心主任 廣州呼吸健康研究院院長</p>
<p>English   英語 Mandarin   普通話 11:40 - 12:00</p>	<p>Panel Discussion   專題討論</p> <h3>Funding Tomorrow: Creating a Thriving Life Science Ecosystem in the GBA</h3> <p>投資未來：在大灣區創建繁榮的生命科學生態系統</p>	<p>Moderator   主持人</p> <p><b>Mr. Joshua Chang   張浩均 先生</b> Director (Investment), Hong Kong Investment Corporation Limited 香港投資管理有限公司投資總監</p> <p>Panellists   講者</p> <p><b>Mr. Fu Shan   付山 先生</b> Managing Partner of Vivo Capital 維格資本管理合夥人</p> <p><b>Mr. Min Fang   方敏 先生</b> Managing Director of Warburg Pincus China; 華平投資董事總經理 Co-Head of China Private Equity 中國私募股權投資聯席總裁</p> <p><b>Mr. Leo Zheng   鄭烜樂 先生</b> Founder &amp; CEO of Lighthouse Capital   光源資本創始人、CEO Founding partner of Lighthouse Capital Innovation Fund   光源創新基金創始合夥人</p> <p><b>Mr. Yan Zhao   趙彥 先生</b> Partner of Trustar Capital 信宸資本合夥人</p> <p><b>Mr. Gao Meng   高猛 先生</b> Chief Investment Officer of Nan Fung Group 南豐集團首席投資官</p>
<p>Mandarin   普通話 12:00 - 12:15</p>	<p>Keynote Speech   主題演講</p> <h3>Registry studies concerning lung cancer in China from the principal investigators</h3> <p>從主要研究者的視野看中國肺癌的註冊研究</p>	<p>Keynote Speaker   主題演講者</p> <p><b>Prof. Lu Shun   陸舜 教授</b> Life Tenured Professor of the Affiliated Chest Hospital of Shanghai Jiao Tong University School of Medicine 上海交通大學醫學院附屬胸科醫院終身教授 Director of Shanghai Lung Cancer Clinical Medicine Center 上海市肺部腫瘤臨床醫學中心主任</p>

<p>Mandarin   普通話</p> <p>12:15 - 12:25</p>	<p>Keynote Speech   主題演講</p> <p><b>Rebuilding Strength: Pioneering Advances in Osteoarthritis and Bone Health for a Better Tomorrow</b></p> <p>重塑力量： 開創骨關節炎與骨骼健康新紀元， 共創美好未來</p> <p>Keynote Speaker   主題演講者</p> <p><b>Prof. Guanghua Lei   雷光華 教授</b> President of Xiangya Hospital, Central South University 中南大學湘雅醫院院長</p>
<p>Mandarin   普通話</p> <p>12:25 - 12:45</p>	<p>Panel Discussion   專題討論</p> <p><b>Innovations in Drug Development: Connecting the GBA to Global Life Science Breakthroughs</b></p> <p>藥物研發： 攜手大灣區， 共鑄全球生命科學新突破</p> <p>Moderator   主持人</p> <p><b>Mr. Mengwei Xin   辛夢葦 先生</b> Managing Director-New Frontier Group; CSO-New Frontier Group 新風天域集團董事總經理；新風天域集團首席戰略官</p> <p>Panellists   講者</p> <p><b>Prof. Jiafu Ji   季加孚 教授</b> Director of Department of General Surgery and GI Cancer Center at Beijing Cancer Hospital 北京大學腫瘤醫院大外科主任、胃腸腫瘤中心主任 Former President of Beijing Cancer Hospital 北京大學腫瘤醫院前任院長</p> <p><b>Prof. Qin Jun   秦鈞 教授</b> Chief Scientist of Life Health at China Resources Research Institute 華潤研究院生命健康領域首席科學家</p> <p><b>Mr. Peter Ding   丁強 先生</b> Co-Founder and CEO, Allorion Therapeutics 安銳生物共同創始人、執行總裁</p> <p><b>Mr. KK Tong   唐嘉其 先生</b> CEO of New Frontier Health Hong Kong; 新風醫療集團（香港）首席執行官</p> <p><b>Mr. Tao Wang   王濤 先生</b> CEO of NF Nova Clinical CRO 新風新研首席執行官</p> <p>Executive Vice Secretary-General of New Frontier GBA Medical 新風大灣區醫療執行委員會常務副秘書長</p>
<p>12:45 - 13:15</p>	<p><b>Lunch Refreshment Reception</b></p> <p>午間茶點招待</p>

	<p>02 Section   主題</p> <h2>AI and Implications on Healthcare</h2> <h3>人工智慧與醫療變革</h3>	
<p>English   英語</p> <p>13:15 - 13:25</p>	<p>Opening Speech   開幕演講</p> <h4>When technology meets with Traditional Medical Practices</h4> <p>當現代技術與傳統醫療實踐融合</p>	<p><b>Dr. CH Leong   梁智鴻 醫生</b>                  Director of New Frontier Corporation                  Honorary President of Shenzhen New Frontier United Family Hospital                  新風醫療董事會成員                  深圳新風和睦家醫院榮譽院長</p>
<p>English   英語</p> <p>13:25 - 13:40</p>	<p>Keynote Speech   主題演講</p> <h4>The Brain Reimagined: AI Meets Neuroscience</h4> <p>重新定義大腦：人工智慧與神經科學的融合</p>	<p>Keynote Speaker   主題演講者</p> <p><b>Prof. Nancy Y. Ip   葉玉如 教授</b>                  President of The Hong Kong University of Science and Technology (HKUST)                  The Morningside Professor of Life Science                  香港科技大學校長                  晨興生命科學教授</p>
<p>English   英語 Mandarin   普通話</p> <p>13:40 - 14:00</p>	<p>Panel Discussion   專題討論</p> <h4>Innovating Health Coverage: Connected Care in Hong Kong and the GBA</h4> <p>創新健康保障：香港與大灣區的互聯醫療服務</p>	<p>Moderator   主持人</p> <p><b>Mr. Jason Zheng   鄭會傑 先生</b>                  Executive Director, New Frontier Group   新風天域集團執行董事                  Co-Founder &amp; President, Prosper Health   柏盛健康聯合創辦人兼總裁                  Co-Founder &amp; President, Better Insurance Brokerage   柏泰保險經紀聯合創辦人兼總裁</p> <p>Panelists   講者</p> <p><b>Mr. Lawrence Lam   林智剛 先生</b>                  CEO of Prudential HK                  保誠保險香港行政總裁</p> <p><b>Mr. Jiaoyan Shang   尚教研 先生</b>                  General Manager of Pacific Health Insurance Co Ltd                  太平洋健康險總經理</p> <p><b>Ms. Sally Wan   尹玄慧 女士</b>                  Chief Executive Officer,                  AXA Greater China                  AXA 安盛中國大陸、香港及澳門行政總裁</p> <p><b>Mr. Clement Lam   林嘉言 先生</b>                  Chief Executive Officer,                  Sun Life Hong Kong Limited (Incorporated in Bermuda with limited liability)                  香港永明金融有限公司行政總裁                  (於百慕達註冊成立之有限責任公司)</p>
<p>Mandarin   普通話</p> <p>14:00 - 14:15</p>	<h4>Demonstration of AI Application in Health Insurance</h4> <p>科技 / 人工智慧在健康保險領域的應用</p>	<p>Speakers   演講者</p> <p><b>Mr. Kevin Zhou   周晞燁 先生</b>                  Co-Founder &amp; CEO at Prosper Health   柏盛健康聯合創始人兼首席執行官</p> <p><b>Mr. Prince Wang   王楨 先生</b>                  CTO-New Frontier Group   新風天域集團首席技術官</p>



<p>English   英語 Mandarin   普通話</p> <p>14:15 - 14:35</p>	<p>Panel Discussion   專題討論</p> <p><b>On the Horizon: Health AI in 2030</b></p> <p><b>展望未來： 2030 年的健康產業人工智慧</b></p>	<p>Moderator   主持人</p> <p><b>Mr. David Zeng   曾瀛先生</b> Managing Director and the Co-COO of New Frontier Group; Director of the Board and the COO of New Frontier Health 新風天域集團董事總經理及聯席首席運營官</p> <p>Panellists   講者</p> <p><b>Prof. Tongyu Zhu   朱同玉教授</b> Vice Dean, Shanghai Medical College of Fudan University 復旦大學上海醫院副院長</p> <p><b>Dr. Alexander Ng   吳文達醫生</b> President of Tencent Healthcare 騰訊健康總裁</p> <p>WHO (World Health Organization) Digital Health Technical Advisory Group Expert 世界衛生組織數字醫療技術諮詢委員會專家</p> <p>Honorary Professor, School of Public Health, The University of Hong Kong 香港大學公共衛生學院名譽教授</p> <p><b>Xiaodong Tao, Ph.D.   陶曉東博士</b> CEO, iFLYTEK Health 訊飛醫療科技股份有限公司總裁</p> <p><b>Ms. Mandy Qiu   邱慧女士</b> Chief Technology Officer of New Frontier Health 新風醫療首席科技官</p>
<p>English   英語</p> <p>14:35 - 14:50</p>	<p>Keynote Speech   主題演講</p> <p><b>Synergism in clinical drug development in the GBA</b></p> <p><b>粵港澳大灣區中的臨床藥物開發協同作用</b></p>	<p>Keynote Speaker   主題演講者</p> <p><b>Prof. Chak-sing Lau   劉澤星教授</b> Dean of LKS Faculty of Medicine The University of Hong Kong 香港大學李嘉誠醫學院院長</p>
<p>English   英語</p> <p>14:50 - 15:05</p>	<p>Keynote Speech   主題演講</p> <p><b>AI in Healthcare and Medical Education: Are We Training the Right Genotype and Phenotype of Physicians?</b></p> <p><b>人工智慧在醫療保健和醫學教育中的應用：我們是否正在培養具有正確基因型與表現型的醫生？</b></p>	<p>Keynote Speaker   主題演講者</p> <p><b>Prof. Davy Cheng   鄭仲煊教授</b> Founding Dean &amp; Presidential Chair Professor, School of Medicine at the Chinese University of Hong Kong, Shenzhen 香港中文大學(深圳)醫學院創院院長兼校長講座教授</p>
<p>Mandarin   普通話</p> <p>15:05 - 15:25</p>	<p>Keynote Speech   主題演講</p> <p><b>The Brain's Blueprint: Unlocking Neurological Health for Lifelong Vitality</b></p> <p><b>大腦藍圖：解鎖神經健康，助力終身活力</b></p>	<p>Keynote Speaker   主題演講者</p> <p><b>Prof. Guo Yi   郭毅教授</b> Director, Department of Neurology, Shenzhen People's Hospital 深圳市人民醫院神經內科主任</p> <p><b>Mr. Brian Siu   蕭毅晃先生</b> Executive Director-New Frontier Group   新風天域執行董事 COO - New Frontier GBA   大灣區首席運營官</p>

03 Section | 主題

## New Trends in Cross-Border Healthcare and Clinical Care 跨境醫療與護理新趨勢

English | 英語  
15:30 - 16:00

Panel Discussion | 專題討論

### Next Destination: Positioning HK and the GBA as a Global Leader in Medical Tourism

下一站：  
將香港和大灣區定位為  
全球醫療旅遊的領導者

Keynote Speaker | 主題演講者

**Dr. Ko Wing Man | 高永文 醫生**

Member of the Executive Council of The Government of The Hong Kong Special Administrative Region

Director of New Frontier GBA Healthcare Group  
香港特別行政區行政會議成員，新風大灣區醫療董事

Panellists | 講者

**Prof. Ronnie Poon | 潘冬平 教授**

Co-Founder-  
Hong Kong Integrated Oncology Centre;  
Medical Director-  
New Frontier GBA Healthcare

香港綜合腫瘤中心聯合創始人  
新風大灣區醫療總監

**Dr. Kenneth Tsang | 曾慶廉 醫生**

Regional CEO of IHH Healthcare North Asia  
CEO of Gleneagles Hospital Hong Kong  
IHH 醫療 (北亞洲) 區域首席執行官  
港怡醫院執行總裁

**Prof. Fung Hong | 馮康 教授**

Executive Director and Chief Executive Officer, CUHK Medical Centre  
Professor of Practice, The Jockey Club School of Public Health & Primary Care, CUHK  
香港中文大學醫院執行董事及行政總裁  
香港中文大學賽馬會公共衛生及基層醫療學院專業應用教授

**Dr. Koon Hung Lee | 勵冠雄 醫生**

Assistant Medical Superintendent of  
Hong Kong Sanatorium & Hospital  
香港養和醫院副院長

**Dr. Chan Chun Kwong | 陳真光 醫生**

President, Hong Kong Chinese Medical Association  
Specialist in Respiratory Medicine

香港中華醫學會會長  
呼吸系統科專科醫生

**Dr. Cheng Chi Man | 鄭志文 醫生**

President of Hong Kong Medical Association  
香港醫學會會長

English | 英語  
Mandarin | 普通話  
16:00 - 16:20

Panel Discussion | 專題討論

### Leading the Future of Clinical Excellence: Lessons from Mainland China's Healthcare System and Hong Kong's Interaction and Innovation

引領臨床卓越的未來：  
中國大陸醫療體系與香港的  
互動與創新

Moderator | 主持人

**Mr. Brian Siu | 蕭毅昇 先生**

Executive Director-New Frontier Group | 新風天域執行董事  
COO - New Frontier GBA | 大灣區首席運營官

Panellists | 講者

**Dr. Kelly Xia | 夏凱莉 醫生**

General Manager,  
Guangzhou United Family Hospital  
廣州和睦家醫院院長

**Mr. Yuan Shuai | 袁帥 先生**

Co-Founder & Co-CEO-Care Alliance &  
New Frontier Vitality  
顧連醫療及大健康策略控股  
聯合創始人及聯席執行長

**Prof. Shuguang Lin | 林曙光 教授**

Chairman of New Frontier GBA  
Advisory Board, Chief Physician  
新風集團大灣區專家委員會主席、主任醫師

**Prof. Kenneth M.C. Cheung | 張文智 教授**

Hospital Chief Executive, the University of  
Hong Kong - Shenzhen Hospital  
Chair Professor and Jessie Ho Professor in Spine  
Surgery at the Li Ka Shing Faculty of Medicine  
The University of Hong Kong  
香港大學深圳醫院院長  
香港大學何馮月燕 (脊柱外科) 講座教授

English | 英語  
16:20 - 16:35

Panel Discussion | 專題討論

### The Next Destination: Shifting Landscape in International Medical Care

下一站：  
國際醫療格局的轉變

Moderator | 主持人

**Mr. Ed Tam | 譚君傑 先生**

Managing Director-New Frontier Group | 新風天域集團董事總經理  
CEO-United Family Healthcare International Medical Service | 和睦家跨境醫療首席執行官  
Vice chairman-New Frontier Group (Hong Kong) | 新風天域集團 (香港) 副董事長

Panellists | 講者

**Ms. Roberta Lipson | 李碧菁 女士**

Vice Chair, New Frontier Health | 新風醫療副董事長  
Chair, AmCham China | 中國美國商會主席

**Prof. Terence Sio | 蕭榮泰 教授**

Radiation Oncologist, Mayo Clinic  
梅奧診所放射腫瘤科教授

**Prof. Hiromichi Ito**

General Surgeon, Cancer Institute Hospital of JFCR | 普外科醫生，日本癌症研究會

<p>English   英語 16:35 - 16:55</p>	<p>Panel Discussion   專題討論</p> <p><b>The Future of Healthcare Investments, IPOs and Capital Market Trends</b> 醫療健康行業投資展望， 聚焦 IPO 與資本市場趨勢</p>	<p>Moderator   主持人</p> <p><b>Mr. Tom Sze   施鴻傑 先生</b> Managing Director and Co-COO of New Frontier Group 新風天域集團董事總經理及聯席首席運營官</p> <p>Panellists   講者</p> <p><b>Mr. John C. Lee   李鎮國 先生</b> Vice Chairman, Managing Director Co-Head of Asia Country Coverage Global Banking, UBS AG 瑞士銀行 (瑞銀) 全球投資銀行部副主席 及亞洲企業客戶部聯席主管</p> <p><b>Mr. Jia Xu   許佳 先生</b> Managing Director and Deputy Head of Global Investment Banking, CICC 中金公司董事總經理、 全球投資銀行部執行負責人</p> <p><b>Mr. David Lau   劉伯偉 先生</b> Co-Head of China Investment Banking Coverage, J.P. Morgan 摩根大通中國投資銀行聯席主管</p> <p><b>Mr. Daizong Wang   王岱宗 先生</b> Partner, TPG NewQuest 合夥人, TPG NewQuest</p> <p><b>Mr. Michael Hui   許予一 先生</b> Partner, Bain Capital 合夥人, 貝恩投資</p>
<p>Mandarin   普通話 16:55 - 17:00</p>	<p>Keynote Speech   主題演講</p> <p><b>Diagnosis and Treatment of Microtia: How We Win Patients' High Trust through Technology and Service</b> 小耳症診療：我們如何用技術 + 服務贏得患者的高度信任</p>	<p>Keynote Speaker   主題演講者</p> <p><b>Dr. Shuzhong Guo   郭樹忠 醫生</b> Plastic Surgeon, Chief Physician, Shenzhen New Frontier United Family Hospital 深圳新風和睦家醫院整形外科主任醫師</p>
<p>English   英語 17:00 - 17:15</p>	<p>Keynote Speech   主題演講</p> <p><b>The Next Pandemic: Exploring Post Pandemic Global Impact and Building Resilience Through Intelligence</b> 下一場疫情： 探索後疫情時代的全球影響，通過智慧構建韌性</p>	<p>Keynote Speaker   主題演講者</p> <p><b>Prof. Yuen Kwok-Yung   袁國勇 教授</b> The Chair in the Department of Microbiology and Henry Fok Professor of Infectious Diseases at the University of Hong Kong, and the Co-Director of the State Key Laboratory of Emerging Infectious Diseases 港大微生物學系傳染病學講座教授及霍英東基金教授 (傳染病學) 新發傳染性疾病國家重點實驗室之共同主任</p>
<p>17:15 - 17:25</p>	<p><b>Partnership Signing Ceremony</b> 合作夥伴簽約儀式</p>	
	<p>04 Section   主題</p> <p><b>Closing Ceremony</b> 閉幕儀式</p>	
<p>English   英語 17:25 - 17:30</p>	<p><b>Closing Remarks</b> 閉幕致辭</p>	<p><b>Dr. CH Leong   梁智鴻 醫生</b> Director of New Frontier Corporation, Honorary President of Shenzhen United Family Hospital 新風醫療董事會成員，深圳和睦家醫院榮譽院長</p>
<p>English   英語 17:30 - 17:35</p>	<p><b>Thank You Note</b> 閉幕感謝致辭</p>	<p><b>Mr. Antony Leung Kam-chung   梁錦松 醫生</b> Chairman and Co-Founder of New Frontier Group 新風天域集團聯合創始人兼董事長</p>
<p>English   英語 17:35 - 17:40</p>	<p><b>What's Next</b> 未來展望</p>	<p><b>Mr. Carl Wu   吳啟楠 先生</b> Co-Founder and CEO of New Frontier Group and CEO of United Family Healthcare 新風天域集團聯合創始人兼首席執行官和睦家醫療首席執行官</p>

Topic | 講題

## Redefining Cancer Care: Smarter Therapies, Global Impact

重新定義癌症護理：  
更智慧的療法與全球影響

Keynote Speaker | 主題演講者



Chairman,  
Department of Clinical Oncology,  
The Chinese University of Hong Kong  
香港中文大學臨床腫瘤學系系主任

### Professor Tony Mok, BBS, JP 莫樹錦教授

- Professor, Department of Clinical Oncology
- Li Shu Fan Medical Foundation Professor of Clinical Oncology
- Fellow of ASCO (FASCO)
- Member of ASCO Board of Director (June 2018 - May 2022)
- Past President, International Association for the Study of Lung Cancer (IASLC)
- Honorary Secretary, Board of Directors of The Hong Kong Academy of Science (ASHK) and Member of ASHK

Professor Tony Mok focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led multiple multi-national studies that help establish the global guidelines in personalized medicine for lung cancer.

腫瘤學系教授、李樹芬醫學基金腫瘤學教授、美國臨床腫瘤學會院士 (FASCO)、美國臨床腫瘤學會董事局成員 (2018 年 6 月至 2022 年 5 月)、國際肺癌研究協會前任主席、香港科學院董事局榮譽秘書及院士。

莫樹錦教授主要研究肺癌的生物標誌物和分子靶向治療。他是肺癌研究組的創辦人之一，領導多個重要的跨國臨床研究，奠定了肺癌個體化治療的基礎。



Topic | 講題

## Precision Redefined: The Future of Non- Invasive Surgery, Cancer Operations, and Lung Transplant Technology

**精準再定義：  
無管手術、癌症手術與  
肺移植技術的未來**

Keynote Speaker | 主題演講者



**Professor He Jianxing**  
何建行教授

Director of National Respiratory  
Medical Center;  
President of Guangzhou Respiratory  
Health Research Institute  
國家呼吸醫學中心主任、  
廣州呼吸健康研究院院長

- Director of National Respiratory Medical Center; President of Guangzhou Respiratory Health Research Institute
- Professor of Thoracic Surgery at First Affiliated Hospital of Guangzhou Medical University, leading in Thoracic Surgery, Transplantation, and Oncology
- Fellow of American College of Surgeons and Royal College of Surgeons (UK)
- Editor of 8 English monographs, contributor to 4 international guidelines, holder of 1 international patent, and 4 national medical product licenses
- Recognized with national awards for scientific progress, innovation, and provincial awards for technological achievements
- Performs 10,000+ thoracic surgeries annually, including 100+ lung transplants
- Pioneer of Tubeless VATS, a globally recognized advancement in thoracic anesthesia
- Research integrated into WHO COVID-19 guidelines, NCCN guidelines, and endorsed by National Cancer Institute
- 390 papers in NEJM, Lancet, Cell, Nature Medicine, with 27 papers IF>30 and 50 papers IF>10 ( Total IF>3,500; Citations=34,000)
- 廣州國家實驗室領銜科學家
- 美國外科醫師學院院士
- 英國皇家外科醫學院院士
- 中國醫學科學院學術諮詢委員會學部委員
- 2020 年 國家科技進步一等獎；  
2018 年 國家科技進步二等獎
- 2023 年 國家創新爭先個人獎；  
2021 年 國家創新爭先團體獎
- 2021 年 廣東省科技進步特等獎；  
2023 年 2015 年 廣東省科技進步一等獎
- 2024 年 何梁何利基金會科學與技術進步獎；  
2023 年 第十屆“樹蘭醫學獎”
- 2023 年 中國醫院協會研發創新獎；  
2021 年 全國五一勞動獎章獲得者
- 2024 年 中國抗癌協會科技一等獎；  
2017 年 中華醫學進步一等獎
- 2017 年 華夏醫學科技一等獎；  
2002 年 中國高校科技進步二等獎
- 1997 年 廣東省科技進步二等獎；  
1999 年 廣東省有突出貢獻專家
- 1997 年 廣東省醫藥衛生科技進步一等獎；  
1996 年 廣州市科技進步一等獎
- 在 NEJM、Lancet、BMJ、Cell 等國內外知名雜誌發表論文 430 篇 (IF>30 分 23 篇；IF>10 分 52 篇)，總 IF >3,400 分，他引 >38,000 次
- ESI 高被引論文 22 篇；  
中國呼吸與胸外“十大高被引學者”
- 無管微創技術 (Tubeless Procedure) 被編為 2022 哈佛大學教科書臨床教程 第 37 章

Topic | 講題

## Registry Studies Concerning Lung Cancer in China from the Perspectives of Principal Investigators

從主要研究者的視野  
看中國肺癌的註冊研究

Keynote Speaker | 主題演講者



**Professor Lu Shun**  
陸舜教授

Life Tenured Professor of the  
Affiliated Chest Hospital of  
Shanghai Jiao Tong University  
School of Medicine  
Director of Shanghai Lung Cancer  
Clinical Medicine Center

上海交通大學醫學院  
附屬胸科醫院終身教授  
上海市肺部腫瘤臨床醫學中心主任

Doctoral supervisor, second-level professor, young and middle-aged expert with outstanding contributions to the national health care, enjoying the special allowance of the State Council.

- Clarivate "Highly Cited Researcher 2024"
- Won the "DIA Global Excellence Award" in 2024
- Top 2% of scientists in the world in the Stanford University and Elsevier database in 2024
- Director of the Chinese Anti-Cancer Association, Honorary Chairman of the Lung Cancer Professional Committee
- Executive Director of the Chinese Society of Clinical Oncology (CSCO), Vice Chairman of the Xisco Foundation
- Former Chairman of the DIA China Advisory Committee
- Member of the Standing Committee of the Chinese Medical Association Oncology Society, Chairman of the Lung Cancer Expert Committee
- Deputy Editor-in-Chief of Lung Cancer, the official journal of the International Association for the Study of Lung Cancer

博士生導師，二級教授，國家衛生健康突出貢獻中青年專家，享受國務院特殊津貼。第一負責人主持科技部國家慢病重點專項，國際合作課題；國家新藥創新重大專項，863 重大課題子課題 2 項；國家自然基金重點項目和面上項目第一負責人，獲上海市科技進步一等獎。

- 2024 科睿唯安“全球高被引科學家名單”
- 2024 獲“DIA 全球卓越獎”
- 2024 年美國斯坦福大學和愛思唯爾資料庫全球前 2% 頂尖科學家
- 中國抗癌協會理事，肺癌專業委員會名譽主委
- 中國臨床腫瘤學會 (CSCO) 常務理事，希斯科基金會副理事長
- DIA 中國區顧問委員會前任主席
- 中華醫學會腫瘤學會常委，肺癌專家委員會主任委員
- 國際肺癌研究會官方雜誌 Journal of Thoracic Oncology, Lung Cancer 副主編

Topic | 講題

## Rebuilding Strength: Pioneering Advances in Osteoarthritis and Bone Health for a Better Tomorrow

**重塑力量：  
開創骨關節炎與  
骨骼健康新紀元，  
共創美好未來**

Keynote Speaker | 主題演講者



President of Xiangya Hospital,  
Central South University

中南大學湘雅醫院院長

### Professor Guanghua Lei 雷光華教授

Professor Lei is currently the director of National Clinical Research Center of Geriatric Disorders, and the director of Hunan Key Laboratory of Joint Degeneration and Injury.

He has rich experience in the diagnosis and treatment of joint diseases and injuries, and specializes in artificial joint replacement, revision and minimally invasive arthroscopic surgery, especially in patellofemoral arthritis, patellar instability/dislocation, and cartilage injury treatment, which is at the leading level in China. Prof. Lei is also the Deputy Editor-in-Chief of the Chinese Medical Journal and Editor-in-Chief of the Chinese Journal of Endoscopy.

雷教授系現任國家老年疾病臨床醫學研究中心（湘雅醫院）主任、老年骨關節疾病防治教育部重點實驗室主任。

在關節疾病和損傷診治方面具有豐富的經驗，擅長人工關節置換、翻修和關節鏡微創手術，尤其在髕股關節炎、髕骨不穩 / 脫位和軟骨損傷治療等方面處於國內領先水平。雷教授同時還擔任《中華醫學雜誌》副總編輯、《中國內鏡雜誌》主編。

Topic | 講題

## The Brain Reimagined: AI Meets Neuroscience

重新定義大腦：  
人工智慧與神經科學的融合

Keynote Speaker | 主題演講者



President of The Hong Kong  
University of Science and  
Technology (HKUST)  
The Morningside Professor  
of Life Science  
香港科技大學校長  
晨興生命科學教授

### Professor Nancy Y. Ip, PhD, SBS, BBS, MH, JP 葉玉如教授

Prof. Nancy Ip is the President of The Hong Kong University of Science and Technology (HKUST) and the Morningside Professor of Life Science. Taking office in October 2022, she is the first female president of a publicly funded university in Hong Kong.

Ip received her PhD degree in Pharmacology from Harvard University, after which she held the position of Senior Staff Scientist at Regeneron Pharmaceuticals Inc. in New York. She joined HKUST in 1993 and served as Head of Biochemistry, Dean of Science, and Vice-President for Research and Development.

Ip is world-renowned for her significant contributions to the field of neuroscience. Her outstanding research has resulted in 334 scientific papers and 70 patents. She is an elected member of the Chinese Academy of Sciences, the US National Academy of Sciences, and the American Academy of Arts and Sciences, among other academies, and is a recipient of numerous awards and honors, including the National Natural Science Awards, the L'OREAL-UNESCO for Women in Science Award, and the 10 Science Stars of China by Nature.

In addition to conducting pioneering neuroscience research, Ip helps shape research policy on a global level. She is a member of various strategic initiatives such as the Leadership Group of the Davos Alzheimer's Collaborative. She also actively serves on local committees, such as the Chief Executive's Council of Advisers, to help steer the strategic development of Hong Kong.

葉教授現任香港科技大學(科大)校長和晨興生命科學教授。她自2022年10月起出任科大校長,是香港八家資助大學首位女校長。

葉教授於美國哈佛大學取得藥理學博士學位,其後在紐約Regeneron製藥公司擔任高級科學家,於1993年起受聘於科大,歷任生物化學系主任、理學院院長、副校長(研究及發展)。

葉教授是國際知名的神經生物學家,長期致力於探索神經科學的前沿領域。她的研究成果備受科學界推崇,在頂尖國際學術期刊發表了334篇論文和綜述,擁有70多項國際科技發明專利權。葉教授還當選為多間學術機構的院士,包括中國科學院、美國國家科學院、美國人文與科學院,並獲頒多個國內外重要學術獎項,包括國家自然科學獎、歐萊雅聯合國教科文組織「世界傑出女科學家成就獎」、《自然》科學雜誌「中國科學之星」等,以表彰她的卓越成就。

在從事科學之餘,葉教授積極參與全球科研政策發展,目前擔任「達沃斯·阿爾茨海默症合作組織」的領導小組成員。葉教授同時擔任香港特區政府特首顧問團成員等多項社會公職,為香港的策略發展出謀獻策。



Topic | 講題

## Synergism in Clinical Drug Development in the GBA

粵港澳大灣區中的  
臨床藥物開發協同作用

Keynote Speaker | 主題演講者



Dean of LKS Faculty of Medicine  
The Hong Kong University

香港大學李嘉誠醫學院院長

### Professor Chak-sing Lau, BBS, JP 劉澤星教授

MBChB (Dundee), MRCP (UK), MD (Honours) (Dundee)  
FHKCP, FHKAM (Medicine), FRCP (Edinburgh), FRCP (Glasgow),  
FRCP (London), Hon DSc (Glasgow)

- Vice-President & Pro-Vice-Chancellor (Health) (Interim)
- Daniel CK Yu Professor in Rheumatology and Clinical Immunology
- Chair Professor of Rheumatology and Clinical Immunology
- Immediate Past President, Hong Kong Academy of Medicine
- 香港大學副校長（健康）（暫任）
- 於崇光基金教授（風濕及臨床免疫學）
- 風濕及臨床免疫學講座教授
- 香港醫學專科學院前任主席

Topic | 講題

## AI in Healthcare and Medical Education: Are We Training the Right Genotype and Phenotype of Physicians?

人工智慧在醫療保健和醫學教育中的應用：  
我們是否正在培養具有正確基因型與表現型的醫生？

Keynote Speaker | 主題演講者



Founding Dean & Presidential Chair Professor, School of Medicine at the Chinese University of Hong Kong, Shenzhen

香港中文大學(深圳)醫學院創院院長兼校長講座教授

### Professor Davy Cheng 鄭仲煊教授

Professor Davy Cheng is the Founding Dean of Medicine and Presidential Chair Professor, School of Medicine at the Chinese University of Hong Kong, Shenzhen, China beginning on July 1st, 2021. He received his BSc (Hon) in Biochemistry at the University of Ottawa in 1977 and completed his MSc in Biochemistry at Western University in 1979. He graduated from the Faculty of Medicine (with an Honor Award from the Medical Society), University of Toronto in 1983, and became the Fellow of the Royal College of Physicians and Surgeons of Canada in 1987. In 2007, Prof. Cheng became the first anesthesiologist inducted as a Fellow of the Canadian Academy of Health Sciences (CAHS) in recognition of his great accomplishment and achievement in the academic health sciences in Canada. In 2013, Prof. Cheng was awarded as a Fellow of the Royal Society of Medicine, United Kingdom and was designated as CCPE (Canadian Certified Physician Executive) by the Canadian Medical Association (CMA) and the Canadian Society of Physician Executives (CSPE). Then in 2014, he was honored with the CSPE Excellence in Medical Leadership Award and became Honorary Fellow, Deutsche Gesellschaft für Anesthesiologie und Intensivmedizin (DGAI). In 2022, he was honored as Honorary Fellow, The Hong Kong College of Anaesthesiologists (HKCA).

鄭仲煊教授于2021年7月1日正式就任香港中文大學(深圳)醫學院創院院長兼校長講座教授。1977年，他畢業于加拿大渥太華大學，獲生物化學學士學位；1979年畢業於加拿大西安大略大學，獲生物化學碩士學位；1983年畢業于加拿大多倫多大學，獲醫學博士學位。1987年，他成為加拿大皇家內外科醫師學院院士；2007年，成為首位當選加拿大健康科學院院士(CAHS)的麻醉醫師；2013年，當選英國皇家醫學會會士(RSM)。2013年，鄭教授被加拿大醫學協會(CMA)和加拿大執業行政領導醫師協會(CSPE)認定為加拿大醫師領袖協會/醫學學會印證高管醫師(CCPE)，並於2014年榮獲加拿大執業醫師協會傑出醫學領袖獎。2014年，鄭教授成為德國麻醉重症醫學學會榮譽會士(DGAI)；2022年成為香港麻醉醫師學院榮譽院士(HKCA)。

Topic | 講題

## The Brain's Blueprint: Unlocking Neurological Health for Lifelong Vitality

**大腦藍圖：  
解鎖神經健康，助力終身活力**

Keynote Speaker | 主題演講者



Director, Department of Neurology,  
Shenzhen People's Hospital

深圳市人民醫院神經內科主任

### Professor Guo Yi 郭毅教授

Doctor of Medicine (Germany), Professor at Jinan University and Southern University of Science and Technology, Ph.D. Supervisor, Dual-appointed PI at Shenzhen Bay Laboratory, Distinguished Professor at Peking University, Director of Neurology at Shenzhen People's Hospital, and Director of the Functional Center at Tianjin Huanhu Hospital.

He has profound clinical expertise in cerebrovascular diseases, sleep disorders, dementia, Parkinson's disease, depression and anxiety, dizziness, headaches, epilepsy, and encephalitis. He established the most influential transcranial magnetic stimulation neuroregulation treatment platform in China and developed a functional brain network database for brain diseases based on EEG, providing effective solutions for diagnosing and treating numerous complex cases.

He currently serves as the Chair of the Neuroregulation Branch of the Chinese Stroke Association, Vice Chair of the Neuroregulation Branch of the Chinese Society of Cognitive Science, and Member of the Neurology Branch of the Chinese Medical Doctor Association. As the lead contributor, he has received the Shenzhen Science and Technology Innovation Award and the Second Prize of Shenzhen Scientific and Technological Achievements Award.

德國醫學博士、暨南大學、南方科技大學教授、博士生導師、深圳灣實驗室雙聘PI、北京大學特聘教授、深圳市人民醫院神經內科主任，天津環湖醫院功能中心主任。

在腦血管病、睡眠障礙、癡呆、帕金森氏病、抑鬱焦慮、頭暈、頭痛、癲癇及腦炎等領域具有深厚的臨床造詣。創建了國內最具影響力的經顱磁刺激神經調控治療平臺，並建立了基於腦電的腦疾病功能腦網路資料庫，為大量疑難病的診治提供了有效手段。

現任中國卒中學會神經調控分會主委、中國認知學會神經調控分會副主委、中國醫師協會神經內科分會委員。曾以第一完成人身份榮獲深圳市科技創新獎及深圳市科技成果二等獎。

Keynote Speaker | 主題演講者

## Diagnosis and Treatment of Microtia: How We Win Patients' High Trust through Technology and Service

**小耳症診療：  
我們如何用技術 + 服務  
贏得患者的高度信任**



**Dr. Guo Shuzhong**  
郭樹忠 教授

Plastic Surgeon, Chief Physician, Shenzhen New Frontier United Family Hospital

深圳新風和睦家醫院整形外科主任醫師

Dr. Guo Shuzhong received his bachelor's degree in Clinical Medicine from the Fourth Military Medical University in 1983, and subsequently obtained his master's and Doctor's degrees in plastic surgery from the Fourth Military Medical University. Dr. Guo has been a visiting scholar at five universities, including the University of Southern California, and a postdoctoral fellow at the Plastic Surgery Wound Healing Laboratory of the University of Virginia School of Medicine. Dr. Guo specializes in ear plastic surgery, nose plastic surgery, breast reconstruction and plastic surgery, abdominal wall molding, genital reconstruction, perineal plastic surgery, finger plastic surgery, hermaphroditism, transsexualism, comprehensive treatment of scars and other plastic and cosmetic complications. The surgeon completed the first Asian and the second international case of "face replacement". Before joining Shenzhen United Family Hospital, Dr. Guo served as the Director of the Military Plastic Surgery Institute of the First Affiliated Hospital of the Fourth Military Medical University (Xijing Hospital), the President of Xijing Plastic Surgery Hospital, and the president of Xi'an International Medical Center Plastic Surgery Hospital.

In addition to focusing on clinical work, Dr. Guo has edited 2 monographs and 65 SCI papers. Dr. Guo is also the Chairman of the Chinese Society of Plastic Surgery, the Executive director of the Global Chinese Association of Plastic Surgeons, the Chairman of the Plastic Surgery Professional Committee of the Chinese Association of Research Hospitals, the vice chairman of the Chinese Association of Plastic Surgery and Aesthetics, the executive vice chairman of the Plastic Surgery Professional Committee of the Chinese

Association of Non-public Medical Institutions, the vice chairman of the Chinese Society of Prosthodontic Surgery, Former chairman of the Plastic Surgery Committee of the whole Army, chairman of Shaanxi Medical Aesthetics and Cosmetology Society. Dr. Guo won the first prize of National Science and Technology Progress, the fourth "Chinese Doctor Award", and enjoys the special allowance of The State Council. At the same time, Dr. Guo is a special professor of Changjiang Scholars and a scholar of Sanqin.

郭樹忠醫生於 1983 年本科畢業於第四軍醫大學臨床醫學專業，隨後先後取得了第四軍醫大學整形外科碩士及博士的學位。郭醫生曾赴美國南加州大學等 5 所大學做訪問學者，並在美國弗吉尼亞大學醫學院整形外科創面癒合實驗室進行博士後工作。郭醫生擅長耳部整形、鼻部整形、乳房再造和整形美容、腹壁塑形術、生殖器再造、會陰整形美容、手指整形、兩性畸形和易性症、癍痕的綜合治療及其他各種整形美容疑難雜症處理。主刀完成了亞洲首例、國際第二例「換臉術」。在加入深圳和睦家醫院之前，郭醫生曾任第四軍醫大學第一附屬醫院（西京醫院）全軍整形外科研究所所長，西京整形醫院院長，西安國際醫學中心整形醫院院長。

除了專注臨床工作外，郭醫生累計主編專著 2 部，SCI 收錄論文 65 篇。郭醫生還是中華整形科學會主任委員，全球華裔整形外科醫師協會常務理事，中國研究型醫院協會整形外科專業委員會主任委員，中國整形美容協會副會長，中國非公醫療機構協會整形美容專業委員會常務副主任委員，中國修復重建外科學會副主任委員，全軍整形外科專業委員會前任主任委員，陝西省醫學美學與美容學會主任委員。郭醫生獲得國家科技進步一等獎，獲第四屆「中國醫師獎」，享受國務院特殊津貼、同時郭醫生是長江學者特聘教授、三秦學者。



Topic | 講題

## The Next Pandemic: Exploring Post Pandemic Global Impact and Building Resilience Through Intelligence

下一場疫情：  
探索後疫情時代的全球影響，  
通過智慧構建韌性

Keynote Speaker | 主題演講者



The Chair in the Department of Microbiology and Henry Fok Professor of Infectious Diseases at the University of Hong Kong, and the co-director of the State Key Laboratory of Emerging Infectious Diseases

港大微生物學系傳染病學講座教授及  
霍英東基金教授 (傳染病學)

新發傳染性疾病國家重點實驗室之共同主任

### Professor Yuen Kwok-Yung, GBS, JP 袁國勇教授

Professor Yuen Kwok-Yung is the Chair in the Department of Microbiology and Henry Fok Professor of Infectious Diseases at the University of Hong Kong, and the co-director of the State Key Laboratory of Emerging Infectious Diseases since 2005. He is a physician and microbiologist, and holds an MBBS and MD from the University of Hong Kong.

Professor Yuen has discovered over 100 novel species of virus, bacteria, fungi and parasites from patients and animals. Several of these novel animal viruses or their close relatives cause emerging infectious diseases by jumping from animals to human. In 2003, he led his team in the discovery of human SARS coronavirus, and the bat SARS related coronavirus. Professor Yuen has published extensively in the areas of coronaviruses, influenza and other emerging virus infections, and was named by Clarivate, in its list of Highly Cited Researchers, among the top 1% of scholars worldwide, for three consecutive years from 2020 to 2022.

袁國勇教授是卓越的微生物學家和內科醫生，他於香港大學修畢內外全科醫學士與醫學博士學位，現擔任港大微生物學系傳染病學講座教授及霍英東基金教授 (傳染病學)，自 2005 年起出任新發傳染性疾病國家重點實驗室之共同主任。

袁教授致力病原研究工作，多年來從病患和動物身上識別出逾百種新病毒、細菌、真菌和寄生蟲，當中數種動物攜帶病毒或其近親可傳播至人類，繼而導致新興傳染病。2003 年，袁教授帶領團隊識別出嚴重急性呼吸系統綜合症 (沙士) 的人類和蝙蝠冠狀病毒。袁教授就冠狀病毒、流感和其他新興病毒感染所發表之論文數量可觀，在學術界中極具影響力，2020 至 2022 連續三年入選科睿唯安「最廣獲徵引研究人員」名單，位列全球首 1% 研究人員。

Topic | 講題

# Funding Tomorrow: Creating a Thriving Life Science Ecosystem in the GBA

## 投資未來： 在大灣區創建繁榮的 生命科學生態系統

Moderator | 主持人

Panellist | 講者



## Mr. Fu Shan 付山先生

Managing Partner of Vivo Capital  
維梧資本管理合夥人

Mr. Fu Shan joined Vivo in 2013 as a Managing Partner, Co-CEO, and CEO of Asia Pacific. Before joining Vivo, Mr. Fu worked for Blackstone as Senior Managing Director in the Private Equity group and the Chief Representative of Blackstone's Beijing Office. Mr. Fu also worked in the Department of Foreign Investment in China's National Development and Reform Commission (NDRC), the State Economic and Trade Commission of China, the Office of Economic and Trade in State Council of China, and the Office of Production in State Council of China. He also serves on the boards of New Frontier Health, Esco Lifesciences Group and Visen Pharmaceuticals.

付山先生於 2013 年加入維梧資本，任公司管理合夥人、聯席 CEO 兼亞太區 CEO。在加入維梧資本之前，付先生曾擔任黑石集團 (Blackstone) 私募股權業務高級董事總經理及黑石北京辦事處首席代表，並曾任職於中國國家發展與改革委員會 (發改委) 外資司、中國國家經濟與貿易委員會、中國國務院經濟貿易辦公室及中國國務院生產辦公室。此外，付先生也是新風醫療集團、Esco 生命科學集團、維昇藥業的董事會成員。

Panellist | 講者



## Mr. Min Fang 方敏先生

Managing Director of  
Warburg Pincus China;  
Co-Head of China Private Equity  
華平投資董事總經理；  
中國私募股權投資聯席總裁

Mr. Min Fang joined Warburg Pincus in 2007 and is a Managing Director and Co-Head of China Private Equity. He is currently the chairman of HTDK and AFIONA, and serves on the boards of Insilico Medicine, Jinxin Fertility Group (01951. HK), Zhenshiming Pharmaceutical, Evercare, 58.com, Ziroom, and Genki Forest.

Prior to joining Warburg Pincus, he worked at the Boston Consulting Group focusing on management consulting for pharmaceutical and medical device companies. Min received a BA in International Finance from Fudan University and an MBA from the Stanford Graduate School of Business.

方敏先生於 2007 年加入華平投資，聯席負責華平投資在中國私募股權領域的投資。方先生目前擔任華瑭大昌以及妍麗董事長，並在英矽智慧、錦欣生殖 (01951.HK)、珍視明、伊美爾、58 同城、自如以及元氣森林擔任董事。

加入華平之前，方先生就職於波士頓諮詢集團，主要負責醫藥和醫療器械領域的管理諮詢業務。方先生持有復旦大學國際金融學士學位以及美國斯坦福大學商學院 MBA 學位。

Panellist | 講者



## Mr. Yan Zhao 趙彥先生

Partner of Trustar Capital  
信宸資本合夥人

Mr. Zhao is responsible for China private equity investment at Trustar Capital. Prior to joining the firm in 2008, Mr. Zhao worked in the Shanghai office of EQT Partners Asia Limited as an Associate, where he focused on China buy-out investments. Before that, he was an Associate, Global Capital Markets of China International Capital Corporation (CICC), focused on equity and debt offerings. Mr. Zhao obtained his Master and Bachelor's degrees in Computer Science from the Shanghai Jiao Tong University.

趙彥先生現為信宸資本中國私募股權投資部門的合夥人。2008年加入本公司前，趙先生於股拓集團 (EQT Partners) 上海辦事處從事直接股權投資業務，專注於中國企業併購。他亦曾任職於中國國際金融有限公司 (CICC) 的資本市場部，從事股本和固定收益專案的承銷業務。趙先生擁有上海交通大學的計算機科學學士和碩士學位。

Panellist | 講者



## Mr. Gao Meng 高猛先生

Chief Investment Officer of  
Nan Fung Group  
南豐集團首席投資官

Mr. Gao is responsible for overseeing Nan Fung's overall investment activities, as well as developing the group's strategic initiatives including Nan Fung Life Sciences. Mr. Gao joined Nan Fung Group in 2015. Prior to joining Nan Fung Group, Mr. Gao was a Managing Director at Blackstone's Private Equity Group in Hong Kong, where he was involved in a number of transactions across multiple industries.

Before joining Blackstone, Mr. Gao was a Senior Vice President at Oaktree Capital Management, where he was involved in sourcing, structuring and executing private equity investments in China. Prior to that, Mr. Gao was an investment banker with Credit Suisse and J.P. Morgan in New York. Mr. Gao received a Bachelor of Economics degree from Peking University, an M.A. from Yale University and an M.B.A. from the Wharton School of the University of Pennsylvania, where he graduated with Honors.

高猛先生現為南豐集團首席投資官，負責管理南豐的整體投資活動以及集團在南豐生命科技等戰略領域的拓展。高先生於2015年加入南豐集團，此前高先生曾擔任黑石集團香港私募股權投資團隊董事總經理，參與了多個行業的專案和交易。在加入黑石集團前，高先生為美國橡樹資本管理公司高級副總裁，參與在中國尋找、構建和執行私募股權投資。

在此之前，高先生曾任紐約的瑞士信貸和摩根大通擔任投資銀行家。高先生擁有北京大學經濟學學士學位、耶魯大學碩士學位和賓夕法尼亞大學沃頓商學院工商管理碩士學位，並以優異成績畢業。



Panellist | 講者



## Mr. Zheng Xuanle

### 鄭烜樂先生

Founder & CEO of Lighthouse Capital

Founding partner of Lighthouse Capital Innovation Fund

光源資本創始人、CEO

光源創新基金創始合夥人

Mr. Zheng Xuanle founded Lighthouse Capital in 2014, transforming it into a leading new-generation investment bank in China. Lighthouse Capital offers a comprehensive range of services including financing, mergers & acquisitions, securities underwriting, asset management, and more. Over the past decade, Lighthouse Capital has been dedicated to identifying exceptional innovative enterprises, providing a full suite of financial services and ecosystem support to foster industrial innovation and development. The company aims to build a long-term, trustworthy investment banking and asset management platform for global entrepreneurs and investors. Today, Lighthouse Capital is recognized as one of China's most influential new-type investment banks, consistently ranked first in the “Financial Advisors in China” and “China's Best New-Type Investment Bank”. Since its inception, Lighthouse Capital has facilitated over 500 private equity financing transactions for more than 300 innovative companies, with a cumulative transaction amount exceeding RMB 280 billion. Among the companies served by Lighthouse Capital, over 50 have become unicorns in their respective fields.

In 2021, Mr. Zheng was named one of the “Top 100 Young Scholars in Chinese Industry Research” by the Research Institute of Machinery Industry Economic & Management. He was also honored as the “Most Influential Young Investor in China 2020-2021” by 21st Century Business Herald and “One of the 36 Most Remarkable Investors Under 36” by 36Kr. Prior to founding Lighthouse Capital, Mr. Zheng gained extensive experience in corporate financing and mergers & acquisitions, holding key positions at Ernst & Young, SinoChem International, and ZeroIPO Capital. Driven by a deep understanding of technological disruption and its impact on industries, Mr. Zheng has honed his ability to uncover hidden value. By developing proprietary frameworks, he accurately predicts and capitalizes on pivotal moments in a company's growth trajectory. His support has been instrumental in the growth of leading

innovative companies such as Kuaishou (HKEX: 01024), Bilibili (NASDAQ: BILI), Lalamove, Poizon, Eswin, Zhihu (NYSE: ZH), and Baichuan Intelligent. Additionally, he has forged close “capital + innovation” strategic partnerships with major industry groups such as SANY Group, GCL-Poly Energy Holdings, Geely Holding Group, Chint Group, and Bull Group. These collaborations have contributed to building effective synergy between industries, universities, and research institutes, thereby fostering innovation through industry-academia collaborations.

鄭烜樂先生 2014 年創建光源資本，帶領其成為中國新一代領軍產業投行，業務覆蓋融資與併購、證券承銷、資產管理等領域，成立十年來，光源資本始終致力於探尋卓越創新企業，以全體系金融服務與生態賦能，助力產業創新升級發展，為全球企業家和投資人打造長期可信賴的投行服務和資產管理一體化平臺。目前光源資本已成長為中國最具影響力新型投行，接連獲評“中國財務顧問榜單”“中國最佳新型投行”首位。成立至今，光源資本已說明 300 餘家創新企業完成超過 500 筆私募融資交易，累計交易金額超過 2800 億人民幣。在光源資本所服務的企業中，有 50 餘家已發展成為所在領域的獨角獸企業。2021 年，鄭烜樂先生入選機械工業經濟管理研究院「中國產業研究青年學者百強」，曾獲 21 世紀經濟報導 2020-2021 年度中國最具影響力青年投資家、36 氦年度 36 位 36 歲以下了不起的投資人等獎項。創建光源資本前，他長期從事企業融資與併購重組相關工作，先後任職於安永（Ernst&Young）、中化國際和清科資本。鄭烜樂先生長期關注技術革命帶來的時代變革、產業變革及企業價值的演變。他善於通過研究發掘價值，並以此建立起行之有效的發現企業價值拐點的範式，發掘並助力快手（HKEX: 01024）、哔哩哔哩（Bilibili）（NASDAQ: BILI）、貨拉拉、得物、奕斯偉、知乎（NYSE: ZH）、百川智慧等極具代表性的頂尖創新企業蓬勃發展，並與三一集團、協鑫集團、吉利集團、正泰集團、公牛集團等多個產業集團建立了緊密的「資本 + 創新」戰略合作，為創新產業企業、科研院所構建起行之有效的產學研體系，助力產業創新落地與升級發展。

# Strong Together, Believe in Better.

連接更美好的未來，從顧連開始

Leading National Rehabilitation Medical Service Provider





# From Cradle to Cane

Committed to Being Your Trusted Professional Home Healthcare Partner.

---

Long-Term Care | Medical Service | Corporate Wellness | Maternity & Infant Care



Topic | 講題

## Innovations in Drug Development: Connecting the GBA to Global Life Science Breakthroughs

藥物研發：  
攜手大灣區，共鑄全球  
生命科學新突破

Moderator | 主持人



Managing Director-  
New Frontier Group;  
CSO-New Frontier Group  
新風天域集團董事總經理  
新風天域集團首席戰略官

### Mr. Mengwei Xin 辛夢葦先生

Mr. Mengwei Xin is the Managing Director and Chief Strategy Officer at New Frontier Group, where he leads the development and execution of strategic initiatives, operational planning, and business growth efforts. At New Frontier, Mr. Xin plays a key role in shaping the group's direction and expanding its integrated healthcare platform across China.

Prior to joining New Frontier, Mr. Xin was a Partner at McKinsey & Company, where he co-led the Healthcare Systems and Services Practice in China and Asia.

Mr. Xin holds a Master of Business Administration at Columbia Business School, a Master of Science in Finance at EDHEC Business School, and a Bachelor of Engineering at Nanyang Technological University.


辛夢葦先生是新風天域集團的董事總經理及集團首席戰略官，負責集團整體的戰略製定、運營規劃及新業務構建。在新風天域，他在明確集團戰略發展方向、整合下屬業務之間資源、持續協同拓展平臺業務等方面承擔關鍵職責。

辛夢葦先生在加入新風天域前，曾擔任麥肯錫公司全球董事合夥人，領導中國及亞太地區醫療服務與醫療體系相關的諮詢業務。

辛夢葦先生是美國哥倫比亞大學工商管理碩士、法國北方高等商學院金融學碩士以及新加坡南洋理工大學工程學學士。



Panellist | 講者



## Professor Jiafu Ji 季加孚教授

Director of Department of General Surgery and GI Cancer Center at Beijing Cancer Hospital;  
Former President of Beijing Cancer Hospital

北京大學腫瘤醫院大外科主任、  
胃腸腫瘤中心主任；  
北京大學腫瘤醫院前任院長

Professor Ji is the Director of the Department of Major Surgery and Director of the Gastrointestinal Cancer Center at Beijing Cancer Hospital. He is also the chairman of Beijing Anti-Cancer Association; Vice president of China Association for the Promotion of International Exchanges in Healthcare; Member of the Standing Committee and Secretary General of Surgery Branch of Chinese Medical Association; Chairman of the Gastric Cancer Quality Control Expert Committee of the National Center for Quality Control of Tumors; Chairman of the Oncological Surgery Committee of Surgery Branch of Chinese Medical Doctors' Association; And member of the Expert Consultation Committee of the Committee for Promotion of the Healthy China Initiative. He is the former President of the International Gastric Cancer Association (IGCA), Fellow of the American College of Surgeons (FACS), Fellow of the Royal College of Surgeons (FRCS), and Standing Committee Member of the Asian Society of Surgery (ASA).

季加孚教授是現任北京大學腫瘤醫院大外科主任、胃腸腫瘤中心主任。兼任北京抗癌協會理事長；中國醫療保健國際交流促進會副會長；中華醫學會外科學分會常委兼秘書長；國家腫瘤質控中心胃癌質控專家委員會主任委員；中國醫師協會外科分會腫瘤外科醫師委員會主任委員；健康中國行動推進委員會專家諮詢委員會委員。是國際胃癌學會 (IGCA) 前任主席、美國外科學會會員 (FACS)、英國皇家外科學院院士 (FRCS)、亞洲外科學會 (ASA) 常委。

Panellist | 講者



## Professor Qin Jun 秦鈞教授

Chief Scientist of Life  
Health at China Resources  
Research Institute

華潤研究院生命健康領域  
首席科學家

Professor Qin Jun currently serves as the Chief Scientist of Life Health at China Resources Research Institute and is a Distinguished Expert of Beijing. He is an internationally renowned expert in proteomics and one of the few scholars worldwide who integrates mass spectrometer design, proteomics method development, bioinformatics, biology, and clinical applications into a single research project. Professor Qin received his bachelor's degree in Chemistry from Tsinghua University, followed by a master's degree in Physical Chemistry from Kansas State University, and a Ph.D. in Life Sciences from Rockefeller University. He was a researcher at the National Heart, Lung, and Blood Institute of the NIH, and subsequently held positions as Assistant Professor, Associate Professor, and Professor in the Department of Biochemistry and Molecular Biology at Baylor College of Medicine.

Professor Qin has achieved several significant breakthroughs in proteomics research, including developing the world's first one-stop proteomics data analysis cloud platform Firmiana, establishing the highest-throughput protein scanning technology internationally, mapping the first proteomic landscape of diffuse gastric cancer, deciphering DNA damage repair mechanisms, and making important advances in urinary protein detection for nephropathy patients and early cancer screening technologies. Currently, he is leading the establishment of a biomedical diagnostic research center at the Hong Kong-Shenzhen Innovation and Technology Park, dedicated to advancing the application of proteomics in clinical medicine.

秦鈞教授現任華潤研究院生命健康領域首席科學家。他是國際知名的蛋白質組學專家，也是世界上少數幾位將質譜儀設計、蛋白質組學方法開發、生物信息學、生物學及臨床應用納入同一個研究項目的學者之一。秦鈞教授在清華大學獲得化學學士學位，隨後在美國堪薩斯州立大學獲得物理化學碩士學位，並於美國洛克菲勒大學獲得生命科學博士學位。他曾在美國國立衛生研究院心臟、肺和血液研究所任研究員，後在美國貝勒醫學院生物化學與分子生物學繫歷任助理教授、副教授、教授。

秦鈞教授在蛋白質組學研究領域取得了多項重要成就，包括開發全球首個一站式蛋白質組學數據分析雲平颱 Firmiana，建立國際最高通量的蛋白質組掃描技術，繪製首個彌漫型胃癌蛋白質組地形圖，解析 DNA 損傷修復機制，以及在腎病患者尿蛋白檢測和腫瘤早篩技術方面取得重要突破。目前，他正領導華潤研究院在港深創科園建設生物診斷研究中心，致力於推動蛋白質組學在臨床醫學中的應用。

Panellist | 講者



**Mr. Peter Ding**  
**丁強先生**

Co-founder and CEO,  
Allorion Therapeutics

安銳生物共同創始人、執行總裁

Peter has more than 24 years of experience in innovative small molecule drug R&D and is an expert in medicinal chemistry and preclinical development. Previously served as Co-founder/R&D Head at Curegenix (2011-2019), where he led the development of first-in-class WNT pathway inhibitor CGX1321 for treating advanced colorectal cancer, which has entered global Phase II clinical trials. He worked in Novartis for 11 years as Principal Investigator and program leader (2000-2011), where his work contributed to two FDA-approved drugs: Asciminib (Bcr-Abl allosteric inhibitor) for treating chronic myeloid leukemia, and Infigratinib (FGFR inhibitor) for treating advanced cholangiocarcinoma.

24 年小分子創新藥研發經驗，藥物化學與臨床前開發專家。前 Curegenix 共同創始人 / 研發總裁 (2011-2019)，領導開發的 first-in-class WNT 通路抑制劑 CGX1321 用於靶向晚期直結腸癌的治療已經進入全球 II 期臨床。前美國諾華製藥藥物化學主任研究員 (2000-2011)，研發工作貢獻了 2 個 FDA 批准上市藥物：Asciminib (Bcr-Abl 變構抑制劑) 用於治療慢性粒細胞白血病，Infigratinib (FGFR 抑制劑) 用於治療晚期膽管癌。

Panellist | 講者



**Mr. Tao Wang**  
**王濤先生**

CEO of NF Nova Clinical CRO  
新風新研首席執行官

Mr. Wang is responsible for the overall business development and operation planning of NF Nova Clinical CRO. Mr. Wang was the Senior Vice President of NuSigma, leading the team to manage and complete a number of domestic and international clinical trials of Phase 1-IV innovative drugs and medical devices, covering a wide range of therapeutic areas, including clinical trials under NMPA, FDA, and EMEA regulatory requirements.

Mr. Wang possesses more than 20 years of experience in clinical research, having worked with several prominent international CROs and foreign pharmaceutical firms. He has significant expertise in managing international clinical research projects. Mr. Wang graduated from the University of Aberdeen with a Master's degree in Public Health.

王濤先生負責 CRO 整體的業務發展與運營規劃。王濤先生曾擔任諾思格高級副總裁，帶領團隊管理並主持完成多項 1-IV 期創新藥物及醫療器械國內及國際臨床試驗，涵蓋多個治療領域，包括在 NMPA、FDA 及 EMEA 法規要求下的臨床試驗。

王濤先生過去二十餘年專注於臨床研究領域的工作，任職於多家國際領先的 CRO 機構及外資藥企，具有豐富的國際臨床研究專案管理經驗。王濤先生畢業於英國亞伯丁大學，獲得公共衛生專業碩士學位。

Panellist | 講者



## Mr. KK Tong 唐嘉其先生

CEO of New Frontier Health  
Hong Kong;

Executive Vice Secretary-General  
of New Frontier GBA Medical  
Executive Committee

新風醫療集團(香港) 首席執行官；  
新風大灣區醫療執行委員會  
常務副秘書長

Mr. KK Tong is the Chief Executive Officer of New Frontier Health (Hong Kong) and the Executive Vice Secretary-General of the New Frontier Greater Bay Area Medical Executive Committee. He is responsible for overseeing the group's medical operations in Hong Kong, which include the Hong Kong Integrated Oncology Centre, HEAL Oncology, HEAL Medical, Hong Kong Integrated Diagnostic Imaging Centre, and Hong Kong Adventist Hospital Oncology Centre.

With over 20 years of experience in the pharmaceutical industry, KK has held key positions at multinational companies such as GlaxoSmithKline and UCB, managing marketing operations across various Asian markets, including Taiwan region, South Korea, and other ASEAN countries. Prior to joining the Hong Kong Integrated Oncology Centre in October 2018, he served as the General Manager for Hong Kong SAR and Macau SAR at Amgen, the world's largest independent biotechnology company, where he led the establishment of Amgen's Hong Kong SAR branch and was responsible for strategic decision-making and operational management. KK has actively contributed to the advancement of innovative healthcare in the medical community. Since 2019, he has been the founding director of the Hong Kong Society for Innovative Medicine and served as a visiting lecturer at the Polytechnic University of Hong Kong's School of Professional and Continuing Education. KK holds a degree in Biochemistry from The Chinese University of Hong Kong and a Master's degree in Health Services Management from The Hong Kong Polytechnic University, as well as a Master's degree in Data Science and Business Statistics from The Chinese University of Hong Kong.

唐嘉其先生是新風醫療集團(香港)的首席執行官兼新風大灣區醫療執行委員會常務副秘書長。他負責管理集團在香港的醫療業務，包括香港綜合腫瘤中心、希愈腫瘤中心、希愈醫療中心、香港綜合影像診斷中心和香港安腫瘤中心等。

在晉身醫療機構管理前，唐嘉其先生在製藥業擁有超過二十年的經驗，曾在葛蘭素史克(GlaxoSmithKline)和優時比(UCB)等跨國製藥公司任職，負責管理亞洲多個市場的市務工作，包括臺灣地區、韓國和其他東盟國家等。在2018年10月加入香港綜合腫瘤中心之前，唐嘉其先生是全球規模最大的獨立生物科技公司安進(Amgen)的香港特別行政區及澳門特別行政區的總經理，領導安進在香港特別行政區成立分公司並負責決策和行政工作。2019年開始，唐嘉其先生一直積極投入推動醫護界創新醫療的工作，分別擔任過香港創新醫療學會創會董事及香港理工大學專業進修學院客席講師等公職。唐嘉其先生畢業於香港中文大學，主修生物化學，同時獲得數據科學和商業統計碩士學位，並擁有香港理工大學的健康服務管理碩士學位。





深圳新风和睦家医院

Shenzhen New Frontier United Family Hospital

位於大灣區的全面整合的醫院生態系統，戰略位置優越，緊鄰福田口岸，擁有世界一流的醫療團隊，能提供全面的臨床服務。醫院憑藉大灣區政策支援、先進醫療設施、專業醫療團隊及廣泛的合作網路，具備促進區域醫療資源互通、技術服務與共享的全面優勢及構建醫療網路平臺。

Located within the Greater Bay Area's fully integrated hospital ecosystem, Shenzhen New Frontier United Family Hospital boasts a strategic location near the Futian Port. It is equipped with a world-class medical team and offers comprehensive clinical services. With the support of Greater Bay Area policies, advanced medical facilities, professional healthcare teams, and an extensive collaboration network, the hospital holds significant advantages in promoting the integration, technical services, and sharing of regional medical resources, as well as in building a robust medical network platform.

構建醫療網路平臺

Open Medical Network Platform

創新醫療技術

Cutting-edge Medical Technology

醫師交流

Physician Collaboration

跨境保險

Cross-border Insurance Services

創新藥物

Innovative Drugs

WhatsApp: +852 6673 5099

網站/Website: <https://hk.ufh.com.cn>

醫院公眾號二維碼

Hospital Official Account QR Code



深圳市福田区沙头街道新洲社区福强路4012号

4012 Fuqiang Road, Xinzhou Community, Shatou Street, Futian District, Shenzhen



Topic | 講題

## Innovating Health Coverage: Connected Care in Hong Kong and the GBA

創新健康保障：  
香港與大灣區的  
互聯醫療服務

Moderator | 主持人



Executive Director, New Frontier Group  
Co-Founder & President, Prosper Health  
Co-Founder & President, Better  
Insurance Brokerage

新風天域集團執行董事  
柏盛健康聯合創辦人兼總裁  
柏泰保險經紀聯合創辦人兼總裁

### Mr. Jason Zheng 鄭會傑先生

Mr. Zheng is currently the Executive Director of New Frontier Group and leads the Insurance Solutions business. He is the Co-Founder and President of Prosper, a leading health insurance solutions provider, and Better, a leading insurance brokerage. He also serves as the Executive Chairman at Hello Toby, a leading local services marketplace in Hong Kong, and played an instrumental role in the creation of Boxful, Asia's largest on-demand self-storage company.

Before joining New Frontier, Jason worked in the Investment Banking Division at JPMorgan where he was involved in a number of high-profile equity transactions across Greater Asia.

Jason was acknowledged by Forbes Asia's "30 Under 30 Entrepreneur". He earned his Master's in Financial Economics degree from the University of Oxford and is also an alumnus of University of British Columbia where he earned his Bachelor's in Commerce.

鄭先生現任新風天域執行董事負責保險服務業務。同時也是中國領先健康險服務公司柏盛健康與保險經紀公司柏泰經紀的聯合創始人兼總裁，並擔任香港最大的互聯網服務平臺 HelloToby 的執行董事長。此外，他亦是亞洲最大的私人儲存服務公司 Boxful 的創始團隊成員之一。

在加入新風天域集團之前，鄭先生曾就職於摩根大通投資銀行部，並參與了多個企業上市及融資項目。

2021年，鄭先生獲選《福布斯》30位30歲以下亞洲傑出青年榜單。鄭先生擁有牛津大學金融經濟碩士及加拿大英屬哥倫比亞大學金融學士學位。

Panellist | 講者



**Mr. Lawrence Lam**  
**林智剛先生**

CEO of Prudential HK  
保誠保險香港行政總裁

Lawrence Lam joined Prudential Hong Kong as CEO in July 2022. He leads the Hong Kong executive management team to drive growth and development, and oversees operations of Prudential's life and general insurance business in Hong Kong, covering a full suite of protection, health, wealth and investment insurance solutions as well as a comprehensive collection of general-purpose insurance products.

Prior to joining Prudential, Lawrence was the Chief Executive of Citi's consumer bank in Hong Kong. He brings with him a wealth of experience in managing multi-channel distribution and servicing network, developing a customer-centric digital ecosystem, and creating client value through segmentation and product innovation. Lawrence has held senior leadership positions at Citi, including Head of Retail Banking, Head of Sales and Distribution, and Director of Consumer Lending, and has played a critical role in building the bank's insurance business through bancassurance partnership.

Lawrence holds a Bachelor of Business Administration (Honours) degree from the Ivey Business School. He is a Chartered Financial Analyst (CFA) and a Financial Risk Manager (FRM). He is a member of the Hong Kong Academy of Finance.

林智剛先生獲委任為保誠保險行政總裁，並於 2022 年 7 月履新。林先生帶領香港管理層推動保誠人壽及一般保險業務拓展和營運，涵蓋健康保障、財富和投資管理，以及一般保險等全面保障產品。

在加入保誠前，林先生為香港花旗零售銀行總經理，於管理多渠道分銷及服務網絡、發展以客戶生活為本的電子生態圈，以及通過客戶分層管理與產品創新提升客戶價值等領域擁有豐富的經驗。林先生於花旗銀行曾任不同管理要職，包括零售銀行主管、銷售及分售業務主管、個人財務總監等，並同時於開拓銀行保險業務擔任關鍵角色。

林先生持有 Ivey Business School 工商管理 (榮譽) 學士學位，並擁有特許財務分析師 (CFA) 及金融風險管理師 (FRM) 的專業資格。林先生為香港金融學院會員。



Panellist | 講者



### Mr. Jiaoyan Shang 尚教研先生

General Manager,  
Pacific Health Insurance Co., Ltd  
太平洋健康險總經理

Mr. Shang has successively served as Manager of Comprehensive Development Department of Ping An Life Beijing Branch, General Manager of Ping An Health Insurance Beijing Branch, Marketing Director of Ping An Health Insurance Headquarter, General Manager of Individual Business Division, and Vice President of Tencent Micro Insurance. He is an actuarial professional with a diverse background in life insurance, professional health insurance and internet platform. He has been working in the market for many years, is familiar with the operational mechanism of internet insurance, has led the development of influential and innovative products in the industry, has rich frontline experience, has in-depth knowledge of strategy, and has strong ability of organization, coordination and management of the overall situation.

尚教研先後歷任中國平安人壽北京分公司綜合開拓部經理、平安健康險北京分公司總經理、平安健康險總部營銷總監、個人業務事業部總經理、騰訊微保副總裁等職務。精算專業科班出身，同時具有頭部壽險、專業健康險和互聯網平臺的復合經歷，深耕市場多年，熟悉互聯網保險營運機制，曾主導開發在業內有影響力的創新產品，一線經驗豐富，兼具對戰略的深入認知，組織協調和駕馭全域能力強。

Panellist | 講者



### Ms. Sally Wan 尹玄慧女士

Chief Executive Officer,  
AXA Greater China

AXA 安盛中國大陸、香港及澳門行政總裁

Sally is the Chief Executive Officer of AXA Greater China and is responsible for the management and operation of AXA Hong Kong & Macau and AXA Tian Ping. She also oversees the ICBC-AXA business and AXA Asian Markets Services which specialises in information technology services in Asia.

Sally holds several positions in industry committees, including Insurance Authority Committee, Motor Insurers' Bureau of Hong Kong and Hong Kong Federation of Insurers Governing Committee. She is also the President of 31<sup>st</sup> East Asian Insurance Congress.

尹玄慧為 AXA 安盛中國大陸、香港及澳門行政總裁，負責 AXA 安盛 (香港及澳門) 及安盛天平的管理和營運。她亦負責工銀安盛業務及專注於亞洲資訊科技服務的 AXA Asian Markets Services。

尹女士任職多個行業委員會成員，包括保險業監管局委員會、香港汽車保險局理事會及香港保險業聯會管制委員會，她亦擔任第 31 屆東亞保險大會主席。



Panellist | 講者

**Mr. Clement Lam****林嘉言先生**

Chief Executive Officer, Sun Life  
Hong Kong Limited (Incorporated  
in Bermuda with limited liability)

香港永明金融有限公司行政總裁  
(於百慕達註冊成立之有限責任公司)

Clement Lam is the Chief Executive Officer at Sun Life Hong Kong. In this role, he oversees and leads the Company's business development and operations. Clement has more than 18 years of experience in the insurance industry in North America and Asia. He joined Sun Life's team in Canada in 2007 and moved to Hong Kong in 2009. Over the years, Clement took on pivotal roles at Sun Life's regional office in Asia, where he led product actuary and product innovation, and spearheaded the development of Telco-Assurance business. He was also a core member of the leadership team that supervised Sun Life's business in mainland China.

In January 2017, Clement was appointed General Manager of Life and Health at Sun Life Hong Kong. Under his leadership, the Life and Health businesses achieved phenomenal growth in product development and business performance, as well as distribution to high-net-worth individuals.

Clement has been supervising the Company's strategic investment in Bowtie Life Insurance Company Limited, the first virtual insurer approved under the Fast Track pilot scheme of the Insurance Authority in Hong Kong and was appointed Chairman of the Board at Bowtie from May 2020 to June 2023, maintaining a close relationship with Bowtie and actively participating in the Health Innovative Committee. Clement is the Chairman of the Life Insurance Council and a Governing Committee Member of the Hong Kong Federation of Insurers. Clement was appointed a member of Product Advisory Committee of The Securities and Futures Commission.

He is also a Member of the Governors' Council of the Canadian Chamber of Commerce in Hong Kong. Clement holds a Bachelor of Mathematics (Distinction) from the University of Waterloo. He is also a Fellow Member of the Canadian Institute of Actuaries (Canada) and Society of Actuaries (FSA).

林嘉言為香港永明金融行政總裁，負責監督及領導公司在香港的業務發展及營運。林氏在北美及亞洲的保險業擁有逾 18 年經驗。2007 年，他加入永明金融在加拿大的團隊，並於 2009 年轉調至香港的辦事處。多年來，林氏出任永明金融亞洲區不同管理層職務，主管產品精算和產品創新，並拓展電訊保險業務的發展。他曾為永明金融監督中國內地業務的管理團隊之核心成員。

2017 年 1 月，林氏獲委任為香港永明金融人壽及康健產品總經理。在他的領導下，人壽及康健業務在產品及業務表現以至高淨值分銷均取得驕人的增長。此外，林氏負責監督公司對保泰人壽保險有限公司的策略投資。保泰為香港保險業監管局之快速通道試驗計劃下首間獲批的虛擬保險公司，林氏由 2020 年 5 月至 2023 年 6 月出任保泰的董事局主席，一直與保泰保持緊密關係，並積極參與「醫療健康創新委員會」事務。林氏為香港保險業聯會壽險總會主席及管治委員會成員，並獲香港證監會委任為產品諮詢委員會委員。他亦為香港加拿大商會諮詢會成員。林氏持有滑鐵盧大學榮譽數學系數學學士（優異）學位，並為加拿大精算協會及北美精算師協會成員。

Topic | 講題

## Demonstration of AI Application in Health Insurance

科技 / 人工智慧  
在健康保險領域的應用

Speaker | 演講者



Co-founder & CEO at Prosper Health  
柏盛健康聯合創始人兼首席執行官

### Mr. Kevin Zhou 周晞燁先生

Kevin has previously held management positions at numerous leading international insurance organizations and benefits consulting firms. He has been deeply engaged in health insurance and corporate employee benefits for more than 20 years, and has accumulated rich local industry experience, as well as international vision in the field of medical insurance and healthcare.

周晞燁曾任職於多家全球領先的國際保險機構和福利諮詢公司，並擔任管理層崗位，深耕健康險和企業員工福利超過 20 年，在醫療和大健康領域積累了豐富的本土行業經驗與國際化視野。

Speaker | 演講者



CTO-New Frontier Group  
新風天域集團首席技術官

## Mr. Prince Wang 王楨先生

Mr. Prince Wang is the CTO at New Frontier where he leads the long-term technology vision of New Frontier's various portfolio companies. Prince currently serves as the CTO for Toby, the leading Marketplace for Services in Hong Kong, where he is responsible for overseeing all technical aspects, including the software architecture, information technology and engineering of the company. Prior to his role at Toby, Mr. Wang has over 10 years of technical experience serving as the Lead Senior Software Engineer in China's most prestigious tech companies including Alipay and Dianpin (now Meituan-Dianpin), as well as the Senior System Architect behind one of the leading transportation management software in North America. Prince graduated from Wuhan University where he received his Master's in Computer Science and Bachelor in Physics.

王楨先生是新風天域的首席科技官，制定新風天域各個控股公司的長期科技策略。王先生現時擔任香港領先本地服務互聯網平臺 Toby 的首席科技官，負責監督和領導所有科技團隊，包括軟件架構、資訊技術和公司資訊工程。在擔任 Toby 首席科技官之前，王先生在中國最負盛名的高科技公司包括阿里巴巴和大眾點評（現在的美團點評）等擔任高級軟件工程師，以及北美領先運輸管理軟體的高級系統架構師。王先生於武漢大學獲得計算機科學碩士與物理學士學位。

Topic | 講題

## On the Horizon: Health AI in 2030

展望未來：  
2030 年的健康產業  
人工智慧

Moderator | 主持人



Managing Director and the  
Co-COO of New Frontier Group  
Director of the Board and the  
COO of New Frontier Health

新風天域集團董事總經理及  
聯席首席運營官

### Mr. David Zeng 曾瀛先生

Mr. David Zeng is the Managing Director and the Co-COO of New Frontier Group and is also a Director of the Board and the COO of New Frontier Health. Mr. Zeng is primarily responsible for the investments efforts at New Frontier Group and the operations of portfolio companies. Mr. Zeng led the acquisition of United Family Healthcare by New Frontier Corporation (renamed as New Frontier Health Corporation) with a total enterprise valuation of us \$1.44 billion. Prior to joining New Frontier, Mr. Zeng was a Senior Associate at Blackstone's Private Equity Group in Hong Kong. At Blackstone, he executed a number of investments across multiple industries in China, including the take-private of Global Sources Limited (one of the world's largest electronics exhibition operators) and the buyout of Shya Hsin Packaging (one of the world's largest color cosmetics plastic packagers). Mr. Zeng was also actively involved in the operations of Blackstone portfolio companies. He was most recently the interim-CFO and Executive Director of Shya Hsin Packaging and led a number of key operational initiatives. Prior to joining Blackstone, Mr. Zeng was a member of the Mergers & Acquisitions Group at Barclays in Hong Kong.

曾瀛先生是新風天域集團的董事總經理及集團聯席首席運營官，同時擔任新風醫療集團董事會董事及首席運營官。曾瀛先生主要負責新風天域集團的投資業務，及集團旗下企業的戰略規劃和運營工作。曾瀛先生主導並負責了新風天域集團紐約上市平臺，新風天域公司（現已更名為新風醫療集團）以 14.4 億美金的企業價值全資收購和睦家醫療。在加入新風天域之前，曾瀛先生曾任黑石集團香港私募基金團隊的副總裁。在任職黑石期間，他執行了黑石在大中華區多個行業的投資，包括環球資源公司（全球最大的電子展覽營辦商之一）的美股私有化，以及中國洽興包裝集團（全球最大的彩妝塑膠包裝生產商之一）的收購項目。曾瀛先生還積極了參與黑石旗下公司的戰略規劃以及日常運營。他曾任中國洽興包裝集團的首席財務官兼執行董事，並領導了一系列重要的運營提升公司業績。在加入黑石集團之前，曾瀛先生曾任職於巴克萊銀行投資銀行部收購兼併組。



Panellist | 講者

**Prof. Tongyu Zhu****朱同玉教授**

Vice Dean, Shanghai Medical  
College of Fudan University

復旦大學上海醫學院副院長

Prof. Zhu is currently Vice Dean of Shanghai Medical College of Fudan University, Director of Shanghai Key Laboratory of Organ Transplantation, Director of Shanghai Joint Innovation Laboratory of Medical Big Data, Director of Shanghai Phage Research Institute, Professor of Urology at Zhongshan Hospital of Fudan University. Prof. Zhu has published more than 200 academic articles in the fields of Surgery, Virology, Basic Medicine and Hospital Management, and has applied for many patents and realized many translations.

朱同玉教授現任復旦大學上海醫學院副院長、上海市器官移植重點實驗室主任、上海市醫學大數據聯合創新實驗室主任、上海噬菌體研究所所長、復旦大學附屬中山醫院泌尿外科教授。朱教授在外科學、病毒學、基礎醫學和醫院管理領域發表學術文章 200 多篇，申請專利並實現轉化多項。

Panellist | 講者



## Dr. Alexander Ng 吳文達 醫生

President of Tencent Healthcare  
WHO (World Health Organization) Digital  
Health Technical Advisory Group Expert  
Honorary Professor, School of Public Health,  
The University of Hong Kong

騰訊健康總裁  
世界衛生組織數字醫療技術諮詢  
委員會專家  
香港大學公共衛生學院名譽教授

Alex is currently leading Tencent Healthcare to support healthcare industry's digital innovation and transformation. Tencent Healthcare currently connects and smoothens the process of accessing online and offline healthcare services for individuals on Tencent Healthcare mini-program, and also provides AI and cloud solutions to health agencies, hospitals, medical institutions, and pharmaceutical companies. Before joining Tencent, Alex was the Deputy Director for Health Innovation and Partnership at the Bill & Melinda Gates Foundation and Associate Partner at McKinsey & Company.

為踐行騰訊“用戶為本，科技為善”的使命和願景，吳文達醫生目前正帶領騰訊健康，助力醫療健康行業的數位化創新和轉型。通過“騰訊健康”小程序，為個人使用者提供線上線下一體化的醫療服務；同時，為公共衛生機構、醫院、醫療機構和製藥企業提供人工智慧與雲端解決方案，通過創新的數位技術支持供給側轉型。加入騰訊之前，吳文達醫生曾在比爾及梅琳達·蓋茨基金會北京辦事處擔任副主任。此前9年，吳文達醫生在麥肯錫公司擔任全球副董事合夥人。

Panellist | 講者



## Xiaodong Tao, Ph.D. 陶曉東 博士

CEO, iFLYTEK Health  
訊飛醫療科技股份有限公司總裁

Xiaodong Tao, graduated from University of Science and Technology of China with a B.S. degree in Electrical Engineering. In 2005, he obtained his Ph.D. in Electrical and Computer Engineering from Johns Hopkins University. Since then, he worked at General Electric Company and Royal Philips Electronics of the Netherlands, where he led teams working on research and development of cutting-edge technologies for healthcare and medical equipment, in particular, imaging devices, imaging methods, clinical applications, and radiology solutions. Dr. Tao joined iFLYTEK Health in Jan. 2017 as the CEO. Since 2021, he was appointed adjunct professor at the School of Biomedical Engineering at the University of Science and Technology of China.

陶曉東，本科畢業於中國科學技術大學，獲電子工程與資訊科學學士學位，2005年於美國約翰霍普金斯大學電子與計算機工程系畢業並獲得博士學位，研究方向為醫學影像。陶曉東博士先後供職於美國通用電氣公司(GE)和荷蘭皇家飛利浦電子公司，領導醫學影像研發團隊進行從影像設備、成像方法、臨床應用，到影像科解決方案的科研和產品開發。2017年1月，他加入訊飛醫療科技股份有限公司，擔任總裁。2021年起，任中國科學技術大學生物醫學工程學院兼職博士生導師。

Panellist | 講者

**Ms. Mandy Qiu****邱慧女士**

Chief Technology Officer of New Frontier Health

新風醫療首席科技官

Ms. Mandy Qiu is the Chief Technology Officer of New Frontier Health, responsible for the technology strategy and AI innovation applications of New Frontier Health and United Family Healthcare. Since joining New Frontier Health, Ms. Qiu has rapidly established an AI and digital intelligence team. They have independently developed products such as the "Medical Translation Large Language Model", "AI Medical Assistant", and "Intelligent Doctor Workbench" based on large language models, which have significantly improved medical quality and patient experience. Before joining New Frontier Health, Ms. Qiu worked at world-renowned high-tech companies such as Microsoft and Tencent. She also led two technology startups to successfully listings on the US stock market. Ms. Qiu obtained a Master's degree in software and microelectronics from Peking University.

邱慧女士是新風醫療的首席科技官，負責新風醫療及和睦家醫療的科技戰略及 AI 創新應用。邱慧女士自加入新風醫療以來快速組建了一支 AI 及數智化團隊，自主研發了基於大語言模型的“醫療翻譯大模型”、“AI 醫療助理”、“智慧醫生工作臺”等產品，極大的提升了醫療品質及患者體驗。在加入新風醫療前，邱慧女士曾就職于微軟及騰訊等世界知名高科技公司，並且曾帶領兩家科技創業公司成功赴美上市。邱慧女士于北京大學獲得軟件與微電子碩士學位。

Topic | 講題

## Next Destination: Positioning HK and the GBA as a Global Leader in Medical Tourism

下一站：  
將香港和大灣區定位為  
全球醫療旅遊的領導者

Moderator | 主持人



Member of the Executive Council  
of The Government of The Hong  
Kong Special Administrative Region;  
Director of New Frontier GBA  
Healthcare Group

香港特別行政區行政會議成員  
新風大灣區醫療董事

### Dr. the Honourable Ko Wing-man, GBS, JP 高永文 醫生

Dr. Ko is a member of the Standing Committee of the National Committee of the Chinese People's Political Consultative Conference and the Standing Committee of the Chao Zhou City Committee of the Chinese People's Political Consultative Conference. He is also Council Member of the Hong Kong Committee for UNICEF, Vice Chairman of the Federation of Hong Kong Chiu Chow Community Organisations and Vice President of the Hong Kong China Chamber of Commerce. Dr Ko was Secretary for Food and Health from July 2012 to June 2017 and previously Chairman of the Hong Kong Anti-Cancer Society and Director of the Hong Kong Red Cross. He was awarded the Gold Bauhinia Star in 2017.

現任全國政協常務委員及政協潮州市委員會常委。他擔任聯合國兒童基金會香港委員會委員、香港潮屬社團總會常務副主席，以及香港中國商會常務副會長。高醫生於2012年7月至2017年6月期間任食物及衛生局局長，亦曾任香港防癌會主席及香港紅十字會總監。2017年獲香港特區政府頒授金紫荊星章。



Panellist | 講者



**Prof. Ronnie Poon**  
**潘冬平教授**

Co-Founder-Hong Kong Integrated  
Oncology Centre;  
Medical Director-New Frontier  
GBA Healthcare  
香港綜合腫瘤中心聯合創始人  
新風大灣區醫療總監

Prof. Poon is the Medical Director of New Frontier Greater Bay Area Healthcare, he is also an Honorary Clinical Professor in the Department of Surgery at the University of Hong Kong and founded the Hong Kong Comprehensive Oncology Center in 2015 to provide a full range of cancer services.

Prof. Poon graduated with MBBS from the University of Hong Kong in 1989, with the award of John Anderson Gold Medal in 1989 and obtained his Master of Surgery and Doctor of Philosophy degrees from HKU. He joined the Department of Surgery at HKU after completing his specialist surgical training at St. Vincent's Hospital in Sydney, Australia and Queen Mary Hospital in Hong Kong. He was the Chair Professor of Hepatobiliary and Pancreatic Surgery at the University of Hong Kong and Head of the Department of Hepatobiliary and Pancreatic Surgery at Queen Mary Hospital. He was also the Assistant Dean of the Faculty of Medicine at the University of Hong Kong and the Deputy Director of Center for Cancer Research.

Professor Poon specializes in hepatobiliary and pancreatic tumor research and has published over 400 research articles and has been invited to speak at over 350 international conferences. He was ranked by Research.com as the 15th best medical scientist in China in 2024 and has developed treatment guidelines for liver cancer for the Asia-Pacific Hepatology Society and the National Cancer Institute of the USA.

潘冬平教授是新風大灣區醫療集團醫療董事，他同時也是香港大學外科名譽教授，2015 年創辦了香港綜合腫瘤中心，提供全方位癌癥服務。

潘冬平教授於 1989 年畢業於港大醫學院，獲 John Anderson Gold Medal，並在港大取得外科碩士及哲學博士學位。他在澳洲悉尼聖雲仙醫院及香港瑪麗醫院完成外科專科訓練後加入港大外科學系。曾任港大肝膽胰外科講座教授及瑪麗醫院肝膽胰外科主管，並擔任港大醫學院助理院長及癌癥研究中心副總監。

潘冬平教授專註於肝膽胰腫瘤研究，發表逾 400 篇國際論文，受邀在國際會議上演講超過 350 場。他被 Research.com 評為 2024 年中國第 15 位最佳醫學科學家，為亞太肝病學會及美國國家癌癥研究院訂立肝癌治療指引。

Panellist | 講者



**Dr. Koon Hung Lee**  
**勵冠雄 醫生**

Assistant Medical  
Superintendent of Hong Kong  
Sanatorium & Hospital  
香港養和醫院副院長

Dr. LEE Koon Hung is a Fellow of the College of Surgeons of Hong Kong, Hong Kong College of Emergency Medicine, and Hong Kong College of Community Medicine. He is currently the Assistant Medical Superintendent of Hong Kong Sanatorium & Hospital and has extensive administrative experience, achieving remarkable results in healthcare management.

Before assuming his current position, Dr. LEE served as the Hospital Chief Executive of Shatin Hospital and Bradbury Hospice, Cluster Performance Chief Manager and Chief Manager (Financial Advisory Service and Costing) of the Hospital Authority. He was responsible for managing and monitoring the performance of hospital clusters and coordinating cross-cluster and multidisciplinary medical services. He successfully established and optimized the Hospital Authority's performance monitoring and accountability reporting systems, while also coordinating medical services across regions and clusters.

勵冠雄醫生是香港外科醫學院、香港急症科醫學院及香港社會醫學學院院士。現為香港養和醫院助理醫療總監，擁有豐富的行政經驗，在醫療管理上成就斐然。

擔任現職前曾任職沙田醫院及白普理寧養中心醫院行政總監、醫管局總行政經理（聯網運作）、醫管局總行政經理（財務規劃），負責管理及監察醫院聯網的服務表現，以及統籌跨聯網及跨專科的醫療服務，成功建立及優化醫管局的績效監察及問責匯報系統，以及統籌跨地區和跨聯網的醫療服務。

Panellist | 講者

**Dr. Kenneth Tsang****曾慶廉 醫生**

Regional CEO of  
IHH Healthcare North Asia  
CEO of Gleneagles Hospital  
Hong Kong

IHH 醫療 (北亞洲) 區域首席執行官  
港怡醫院執行總裁

Dr. Kenneth Tsang serves as Regional Chief Executive Officer of IHH Healthcare's operations in North Asia. In conjunction with his role as Chief Executive Officer of Gleneagles Hospital Hong Kong, he provides oversight for Gleneagles Hospital, Gleneagles Healthcare ambulatory care centres and primary clinics, and Parkway Laboratory Services in Hong Kong.

Dr. Tsang leads the hospital to provide excellent and innovative healthcare services in Hong Kong and at a regional level. He also steers the hospital's development in the realms of digital health, clinical innovations and clinical research to foster its growth into a leading healthcare provider locally and regionally.

曾慶廉醫生為 IHH 醫療 (北亞洲) 區域首席執行官。他同時兼任港怡醫院執行總裁，負責監督在香港營運的港怡醫院、港怡醫療日間中心和基層醫療診所及百匯化驗服務。

曾醫生帶領醫院在香港和區域內提供卓越和創新的醫療服務。他亦引領醫院在數碼醫療、創新臨床服務和臨床研究領域方面的發展，促進港怡發展成為本地和區域內領先的醫療服務機構。

Panellist | 講者



### Dr. Jane CK Chan 陳真光 醫生

President, Hong Kong Chinese  
Medical Association

Specialist in Respiratory Medicine

Honorary Clinical Associate Professor,  
University of Hong Kong

香港中華醫學會會長

呼吸系統科專科醫生

香港大學醫學院榮譽副教授

- Graduate from Univ of Chicago in 1982.
- Returned to Hong Kong in 1990 after completion of advanced training in Respiratory and Critical Care Medicine at Stanford University.
- Served as Clinical Lecturer at HKU/QMH for 9 years.
- Became ICU Consultant/Director at QMH in 1995.
- Joined private practice in 2005.
- Took up the Presidency of Hong Kong Chinese Medical Association in 2021, with goals of advancing medical professionalism and professional exchange with Mainland counterparts.

- 1982 年畢業於美國芝加哥大學醫學院，繼而在美國實習。
- 1989 年在史丹福大學醫院完成呼吸系統和深切治療深造。同年回港服務，在香港大學 / 瑪麗醫院教學。
- 1995 年轉到香港醫管局 / 瑪麗醫院深切治療部服務。
- 2005 年開始私人執業。
- 2021 年開始擔任香港中華醫學會會長一職，致力為香港醫學界謀求福祉和與國內交流。

Panellist | 講者



### Dr. Cheng Chi Man 鄭志文 醫生

President, Hong Kong Medical  
Association

香港醫學會會長

- MBBS (HK) 1989
- MRCGP (UK) 1999
- DFM (CUHK) 2000
- PDipComPsychMed (HK) 2003
- Master of Family Medicine (CUHK) 2005
- 香港大學內外全科醫學士 1989
- 英國皇家全科醫學院院士 1999
- 香港中文大學家庭醫學文憑 2000
- 香港大學社區精神醫學深造文憑 2003
- 香港中文大學家庭醫學碩士 2005



Panellist | 講者



## Prof. Fung Hong 馮康教授

Executive Director and Chief Executive Officer, CUHK Medical Centre;

Professor of Practice, The Jockey Club School of Public Health & Primary Care, CUHK

香港中文大學醫院執行董事及行政總裁

香港中文大學賽馬會公共衛生及基層醫療學院專業應用教授

Prof Fung joined CUHK in 2014. Before that, Prof. Fung was Cluster Chief Executive of the New Territories East Cluster and Hospital Chief Executive of the Prince of Wales Hospital at the Hospital Authority (HA) from 2002 to 2013, overseeing the management and operations of 7 public hospitals in New Territories East.

Prior to that, he worked in the HA Head Office for 11 years, where he was responsible for the planning and development of the public hospital services and facilities, and also spearheaded the development of HA's Clinical Management System and electronic patient records.

On the professional side, Prof. Fung was President (2014-2018) and Chief Censor (2010-2013) of the Hong Kong College of Community Medicine. Prof. Fung is well recognized for his expertise in medical leadership, health planning, health informatics, and health services management.

馮教授於 2014 年加入香港中文大學。在此之前，馮教授於 2002 至 2013 年任醫院管理局新界東聯網行政總監及威爾斯親王醫院行政總監，負責新界東 7 所公立醫院的管理及營運。

再之前，他在醫管局總辦事處工作 11 年，負責公營醫院服務及設施的規劃和發展，並領導發展醫管局的臨床管理系統及電子病歷紀錄。

在專業領域，馮教授曾任香港社區醫學院院長 (2014-2018 年) 及主考官 (2010-2013 年)。他在醫療領導、衛生規劃、衛生信息學和醫療服務管理方面的專業知識廣受認可。

# Make Insurance Simple and Human

讓 | 保 | 險 | 簡 | 單 | 且 | 人 | 性 | 化

Health Insurance  
健康保險

Personal Care Manager  
私人健康管家

AI Powered Operation  
AI賦能運營

Retirement Plan  
養老傳承



Topic | 講題

## Leading the Future of Clinical Excellence: Lessons from Mainland China's Healthcare System and Hong Kong's Interaction and Innovation

引領臨床卓越的未來：  
中國大陸醫療體系與香港的  
互動與創新

Moderator | 主持人



Executive Director-  
New Frontier Group  
COO - New Frontier GBA  
新風天域執行董事  
大灣區首席運營官

### Mr. Brian Siu 蕭毅晃先生

Mr. Brian Siu is an Executive Director of New Frontier. Brian currently helps with the new project development and ventures portfolio management in New Frontier. Brian works closely with the venture team at New Frontier and is involved in formulating deal terms, structuring and execution of investment opportunities.

Brian was a key member of the New Venture Medical Company's listing on the New York Stock Exchange in 2018, and he also played pivotal roles in group project development, investments, and management, primarily overseeing the construction and operation of Shenzhen New Frontier United Family Hospitals.

Before joining New Frontier, Brian spent 6 years in management consulting and venture capital. Brian worked in McKinsey & Company, Greater China first as a Business Analyst and an Associate.

蕭毅晃先生是新風天域公司的執行董事。蕭先生目前在新風天域幫助新項目開發和控股公司管理。蕭先生與新風天域的風險投資團隊密切合作，並參與制定交易條款，專案構建和執行投資項目。

蕭先生是新風醫療公司 2018 年紐交所上市的重要成員，也在集團新專案開發和投資、管理擔任重要角色，並主要負責深圳新風和睦家醫院的建設及運營。

在加入新風天域之前，蕭先生在管理諮詢和風險投資領域工作了 6 年。蕭先生曾在麥肯錫公司大中華區擔任商業分析師和諮詢經理。

Panellist | 講者

**Dr. Kelly Xia****夏凱莉 醫生**

General Manager,  
Guangzhou United Family Hospital  
廣州和睦家醫院院長

- Member of the Standing Committee of Non-government Medical Doctor Branch of Guangdong Medical Doctor Association
  - Vice Chairman for Non-government Medical Institution Management Branch of Guangzhou Hospital Association
  - Vice Chairman for Guangzhou Medical Doctor Association
  - Vice Chairman for "GBA Medication and Device Policy" Professional Working Committee of Guangzhou Hospital Association
  - Governor for The American Chamber of Commerce In South China
  - Member of the Hematology Committee of Guangdong Society of Pediatrics, Chinese Medical Association
  - Member of the Child Immunization Committee of Guangdong's Chinese Association For Improving Birth Outcome and Child Development
  - Member of the Standing Committee of International and Premium Medicine, Cross-Strait Medicine Exchange Association
- 
- 醫學博士 MD
  - 高級工商管理碩士 EMBA
  - 兒科主任醫師
  - 廣東省醫師協會非公機構醫師分會常務委員
  - 廣州市醫院協會社會辦醫管理分會副主任委員
  - 廣州市醫師協會副主任委員
  - 廣州市醫院協會“港澳藥械通”專業工作委員會副主任委員
  - 華南美國商會理事
  - 中華醫學會廣東省兒科分會血液學組委員
  - 廣東省優生優育協會兒童免疫專委會委員
  - 海峽兩岸國際醫療與特需服務常務委員



Panellist | 講者



## Professor Shuguang Lin 林曙光教授

Chairman of New Frontier GBA  
Advisory Board, Chief Physician  
新風集團大灣區專家委員會主席、  
主任醫師

Former President of Guangdong Provincial People's Hospital, Post-doctoral Fellow of Johns Hopkins University, Fellow of the American College of Cardiology, Honorary Fellow of the Hong Kong Heart Institute. Specializes in the diagnosis and treatment of cardiovascular diseases such as hypertension, hyperlipidemia, metabolic syndrome, coronary heart disease, heart failure, valvular heart disease.

Ex-president Guangdong Medical Association; Expert of the Central Health Commission, China's National Scientific and Technological Achievements and Projects, National New Drugs.

林曙光曾任廣東省人民醫院院長，是美國霍普金斯大學心臟科博士後、美國心臟學院院士、香港心臟學院榮譽院士。擅長高血壓、高脂血症、代謝綜合症、冠心病、心力衰竭、心臟瓣膜病等心血管疾病的診治。

林曙光院長曾任廣東省醫師協會會長，同時是中央保健委員會會診專家、中國國家科技成果和科技專案評審專家、國家新藥評審專家。

Panellist | 講者



## Mr. Yuan Shuai 袁帥先生

Co-Founder &  
Co-CEO-Care Alliance &  
New Frontier Vitality

顧連醫療及大健康策略控股  
聯合創始人及聯席執行長

Mr. Shuai Yuan is the Co-founder and Co-CEO of Care Alliance. Care Alliance operates post-acute rehabilitation hospitals, pediatric rehabilitation centers, geriatric hospitals and long-term nursing facilities. It is committed to promoting modern principles and practices as well as cultivating talents across the rehabilitation and age care continuum in China.

Prior to forming Care Alliance, Mr. Yuan previously worked at Morgan Stanley Private Equity Asia, leading the assessment, execution and management of healthcare investment opportunities in Asia, including privatization of public hospitals and acquisition and set-up of rehabilitation hospitals. Mr. Yuan received his Bachelor of Arts degree in Economics and Political Science with Distinction from Yale University.

袁帥先生是顧連醫療的聯合創始人及聯席執行長。顧連醫療專注於投資、管理和運營亞急性期康復醫院、兒童康復中心、老年醫療機構、長期照護機構、專業人才培養等相關醫療服務，致力於推動康復與老年醫學在中國的快速發展。

袁先生曾就職於摩根士丹利亞洲私募基金，主要負責其在亞洲醫療行業投資項目的評估、執行和投後管理，參與並負責了包括公立醫院私有化、康復醫院的收購與新建等重大醫院並購項目。袁先生畢業於美國耶魯大學，獲政治學及經濟學雙學位。

Panellist | 講者



**Professor**  
**Kenneth M.C. Cheung**  
**張文智 教授**

Hospital Chief Executive,  
the University of Hong Kong -  
Shenzhen Hospital

Chair Professor and Jessie Ho  
Professor in Spine Surgery at the  
Li Ka Shing Faculty of Medicine,  
the University of Hong Kong

香港大學深圳醫院院長  
香港大學何馮月燕 (脊柱外科)  
講座教授

Prof. Cheung is a special expertise in the treatment of spinal deformities in children and adults. He is the Past President of the Hong Kong College of Orthopaedic Surgeons, and he was the first Chinese President of the international Scoliosis Research Society (SRS), the world's highest academic institution of spinal surgery (2016-2017). He not only led the development of orthopaedics in Hong Kong, but also played a significant role on the international stage on behalf of China's orthopaedics. In 2021, he was awarded the prestigious Walter P. Blount Humanitarian Award by the Scoliosis Research Society for his outstanding service to those with spinal deformity, and for generosity to the profession and society.

Since 1987, Prof. Cheung has been working in the front line of orthopaedic clinical services, teaching and research. His clinical and translational research in the prevention and treatment of scoliosis has reached international level. He has been invited to give lectures at many international academic events and has extensive experience in science and medicine related matters. He has received 37 awards for research excellence, published over 370 peer reviewed scientific articles, 22 book chapters and holds 63 patents. He also serves as the Emeritus Editor of the Journal of Orthopaedic Surgery and the Deputy Editor of The Journal of Bone and Joint Surgery.

張文智教授是兒童和成人脊柱畸形治療的專家，曾先後擔任國際脊柱學會 (AO Spine) 國際研究委員會的創會主席 (2006-2008 年)、香港骨科醫學院院長 (2013-2015 年)，2016 年他成為脊柱外科全球最高學術機構——國際脊柱側彎研究協會 (SRS) 首位華人主席 (2016-2017 年)，不僅引領了香港骨科的發展，也代表中國骨科專業在國際舞臺上發揮顯著影響力。2021 年，他榮獲脊柱側彎研究學會著名的國際 Walter P. Blount 人道主義獎，以表彰他在脊柱側彎領域的卓越貢獻和仁慈服務。

從 1987 年至今，張文智教授一直堅持工作在骨科臨床和教研前線，他在脊柱側彎綜合防治一體化的臨床及轉化研究已達國際領先水準。張教授多次獲邀在重要國際學術會議發表演講，他在科學和醫學相關領域有豐富的經驗，曾獲 37 項科研榮譽，並在 Lancet 等國際期刊上發表 SCI 論文 370 篇，出版專著 22 章，擁有 63 項專利。他也是知名專業雜誌《Journal of Orthopaedic Surgery》名譽編輯及《The Journal of Bone and Joint Surgery》副編輯。

Topic | 講題

## The Next Destination: Shifting Landscape in International Medical Care

下一站：  
國際醫療格局的轉變

Moderator | 主持人



**Mr. Ed Tam**  
譚君傑先生

Managing Director-  
New Frontier Group  
CEO-United Family Healthcare  
International Medical Service  
Vice chairman-  
New Frontier Group (Hong Kong)  
新風天域集團董事總經理  
和睦家跨境醫療首席執行官  
新風天域集團 (香港) 副董事長

Mr. Ed Tam is a seasoned healthcare entrepreneur and executive, bringing over twenty years of global expertise in corporate strategy. In addition to his role at NFG, Mr. Tam serves as the Chief Executive Officer of United Family International Medical Service. In this capacity, he is committed to enhancing access to global healthcare for Chinese patients, with a specific focus on oncology, fertility, and longevity medicine. Furthermore, he facilitates collaboration with neighboring countries to provide access to exceptional surgical, as well as pharmacological solutions available in China.

Mr. Tam is also the founder of the HEAL Medical Group - a micro-healthcare network that encompasses, a dedicated cancer care center, a surgically-led multi-specialist centre, a state-of-the-art aesthetic treatment centre; and also a leading fertility centre.

譚先生是一位經驗豐富的醫療行業企業家和高級管理人員，除了在新風集團的任職外，譚先生還擔任和睦家國際醫療服務的首席執行官，致力於提高中國患者獲得全球醫療服務的機會，尤其是在腫瘤、輔助生殖和長壽醫學方面。此外，他還促進中國與周邊國家的合作，為中國患者提供卓越的手術和藥物治療方案。

譚先生還是希愈醫療集團的創始人，該集團是一個微型醫療保健網絡，包括一個專門的癌症治療中心、一個以外科為主導的綜合專科中心、一個先進美容治療中心，以及輔助生殖中心。

Panellist | 講者



**Ms. Roberta Lipson**  
**李碧菁女士**

Vice Chair, New Frontier Health  
Chair, AmCham China

新風醫療副董事長  
中國美國商會主席

Roberta Lipson is the Vice Chair of New Frontier Health, as well as the Chair of AmCham China. With over 40 years of experience in China's healthcare industry, she co-founded Chindex in 1981, which evolved into China's first and largest foreign-invested healthcare system. UFH now operates 11 hospitals and nearly 20 clinics across major cities in China, including Beijing, Shanghai, Guangzhou, Tianjin, Qingdao, Hainan, and Shenzhen, along with a national internet hospital. It has been recognized as "The Most Trusted Healthcare Brand of China" by the Chinese Business Journal in 2016.

Lipson also founded and leads the United Foundation for China's Health, which provides lifesaving interventions and health management services to underserved populations. The foundation has spearheaded pilot programs to eradicate cervical cancer, serving thousands of rural women annually and training local healthcare workers. She has received the "Great Wall Friendship Award" from the Beijing government and the Pioneer Award from AmCham China. Lipson holds a BA from Brandeis University and an MBA from Columbia University and has lived and worked in Beijing for over 40 years.

Roberta Lipson (李碧菁) 是新風醫療 (New Frontier Health) 的副主席和中國美國商會的主席。她在中國醫療行業擁有超過 40 年的豐富經驗。1981 年，李碧菁女士與他人共同創辦了美中互利公司 (Chindex)，將其發展成為中國第一個也是最大的外資醫療體系。和睦家醫療目前在中國的北京、上海、廣州、天津、青島、海南和深圳等地擁有 11 家醫院和近 20 家診所，以及一家全國性的網路醫院，成為提供優質、個人化醫療服務的首選品牌。2016 年，《中國商業雜誌》將其評為「中國最值得信賴的醫療品牌」。

李碧菁女士也創立並領導了北京和睦家醫療救助基金會，該基金會為貧困人群提供救生干預和健康管理服務，並開展了根除子宮頸癌的試點項目，每年為數千名農村婦女提供篩檢和治療服務，並訓練當地醫護人員。她曾獲得北京市政府授予的“長城友誼獎”，並被中國美國商會授予“中國先鋒獎”。李碧菁女士擁有布蘭迪斯大學學士學位和哥倫比亞大學工商管理碩士學位，並在北京生活和工作了 40 多年。



Panellist | 講者



**Professor Terence Sio,  
MD, MS**  
蕭榮泰教授

Radiation Oncologist, Mayo Clinic  
梅奧診所放射腫瘤科教授

**Present Academic Rank and Position:**

07/2015 - Present	Investigator - Cancer Trials Support Unit (CTSU), Phoenix, Arizona
01/2019 - Present	Clinical Assistant Professor - Division of Clinical Education, Midwestern University/Arizona College of Osteopathic Medicine, Glendale, Arizona
06/2019 - Present	Consultant - Department of Radiation Oncology, Mayo Clinic, Phoenix/Scottsdale, Arizona
04/01/2023 - Present	Professor of Radiation Oncology - Mayo Clinic College of Medicine and Science

**Honors and Awards**

06/2015	<b>Roentgen Resident/Fellow Research Award</b> - Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota In Recognition of Outstanding Radiologic Research, Radiological Society of North America Research & Education Foundation and Department of Radiation Oncology, Mayo Clinic, MN
07/2015	<b>Recipient - Listed in the 2016, 70th Edition</b> - Marquis Who's Who in America
11/2015	<b>Travel Honorarium Recipient</b> - Symptom Intervention, Alliance Semi-annual Subcommittee Meeting
07/2016	<b>Employee Appreciation Award</b> - Mayo Clinic in Arizona, Mayo Clinic For excellence in providing nursing education
05/2018	<b>KAS Summer Research Fellowship Award</b> - Midwestern University Mentor for Alex Erikson, DO
12/2018	<b>Co-Recipient, Top Poster Award</b> - 2018 ESTRO Meets Asia Annual Meeting-Singapore. N-Acetylcysteine Rinse for Thick Secretion and Mucositis of Head and Neck Chemoradiotherapy (Alliance MC13C2): A Double-Blind Randomized Clinical Trial
05/2019	<b>Travel Honorarium Recipient</b> - Health Outcomes, Alliance Semi-annual Subcommittee Meeting
02/2020	<b>International Atomic Energy Agency (IAEA) Fellowship</b> - International Proton Beam Radiotherapy Educational Program and Training, Mayo Clinic Arizona
02/2021	<b>Highest Patient Accrual into Clinical Trials by a Faculty Member in 2020</b> - Department of Radiation Oncology, Mayo Clinic Arizona Certificate of Achievement
03/2022	<b>Top Cited Article Award (Co-author)</b> - Journal of Applied Clinical Medical Physics Wiley Publications, Hoboken, NJ
05/2022	<b>Mayo Clinic Experience Top Performing Provider Award (2021)</b> - Mayo Clinic 99th Percentile Rank in "Likelihood to Recommend Your Provider"
05/2022	<b>Nomination - Teaching Award</b> - Arizona Campus, Mayo Fellows' Association
07/2022	<b>Above and Beyond Recognition Program for Excellence</b> - Mayo Clinic By Paul Haren (Clinical Research and Trial Unit/Protocol Development Team)
12/2022	<b>Volunteer Service Award 2022 - For 3 Years of Service</b> - American Board of Radiology
03/2023	<b>Senior Fellow, Academy of Educational Excellence</b> - Mayo Clinic Category: Excellence in Curriculum Design and Assessment (Pending)
10/2023	<b>2023 RO-ILS Radiation Oncology Safety Star Award</b> - ASTRO Quality Council, American Society for Radiation Oncology (ASTRO)

Panellist | 講者



## Professor Hiromichi Ito, MD, FACS

JFCR

日本癌症研究會

### Scientific and Medical Societies:

- Japan Surgical Society, active member (since 1997)
- American College of Surgeon, active fellow (since 2001)
- American Association of Cancer Research, active member (since 2001)
- International Hepato-Pancreato-Biliary Association, active member (since 2003)
- Society for Surgery of the Alimentary Tract, active member (since 2007)
- Society of Surgical Oncology, active member (since 2008)
- American Society of Clinical Oncology, active member (since 2008)
- Americas Hepato-Pancreato-Biliary Association, active member (since 2010)
- Association for Academic Surgery, active member (since 2010)
- Pancreas Club, active member (since 2010)

### Research Fellowship:

- |               |   |
|---------------|---|
| 7/2001-6/2004 | General Surgery (Research fellow)<br>Topic: Molecular biology in pancreatic cancer<br>Brigham and Women's Hospital, Boston, MA  |
| 7/2007-6/2008 | Hepato-pancreatico-biliary Surgery (Research fellow)<br>Topic: Gene-expression profiling in metastatic colorectal cancer in liver<br>Memorial Sloan-Kettering Cancer Center |
| 7/2009-6/2010 | Surgical Oncology<br>Topic: Molecular biology in pancreatic cancer<br>Brigham and Women's Hospital  |

### Honors and Awards:

- |               |   |
|---------------|---|
| 3/1999        | Best resident of the year 1999<br>St. Luke's International Hospital, Tokyo, Japan                       |
| 10/2001       | Mannick Award for surgical research<br>Brigham and Women's Hospital, Harvard Medical School, Boston, MA |
| 5/2003        | Invited SSAT resident conference (top 20 resident papers)<br>SSAT,Orland, FL                            |
| 5/2003        | Distinguished Poster, SSAT, Orland, FL  |
| 4/2004        | Best papers award, Pancreatic Cancer 2004, Pisa, Italy  |
| 5/2004        | Invited SSAT resident conference (top 20 resident papers)<br>SSAT, New Orleans, LA                      |
| 5/2004        | Distinguished Poster, SSAT, New Orleans, LA   |
| 10/2004       | Mannick Award for surgical research<br>Brigham and Women's Hospital, Harvard Medical School, Boston, MA |
| 11/2004       | Distinguished Poster, Mass Chapter, American College of Surgeons, MA                                    |
| 12/2005       | Young Investigator Travel Grant Award<br>World Congress of Digestive Surgery, Yokohama, Japan           |
| 7/2007-6/2008 | Kenneth Warren Fellowship Award, IHPBA  |
| 6/2008        | Excellence in Teaching Citation,<br>2006-2007 Tufts University School of Medicine                       |
| 1/2009        | Merit Young Investigator Award, GI ASCO, San Francisco, CA  |
| 4/2010        | Young Investigator Travel Grant Award<br>Annual Congress of Japan Surgical Society                      |
| 5/2010        | Invited SSAT resident conference (top 20 resident papers)<br>SSAT, New Orleans, LA                      |

Topic | 講題

## The Future of Healthcare Investments, IPOs and Capital Market Trends

醫療健康行業投資展望，  
聚焦 IPO 與資本市場趨勢

Moderator | 主持人



Managing Director and  
Co-COO of New Frontier Group

新風天域集團董事總經理  
及聯席首席運營官

### Mr. Tom Sze 施鴻傑先生

Mr. Tom Sze is a Managing Director and Co-COO - New Frontier Group. Prior to joining New Frontier, Tom was an Investment Professional at Viking Global Investors, one of the largest global hedge funds, where he was responsible for a few billion dollars in the Asia Internet, Technology, Media and Telecom, and Industrial sectors. Prior to Viking, Tom was at Blackstone's Private Equity Group in Hong Kong. He was one of the earlier members of the Blackstone Asia team, where he led and executed a number of investments in China, Korea, South East Asia and Australia. Prior to Hong Kong, Tom worked at Francisco Partners and McKinsey in San Francisco.

Tom received his Bachelor of Science degree in Electrical Engineering and Computer Science with Magna Cum Laude from Harvard University, and a Masters degree in Management Science and Engineering from Stanford University.

施鴻傑先生是新風天域 (New Frontier) 公司的董事總經理兼集團聯席首席運營官。施先生於加入新風天域前，曾是萬金全球 (Viking Global)、全球最大規模的對沖基金之一的職業投資者。在任職萬金期間，他負責管理幾十億美元的資產，投資範圍覆蓋亞洲互聯網、科技、媒體和電信及工業行業。在加入萬金之前，施先生就職於黑石集團香港私募基金團隊，為黑石亞洲團隊的最早期成員之一，負責黑石大中華區、韓國、東南亞和澳大利亞的私募投資業務。在加入黑石之前，施先生先後就職於麥肯錫諮詢公司和 Francisco partners 的美國舊金山辦事處。

施先生以極優等學業成績於哈佛大學的電子工程系及計算機科學系學士畢業，並擁有斯坦福大學的工程管理碩士學位。

Panellist | 講者

**Mr. John C. Lee****李鎮國先生**

Vice Chairman, Managing Director  
Co-Head of Asia Country Coverage  
Global Banking  
UBS AG

副主席  
亞洲企業客戶部聯席主管  
全球投資銀行部

John C. Lee is Vice Chairman and Co-Head of Asia Country Coverage, Global Banking for UBS AG. Mr. Lee joined UBS AG in March 2017 and is currently responsible for senior client coverage and origination efforts for M&A and equity and debt capital markets in the Greater China region. He has over 30 years of investment banking experience with transactions across Asia in a wide range of product areas. Prior to joining UBS AG, John worked at Bank of America Merrill Lynch for 20 years from 1996-2016 as Vice Chairman of Asia Coverage and Head of Hong Kong, Taiwan and Macau coverage and at Bear Stearns Asia Limited for 2 years from 1994-1996.

Mr. Lee is currently a Member of the Listing Review Committee of The Hong Kong Exchanges and Clearing Limited as well as Council Member of The Better Hong Kong Foundation, Council Member for Advisory Council on Career Development for The Hong Kong University of Science and Technology, and Vice Chairman of Hong Kong-Mainland International Investment Society.

John holds a BBA degree from Southern Methodist University in the U.S., with a concentration in Finance and Real Estate.

李鎮國先生目前擔任瑞士銀行（瑞銀）全球投資銀行部副主席及亞洲企業客戶部聯席主管。李先生於 2017 年 3 月加入瑞銀，目前負責大中華地區的投資銀行業務，包括併購及股票及債務資本市場業務。他擁有超過 30 年的投資經驗，並參與亞洲各地多種產品領域的專案。在加入瑞銀之前，他在美銀美林工作了 20 年（1996-2016），曾任美銀美林亞洲業務副主席及香港、台灣和澳門業務主管。1994-1996 年，他在貝爾斯登亞洲有限公司工作了兩年。

李先生是香港交易及結算所有限公司上市複核委員會、「香港明天更好基金」理事委員、香港科技大學職業發展顧問委員會委員以及香港國際投資總會副主席。

李先生持有美國南方衛理公會大學的工商管理學士學位，主修金融與房地產。



Panellist | 講者



### Mr. Jia Xu 許佳先生

Managing Director of CICC, Deputy Head of Investment Banking Department, Head of International Group

中金公司董事總經理、投資銀行部執行負責人、全球組負責人

Mr. Xu joined CICC in 2006, and he is the Managing Director of CICC. He now serves as the Deputy Head of Investment Banking Department and Head of International Group.

Mr. Xu has been actively participating in many transactions including the sectors of financial service, TMT, consumer products and general industries, in mainland China, Hong Kong and international markets. The total transaction volume that he was involved has exceeded \$140 bn in ECM and \$300 bn in DCM.

Mr. Xu's past accomplished equity deal experiences mainly include: Midea Group's \$4.6 bn H share IPO (2024), Linklogis' \$1.2 bn HK IPO(2021), CICC's ¥13.2 bn A share IPO(2020), PSBC's ¥32.7 bn A share IPO(2019), Chongqing Rural Commercial Bank's ¥9.99 bn A share IPO(2019), CICC's 2.5 bn HKD H share placement(2019), Budweiser APAC's \$5.75 bn Hong Kong IPO(2019), China Tower's \$7.5 bn Hong Kong IPO(2019), China Cinda's 6.1bn HKD H-share placement (2016), PSBC's \$7.6 bn Hong Kong IPO (2016), China Zheshang Bank's \$1.94 bn Hong Kong IPO (2016), PSBC's \$7 bn pre-IPO equity financing (2015), CICC's \$930 million Hong Kong IPO (2015), Agricultral Bank of China's ¥\$22.1 bn A+H-share IPO (2010), China Minsheng Bank's \$4 bn Hong Kong IPO (2009), ICBC's \$21.9 bn A+H-share IPO (2006). Mr.Xu also has rich experiences in terms of fixed income financing as well as mergers and acquisitions.

Mr. Xu graduated from Shanghai Jiao Tong University with a Master's degree of management science. Mr. Xu is a registered A share Sponsor Representative in the PRC market as well as the registered Signing Sponsor

Principal of Hong Kong.

許佳先生 2006 年加入中金公司，現為中金公司董事總經理，投資銀行部執行負責人，國際組負責人。

許先生曾經作為專案負責人或核心成員完成過多個金融、電信、消費、工業等行業的大型國有企業和民營企業的私募、IPO、再融資等股本融資和各類債券、優先股融資專案，多次實現全球資本市場記錄，共實現 IPO 和私募等股權融資專案金額超 1,400 億美元，固定收益融資專案金額超過 3,000 億美元。

許先生作為專案負責人完成的主要境內外 IPO 專案包括：2024 年美的集團 45.8 億美元的 H 股 IPO、2021 年聯易融 11.8 億美元的香港 IPO、2020 年中金公司 132 億的 A 股 IPO、威海銀行和渤海銀行的 H 股 IPO、2019 年郵儲銀行 327 億元的 A 股 IPO、浙商銀行 126 億元的 A 股 IPO、重慶農商行 99.9 億元的 A 股 IPO、2019 年百威亞太 57.5 億美元的香港 IPO，2018 年中國鐵塔 74.9 億美元的 H 股 IPO、2017 年眾安線上 17.5 億美元的 H 股 IPO、2017 年廣州農村商業銀行 11.9 億美元的 H 股 IPO，2017 年廈門億聯網絡 15.6 億元 A 股創業板 IPO、2016 年郵儲銀行 76.3 億美元的 H 股 IPO、浙商銀行 19.4 億美元的 H 股 IPO、2015 年中金公司 9.3 億美元的 H 股 IPO、2014 年拉夏貝爾 2.5 億美元的 H 股 IPO、2012 年吉艾科技 8.68 億元的 A 股創業板 IPO、2010 年農業銀行合計 221 元美元的 A+H 同步 IPO 以及 2006 年工商銀行合計 219 億美元的 A+H 股 IPO 等。

許先生畢業於上海交通大學，獲管理學學士和碩士學位。許先生是國內 A 股資本市場的註冊保薦代表人，同時也擁有香港資本市場 Signing Sponsor Principal 資格。

Panellist | 講者

**Mr. David Lau****劉伯偉先生**

Co-Head of China Investment  
Banking Coverage, J.P. Morgan

摩根大通中國投資銀行聯席主管

David PW Lau is Co-Head of China Investment Banking Coverage at J.P. Morgan, responsible for global investment banking strategies for clients in Mainland China and Hong Kong. He joined J.P. Morgan in 1995. David has served various functions during his career at J.P. Morgan, including Equity Capital Markets, Mergers & Acquisitions, China Corporate Finance, and Hong Kong Investment Banking, and worked on a large number of Capital Markets and M&A transactions. David has been serving as a member of the SFC REIT Committee, a member of the Economic Advancement Expert Group of the Chief Executive's Policy Unit (CEPU) of the Hong Kong Government, the Policy Research Committee of the Hong Kong Financial Services Development Council (FSDC) and a council member of The University of Hong Kong.

Prior to joining J.P. Morgan, David worked in Private Equity. David also worked at both the Listing Division of the HKEX and the Hong Kong Securities and Futures Commission (SFC) between 2002 and 2004, and was responsible for IPO vetting and formulating capital market policies. David was a member of the Listing Committee of HKEX from 2017 to 2023, responsible for providing policy advice and taking decisions on listing matters. Between January 2016 to June 2017, David was an Associate Member of the Central Policy Unit of the Hong Kong Government.

劉先生是摩根大通中國投資銀行業務聯席主管，負責為中國大陸和香港客戶制定全球投資銀行戰略。他於 1995 年加入摩根大通，在摩根大通的職業生涯中曾擔任過多項職務，包括股權資本市場、並購、中國企業融資和香港投資銀行，並參與了大量資本市場和並購交易。他曾擔任證監會房地產投資信託基金委員會委員、香港政府行政長官政策組 (CEPU) 經濟發展專家組成員、香港金融發展局 (FSDC) 政策研究委員會委員以及香港大學校董會成員。

在加入摩根大通之前，David 曾在私募股權投資部工作。2002 年至 2004 年期間，劉先生還曾在香港交易所上市科和香港證券及期貨事務監察委員會 (SFC) 工作，負責首次公開募股 (IPO) 的審核和資本市場政策的制定。2017 年至 2023 年，劉先生擔任香港交易所上市委員會成員，負責就上市事宜提供政策建議並做出決策。2016 年 1 月至 2017 年 6 月期間，劉先生擔任香港政府中央政策組聯繫成員。

Panellist | 講者



**Mr. Daizong Wang**  
**王岱宗先生**

Partner, TPG NewQuest  
合夥人, TPG NewQuest

Daizong joined TPG NewQuest in 2016 and co-heads the firm's Greater China business. Daizong has more than 25 years of investment and private equity experience in China and brings with him a diverse set of skills from deal origination and structuring to hands-on operating experience with portfolio companies. He has worked closely with China-based GPs and led a number of secondary transactions including GP-led continuation vehicle deals in China.

Prior to TPG NewQuest, he was Managing Director at CVC Capital Partners, based in Beijing. Before CVC, he served as Senior Vice President and CIO of a Chinese investment holding group, and CFO of Little Sheep Group Ltd., a Hong Kong-listed restaurant group, which was subsequently sold to Yum! Brands. Daizong also previously worked for 3i plc and the investment banking division of Goldman Sachs in Hong Kong.

He holds an MBA from the Wharton School at the University of Pennsylvania and a Bachelor's in Engineering from Shanghai Jiao Tong University. He is fluent in English and Mandarin.

王岱宗先生於 2016 年加入 TPG NewQuest，聯合負責新程投資大中華區業務。他在中國的投資和私募股權領域擁有超過 25 年的經驗，並曾經多年參與企業的營運及管理。他幫助數個國內 GP 完成 S 基金交易包括接續基金的募集。

在加入 TPG NewQuest 之前，他擔任 CVC Capital Partners 的董事總經理。此前，他於國內一家投資控股集團擔任資深副總裁負責多領域的投資與管理。他還曾任職於 3i 集團並投資了小肥羊等知名品牌；他隨後出任小肥羊公司的 CFO，主導公司 2008 年在香港上市至被百勝中國收購。

王岱宗先生曾在高盛香港的投資銀行部門工作多年。他擁有賓州大學華頓商學院工商管理碩士學位和上海交通大學工程學士學位。王先生說英語及普通話。

Panellist | 講者



**Mr. Michael Hui**  
**許予一先生**

Partner, Bain Capital  
合夥人，貝恩投資

Michael Hui joined Bain Capital in 2024. He is a Partner and Head of Special Situations and Real Estate in China. Michael also supports transactions with equity and real estate components across Asia.

Prior to joining Bain Capital, Michael was a Partner and a member of the Global Corporate and Growth Investment Committees at Goldman Sachs's Asset Management Division. At Goldman Sachs, he focused on several asset classes including real estate, private equity, and growth equity at different points during his 20-year tenure across the Hong Kong and Shanghai offices. Michael most recently served as the Head of China Private Equity and Growth Equity. John holds a BBA degree from Southern Methodist University in the U.S., with a concentration in Finance and Real Estate.

許先生於 2024 年加入貝恩資本。他是貝恩資本合夥人，同時領銜大中華區特殊機會和房地產投資，為整個亞洲市場的股權和房地產投資業務做出貢獻。

在加入貝恩資本之前，許先生是高盛資產管理部的合夥人和全球企業與成長投資委員會成員。在高盛任職的 20 年中，他曾在香港和上海辦事處的不同時期負責多個資產類別，包括房地產、私募股權和成長型股權投資。許先生曾任高盛集團中國區私募股權及成長股權負責人。





深圳新风和睦家医院

Shenzhen New Frontier United Family Hospital

# 深港醫療

Shenzhen-Hong Kong Medical Practice

# 北上執業 輕鬆便捷

Easily Accessible Medical Practice in Mainland China

周全考慮：執照申請、病人管理、醫療責任保障、原研藥品等

Comprehensive Support: Licensing Applications, Patient Management, Medical Liability Insurance, Original Drugs, and more.



更多諮詢問題 請聯繫 For more inquiries, please contact:

WhatsApp: +852 6126 4345  
微信/WeChat ID: Oscar\_cck

連絡人/Contact Person: Oscar Chan  
聯繫郵箱/Email Address: oscar.chan@ufh.com.cn

## 讯飞同传

# iFLYTRANS

讯飞同传集成了实时机器转写翻译能力、AI 字幕投屏、多语种语音合成播报和会议全生命周期记录等多种功能，可分为 SaaS 服务、软硬件一体机和私有化解决方案等产品形态。满足国际会议、大型展会、导游讲解、商旅交流等多种使用场景。依托科大讯飞的语言转写、机器翻译、语音合成等核心技术，可提供多语种实时语音识别和机器翻译，在记录多语种会议内容的同时，辅以全屏或字幕条投屏模式的 AI 字幕，提升国际化沟通效率。配合讯飞同传耳机，佩戴者可实时收听多语种语音合成播报内容，解决演讲者一对多的同声传译需求。



iFLYTRANS integrates real-time machine transcription and translation capabilities, AI-powered subtitle projection, multilingual voice synthesis broadcasting, and full lifecycle meeting records across various product forms, including SaaS Services, integrated hardware and software, and privatized solutions. It caters to a wide range of needs such as international conferences, large-scale exhibitions, guided tours, business travel communication, and more.

Relying on iFLYTEK's core technologies in language transcription, machine translation, and voice synthesis, iFLYTRANS offers real-time voice recognition and machine translation in multiple languages. While recording multilingual meeting content, it supports AI subtitles in either full-screen or subtitle strip projection modes, significantly enhancing the efficiency of international communications. With iFLYTRANS earphones, users can listen to real-time multilingual voice synthesis broadcasts, addressing the need for simultaneous interpretation.

## 使用场景 Application Scenarios

- 会议论坛  
Conferences and Forums
- 大型展会  
Large-Scale Exhibitions
- 线上直播  
Online Live Broadcasts
- 国际会议  
International Conferences
- 导游讲解  
Guided Tours
- 视频会议  
Video Conferences
- 商旅交流  
Business Travel Communication
- 演讲培训  
Speech Training

## 产品形态 Product Forms

- SaaS服务  
SaaS Services
- 软硬件一体机  
Hardware-Software Integrated Machine
- 私有化解决方案  
Privatized Solutions

## 产品功能 Product Features

- 实时语音转写  
Real-time Voice Transcription
- 多语种机器互译  
Multilingual Machine Translation
- 实时字幕上屏  
Real-time Subtitles on Screen
- 语料优化  
Corpus Optimization
- 同传耳机收听  
SI Listening via Earphone
- 语音合成播报  
Voice Synthesis Broadcasting
- 会议扫码分享  
Meeting QR Code Sharing
- 会议记录管理  
Meeting Record Management
- 远程上会  
Remote Meeting Participation
- 专业团队保障  
Professional Team Support


## 相关案例 Related Cases

国际体育赛事  
多语种同声传译助力全球赛事传播  
**International Sports Events**  
Multilingual Simultaneous Interpretation, Empowering Global Event Broadcasting

中国国际进口博览会  
实时字幕成国际顶级会议标配  
**China International Import Expo**  
Real-time Subtitling, Becoming a Standard for Top International Conferences

澳门Beyond国际创新博览会  
独家翻译支持共同展望亚太科技创新未来  
**Macao Beyond Expo**  
Exclusive Translation Support, Looking Forward to the Future of Asia-Pacific Technology Innovation

中东迪拜消费电子及通讯展览会  
搭建一座中国和中东地区跨语言沟通桥梁  
**GITEX**  
Building a Cross-Language Communication Bridge between China and the Middle East Development of Communication and Digital Economy



讯飞同传服务超过全球50个国家地区，服务支撑40万+场会议，覆盖人次超过4亿，已成为国际会议标配。

iFLYTRANS has served over 50 countries and regions worldwide, supported more than 400,000 meetings, and reached over 400 million people, becoming a standard for international conferences.

# AI，科技健康閉環

新風天域  
邱慧、王楨

全球醫療正面臨三重結構性變革：**老齡化加速、家庭結構變遷以及使用者對個人化健康管理的需求**。數據顯示，到 2050 年全球 60 歲以上人口將達到 21 億，慢病管理、多學科診療和全生命週期健康照護需求激增。同時，超 40% 的高淨值家庭呈現「四代同堂」或「跨境分散居住」的特徵，健康管理顆粒度應從個人向家庭躍遷，需同時滿足老年人生活陪護、中青年亞健康干預、兒童成長服務追蹤等差異化需求。此外，用戶對於個人化健康管理、隱私化診療流程及全球頂尖資源的觸達，使高端私立醫療機構需在“精準醫療”和“服務關懷”間尋找平衡點，持續提升使用者就醫體驗。

為應對這些挑戰，可以從個體到家庭的科技健康閉環入手。通過智慧監測矩陣，如老年人防反覆運算監測、成年人壓力監測，與智慧家居聯動，實時採集家庭環境數據（空氣品質、睡眠品質等），形成「家庭健康指數」。同時，基於家庭健康大數據，AI 自動生成健康預警及干預方案，聯動醫療機構看診，管理家庭的健康。在 AI 和大數據驅動下的服務體驗升級方面，AI 基於使用者的健康數據、生活習慣數據、行為數據等分析，智慧化在使用者全生命週期內提升服務體驗。此外，搭建智慧運營鏈路及服務鏈路，快速響應使用者需求。在院內系統升級方面，通過 AI 多模態及數據分析，在病歷書寫、輔助診療、疾病風險預測等方面，全面提升醫療品質和效率。



# 減輕國民醫療負擔： 康復醫療的獨特價值

顧連醫療  
袁帥、徐宸

中國正加速步入中度老齡化社會，2023 年中國 65 歲及以上人口佔比已達 15.4%，老年人口撫養比升至 22.5%，預計到 2030 年，老年人口撫養比將快速攀升，2035 年、2050 年分別達 36.3%、53.5%。隨著年齡的增長，老年人由於衰老、急慢性疾病等原因導致失能、失智等風險將不斷增加，這將給家庭、社會、政府等帶來極大的照護負擔，也對中國以三級醫院為核心提供急性期治療的醫療服務體系帶來巨大衝擊。

康復醫學作為現代醫療服務體系中的重要一環，正逐步成為老齡健康化、健康老齡化的重要醫學支援，在患者的整個生命週期中佔據著至關重要的位置，康復醫學不僅關乎患者生理功能的康復，更關乎其心理和社會功能的全面康復。在人口老齡化加劇、慢性疾病發病率攀升以及損傷性功能障礙日益增多的背景下，康復醫療的獨特價值愈發凸顯，已然成為減輕國民醫療負擔的關鍵突破口。

**康復醫療在疾病恢復過程中扮演著至關重要的角色，能有效降低致殘率及再入院率，說明患者更好地回歸社會，降低社會經濟負擔：**

世界衛生組織曾提出有效的康復護理介入可使至少 50% 的殘疾得以控制或延遲發生。《2019 年國家康復醫學專業醫療服務與品質安全報告》顯示，中國康復醫學科的平均日常生活活動 (ADL) 改善率為 73.75%，表明患者功能有明顯提升。以中國發病率和患病率均排名世界第一的腦卒中為例，美國腦卒中的殘疾率約為 30%，而中國的殘疾率則高達 75% 以上，其主要原因就是缺乏急性後期康復環節。根據相關數據，康復治療可以使 90% 的腦卒中患者恢復步行和自理生活，30% 的患者恢復較輕的工作，衛生部衛生經濟研究所報告顯示，因腦卒中而殘疾的患者給我國每年帶來的社會經濟負擔高達 400 億元。全國心血管專業委員會報導，我國腦卒中患者平均每年住院 3-4 次，缺乏有效和系統的急性後期康復護理服務，是導致患者再次入院的主要原因。在創傷方面，以外傷性截癱為例，1950 年前截癱后只能

存活 2.9 年，50 年代后因康復醫療的介入，存活時間延長至 5.9 年。以上數據表明，康復醫療不僅顯著提升了患者的生活品質，更在降低社會醫療成本方面發揮了重要作用。

**康復醫療是中國現有醫療體系的有力補充，通過分層級、分階段的康復服務模式，實現醫療資源的高效利用，降低整體醫療成本：一方面，確保優質急性期醫療資源聚焦於危重疑難疾病的救治；另一方面，通過及時轉診保證患者接受恰當的康復治療服務，降低醫療支出。**

在諸多發達經濟體，醫療照護服務體系是一個連續體，涵蓋並協調從急性期治療、急性後期康復護理、長期生活照料和臨終關懷等的一體化服務，實現患者在不同類型醫療及照護機構之間的無縫對接。而中國現有醫療服務機構的設置多以急性期醫療資源進行配置，急性後期照護模式尚不成熟，跨不同醫療機構間的轉介體系整合不佳，急性期穩定的患者因擔心回家后的照護而滯留醫院，或因急性後期康復和護理需要而反覆住院、超長住院的情況均屢見不鮮。大量病殘性失能老人因缺乏專業護理機構而住進醫療機構的普通病房，佔用了優質急性期醫療資源，以成本更高的急性期醫療床位去滿足急性後期照護的康復護理需求，給醫保基金帶來巨大挑戰，並最終形成巨大的壓力向公共財政體系傳導。

構建連續康復醫療服務體系，是持續打造優質高效的衛生健康服務體系的重要舉措。顧連醫療長期致力於中國康復醫療服務體系建設，截至目前，我們已搭建了以老年康復為基礎、功能康復為特色、重症康復為核心、居家護理為補充的業務架構，在全國運營管理近 30 家康復機構，運營和在建床位數近 8,000 張，業務覆蓋全國各主要區域。目前，顧連醫療擁有超 3,000 名醫療專業人員，每年服務患者逾 4 萬名。隨著粵港澳大灣區一體化的深入推進，區域內醫療資源加速聚集，有望成為全國領先的醫療高地，顧連醫療將積極投身大灣區醫療建設，助力大灣區連續性康復醫療體系構建，為塑造健康灣區貢獻顧連力量！

# Tales of Two Systems: Maximizing Medical Strengths in the Greater Bay Area

Dr. Alastair Mah

**The Greater Bay Area (GBA), comprising Hong Kong, Macau, and nine cities in Guangdong Province, presents a unique opportunity for healthcare innovation and collaboration. With its diverse medical systems, each region possesses distinct strengths and challenges. By understanding and leveraging these differences, we can enhance the quality and safety of healthcare across the GBA, ensuring that all residents benefit from improved medical services.**

## Understanding the Medical Systems

The GBA is characterized by two primary medical systems: the public healthcare system and the private healthcare system. Each system has its strengths. The public healthcare systems in Hong Kong and Macau are known for its extensive reach, affordability, quality and patient-centredness. It provides essential services to a large portion of the population, ensuring access to basic healthcare regardless of socioeconomic status. In the Mainland, the public sector provides timely access for the vast majority of patients, and in recent years leading public hospitals have contributed to technological advances on the world stage. In contrast, the private healthcare system in Hong Kong and Macau offer unparalleled access to innovative drugs and equipment due to an accommodating regulatory framework, while in cities like Shenzhen and Guangzhou, private healthcare is marked by its advanced technology, shorter wait times, and exceptional value.

Despite the advantages of both systems, they also face significant challenges. The public systems can often struggle with overcrowding, long waiting times and a reduced focus on patients' experience, while the private system may be criticized for high costs and lack of clinical governance. Leveraging the strengths of these various systems and cross-collaborating could lead to a more integrated, efficient healthcare framework that optimizes the quality of care for all patients.

## Collaboration and Integration

A collaborative approach is essential for integrating the strengths of both systems. One potential strategy is the development of a shared digital health platform. By creating a unified electronic health record (EHR) system that is accessible across the GBA, medical professionals can share patient data, treatment histories, and best practices. This would facilitate continuity of care, especially for patients who move between regions for work or residency.

Additionally, establishing cross-border medical partnerships can enhance service delivery. For instance, public hospitals in Hong Kong could collaborate with private hospitals in Shenzhen to offer specialized services at an efficient price-point, such as advanced surgical procedures, radiological procedures or oncology treatments, that may be difficult to access in the public system. This would not only improve access to care but also reduce the burden on public hospitals.

Another example is to leverage Hong Kong's broad availability of international innovative drugs and therapies, to provide residents in the GBA access to the newest treatment modalities not yet available in the Mainland.

### **Workforce Development and Training**

The healthcare workforce in the GBA is diverse, comprising professionals trained in various systems and specialties. By promoting joint training programs and exchange initiatives, we can enhance the skills of healthcare workers. Going forwards across the region, there is a pressing need to standardize training for specialists to ensure clinical standards, and to prepare the future health workforce to be ready for hugely different healthcare delivery systems of tomorrow.

Moreover, fostering a culture of continuous professional development can motivate healthcare professionals to stay updated with the latest medical advancements and best practices on patient safety and clinical protocols. This can be achieved through workshops, seminars, and online courses that are accessible to all healthcare workers in the GBA, regardless of their system affiliation.

### **Patient-Centered Care**

To improve quality and safety, the focus must shift towards patient-centered care. In both public and private systems, understanding patient needs and preferences is crucial. Implementing patient feedback mechanisms can provide valuable insights into service quality and areas for improvement. The GBA cities tend to possess different strengths to improve the patient experience, such as the Mainland's online technological capability to support pre- and post-hospital care, or Hong Kong's established culture of partnering with patients to co-develop goals of care. There is much scope for cross-pollination.

Moreover, enhancing health literacy among the population is vital. Educating residents about their health options, preventive care, and the navigation of healthcare services can empower them to make informed decisions. Key health promotion messages can be shared across populations to maximize focus and support integration.

### **Regulatory Harmonization**

Regulatory differences can often impede the integration of healthcare systems across regions. This is certainly the case across Hong Kong, Macau, and the Mainland cities. To address this, a collaborative regulatory framework should be established. This would involve harmonizing regulations related to medical practice, research governance, as well as pharmaceutical and technology adoption across the region. Such alignment would facilitate smoother cooperation and ensure that patients receive consistent and safe care, regardless of where they are treated.

In addition, establishing joint accreditation bodies for healthcare facilities can enhance standards of care. By developing shared guidelines and performance metrics, healthcare providers can be held accountable to the same quality benchmarks, fostering a culture of excellence.

### **Conclusion**

The Greater Bay Area stands at a crossroads in its healthcare journey. By maximizing the strengths of its various medical systems, we can create a more integrated, efficient, and patient-centered healthcare environment. Collaboration, workforce development, patient engagement, and regulatory harmonization are critical building blocks of this vision. By working together, the region can ensure that quality and safety in healthcare are not just aspirations but realities for all residents of the GBA. The tales of our two systems need not be separate; together, they can tell a story of innovation, cooperation, and improved health outcomes for everyone.

# A Global Race: The Shifting Landscape of International Medical Care

United Family Healthcare  
International Medical Service  
Ed Tam

**In an increasingly interconnected world, the pursuit of better health outcomes transcends borders. Medical tourism, once seen as a niche option for the affluent or those seeking specific treatments unavailable at home, is now a mainstream phenomenon. The global medical tourism market was valued at approximately \$105 billion in 2019 and is projected to grow at a compound annual growth rate (CAGR) of 12.8%, reaching over \$200 billion by 2027. For affluent patients in China facing rare and complex diseases, the allure of advanced treatments, cutting-edge technologies, and renowned specialists abroad has created a burgeoning demand for international medical care. At the heart of this transformation lies the confluence of global expertise and localized patient support.**

## The New Patient Journey

Medical tourism once meant patients navigating foreign systems and language barriers alone. Today, it offers a seamless, patient-focused experience driven by advanced technologies and dedicated support systems. At United Family International Medical Service, we streamline this process by providing each patient with a dedicated case manager. These professionals bridge gaps between patients and specialists worldwide, ensuring medical histories are prepared and shared with global providers. Teleconsultations allow patients to connect with experts from renowned institutions in the U.S., Hong Kong, Japan, and beyond.

This approach reduces uncertainty, offering personalized care tailored to each patient's unique needs. Chinese patients seek not only expertise but also expedience. Timely interventions for conditions like oncology, neurology, cardiology, and fertility are critical, where delays can significantly impact outcomes. By prioritizing communication, coordination, and global access, we transform a daunting process into a carefully managed, patient-first journey.

## Building a Bridge Between Systems

Bridging the gap between disparate healthcare systems is a significant challenge in medical tourism. Differences in treatment protocols, regulatory environments, and cultural expectations can create friction. To address these challenges, partnerships with leading medical institutions worldwide have become a cornerstone of effective medical tourism programs.

Our collaborations with globally recognized hospitals and clinics allow patients access to the latest treatments, including surgical solutions, innovative drug therapies, and clinical trials. Post-treatment, we ensure continuity of care by working closely with local providers to monitor recovery and manage long-term outcomes.



### China's Role in Global Healthcare

China is becoming a major player in global healthcare, attracting patients from Russia, Central Asia, and Southeast Asia with high-quality, cost-effective care. Specialties like oncology, cardiology, and advanced surgeries make cities like Shanghai and Beijing hubs for innovation.

China's drug development also draws patients from developed countries, offering groundbreaking treatments in oncology and rare diseases. Advanced surgical expertise enhances China's reputation, delivering superior outcomes for complex procedures. Chinese patients benefit from advanced treatments and expedited care, where timely interventions can mean the difference between life and death.

This dual dynamic positions China as both a provider and consumer of medical tourism, meeting inbound and outbound patient needs while cementing its role as a global healthcare leader.

### Transparency and Trust

In an industry often criticized for hidden costs and a lack of clarity, transparency is essential. Patients need clear information about treatment options, costs, and expected outcomes to make confident decisions. Medical tourism isn't just about seeking advanced solutions—it's about considering factors like time away from home, unfamiliar environments, financial implications, lifestyle disruptions, and balancing risks with rewards. These considerations are as crucial as the treatment itself, helping patients make informed choices that align with their medical and personal circumstances.

### The Future of Medical Tourism

As medical tourism evolves, its future will be shaped by advancements in technology, personalized care, and global collaboration. Artificial intelligence, for example, addresses key challenges such as:

- **Streamlining Medical Records:**  
AI efficiently sorts, translates, and transfers records, ensuring seamless communication between healthcare providers.
- **Global Expert Matching:**  
AI matches patients with the best medical experts worldwide based on specific needs and protocols.
- **Global Search for Drugs and Clinical Trials:**  
AI tools help patients access cutting-edge drugs and clinical trials unavailable in their home country.

These applications enhance efficiency, precision, and personalization, making global healthcare more accessible and effective.

### A Call to Action

The global race for better health is accelerating. For patients, it's about accessing the best possible care—wherever it may be. For providers, it's about creating systems that are responsive, adaptive, and patient-focused. At United Family International Medical Service, our mission is to lead this charge, bridging borders and building a future where exceptional healthcare knows no bounds. In a world where health is wealth, medical tourism is not just a journey—it's a lifeline. And for those willing to embrace its possibilities, the rewards are transformative.

# Sustainability and Technology: The Future of High-End Medical Insurance in China

Prosper Health  
Jason Zheng

In the mid-to-high-end medical insurance sector, which Prosper Health focuses on, we have observed two main significant changes over the past decade:

Firstly, there has been a shift in the primary target audience, from expatriates to local executives or core talents. When high-end medical insurance was introduced to China, it was primarily designed to meet the medical needs of foreign senior managers across various industries. However, over the past decade or so, the localization of executives and core talents in foreign enterprises has accelerated, and private enterprises, especially those in the internet sector, have risen rapidly. This has led to a gradual disappearance of the differentiation in employee medical benefits based on nationality.

The second change we have noticed is an increasing emphasis on the sustainability of benefit programs. Previously, many companies in the market did indeed invest heavily in medical benefits to meet the needs of core talents, almost at any cost, to ensure that they provided the best benefit policies in the industry. However, in the current economic cycle, while companies still need to provide the best medical coverage to key executives and talents, they are also under extremely high pressure to control benefit costs.

These changes also reflect the market trends for the next decade. Firstly, the rise in medical costs and the deterioration of claim ratios are calling for more personalized and refined operational service solutions. The one-fits-all approach will definitely be phased out.

Secondly, technology will play an increasingly important role. Digital tools provide customers with a simpler and more user-friendly experience, helping them find the right medical resources at the right time. Big data and AI will also open up broad application scenarios in the field of medical services, contributing to comprehensive improvements in pricing, underwriting, member experience, and operational efficiency.